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Abstract 
 
Prostaglandin E2 (PGE2) may provide a novel therapy for the treatment of 
inflammatory airway diseases as it has been shown to confer both bronchodilator 
and anti-inflammatory activity in asthmatic subjects. However, PGE2 can cause 
irritancy of the upper airway resulting in a reflex cough. The aim of this thesis 
was to identify which of the 9 prostanoid receptors (EP1, EP2, EP3, EP4, DP, FP, 
IP, TP and CRTh2) mediate the PGE2-induced cough. The cough reflex is under 
the control of sensory afferent nerve fibres that innervate the lungs via the vagus 
nerve. Using an in vitro model of vagal sensory nerve depolarisation, gene and 
protein expression techniques and a guinea-pig cough system, I investigated the 
prostanoid receptor(s) responsible for the PGE2-induced depolarisation of the 
vagus nerve and cough. 
 
A conscious guinea-pig cough system was characterised and I confirmed that 
guinea-pigs, like humans, cough in response to PGE2. Isolated vagus nerves from 
guinea-pig, mouse and human were characterised in response to PGE2 and other 
tussive stimuli, capsaicin and low pH. Isolated nerves from these species behave 
similarly suggesting that effects observed in these small animals translate to man. 
It was discovered that depolarisation to PGE2 was virtually abolished in isolated 
vagus nerves from EP3 receptor knockout (KO) mice. This suggests that the 
response to PGE2 is mediated by the EP3 receptor, supported by evidence that an 
EP3 receptor antagonist (L826266) inhibited the response to PGE2 in isolated 
vagus nerves from guinea-pig, mouse and human.  
 
Expression of the EP3 receptor was confirmed in guinea-pig vagal nerve ganglia 
(containing the cell bodies of nerves carried in the vagus) using Taqman RT-PCR 
and immunohistochemical staining. Ultimately, I demonstrated the role of the EP3 
receptor in vivo using a selective EP3 receptor antagonist to attenuate PGE2-
induced cough. 
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This thesis identifies the receptor responsible for PGE2-induced cough 
representing a key step in developing a drug that is anti-inflammatory and a 
bronchodilator but devoid of tussive side effects. 
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1.1 PROSTANOIDS AND PROSTANOID RECEPTORS 
 
1.1.1. Introduction to prostanoids 
 
Prostanoids were first identified in 1936 by Ulf von Euler who injected semen 
into animals which lowered blood pressure. The biologically active components 
were named „prostaglandins‟ since they were apparently produced in the prostate 
gland (von Euler 1936). It is now known that these prostanoid types of 
eicosanoids are involved in a wide range of biological processes including 
inflammatory reactions, controlling the cardiovascular system, cancer and cell 
proliferation. 
 
Prostanoids are described as lipid mediators belonging to the family of 
eicosanoids which are produced from the oxidation of fatty acids comprising 20 
carbon atoms and a cyclic ring. They can be classed as prostacyclin, 
prostaglandins (PG) and Thromboxanes (Tx). Prostaglandins can be classified as 
A to I based on modifications of their cyclopentane ring of which A, B and C are 
not thought to exist naturally. Endogenous prostanoids can therefore be classed as 
prostacyclin (PGI2), PGD2, PGE2, PGF2α, and TxA2. The index number indicates 
the number of double bonds present in the side chains. Based on this numbering 
system, the prostanoid series can be further classified into 1, 2 and 3 synthesised 
from the precursor fatty acids γ-homolinolenic acid, arachidonic acid and 
5,8,11,14,17-eicosapentaenoic acid. Arachidonic acid is the most common 
precursor in mammals rendering the series 2 prostanoids the most abundant (Bos 
et al. 2004).   
 
1.1.2. Synthesis of prostanoids 
 
Prostaglandins and thromboxane are derived from metabolism of arachidonic acid 
by cyclo-oxygenase enzymes (COX) 1 (constitutively expressed) and COX-2 
(inducible) and subsequent metabolism by prostaglandin synthase enzymes 
(Figure 1). Arachidonic acid is liberated from the membrane by phospholipase A2 
and oxidised by COX enzymes into PGG2. This is then followed by a reduction by 
COX to an unstable endoperoxidase PGH2. PGH2 acts as a substrate for a variety 
 19 
of synthase enzymes responsible for producing the bioactive prostaglandins; PGI2, 
PGD2, PGE2, PGF2α and TxA2. Because prostanoids are either chemically or 
metabolically unstable, they are usually immediately released by the cell and are 
thought to act in an autocrine manner on neighbouring cells (Hata & Breyer 
2004).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Biosynthesis of prostaglandins.  
Arachidonic acid is metabolised by COX-1 or -2 to PGH2, the common precursor 
for the prostaglandin synthase enzymes. The prostanoids TxA2, PGD2, PGE2, 
PGI2 and PGF2α are produced by their individual synthase enzymes TxAS, PGDS, 
PGES, PGIS and PGFS respectively. Adapted from (Hata & Breyer 2004).  
 
1.1.3. Prostanoid receptors 
 
The prostanoids (PGD2, PGE2, PGF2, PGI2 and TxA2) act at five classes of 
receptors named DP, EP, FP, IP and TP respectively according to the prostanoid 
that has the highest affinity at the receptor type. The PGE2 receptor, EP, can be 
further classified into 4 distinct subtypes EP1-4 (Coleman et al. 1994; Narumiya et 
al. 1999). Furthermore, the PGD2 class of receptors is comprised of DP1 and DP2. 
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DP2 is also known as CRTh2 (chemoattractant receptor-homologous molecule 
expressed on T helper Type 2 cells) (Hirai et al. 2001; Monneret et al. 2001).  
However, all the prostanoids can activate the various receptor subtypes to some 
degree (Breyer et al. 2001). The prostanoid receptors are seven trans-membrane 
G-protein coupled rhodopsin-like proteins acting through different types of G 
proteins and signalling cascades allowing the prostanoids to produce their diverse 
range of physiological effects. In general, IP, EP2, EP4 and DP receptors activate 
Gs stimulating cAMP production by adenylyl cyclase. TP, EP1 and FP receptors 
mediate contractile-type responses by activating the G protein Gq and increasing 
intracellular Ca
2+
. Finally, EP3 is generally thought to be inhibitory and inhibits 
adenylyl cyclase and increases in cAMP via Gi. However, these guidelines are not 
always true and receptor signalling can depend on the existence of splice variants, 
the cell and tissue type or changes in disease (Bos et al. 2004). Specific receptors 
are discussed in more details below. 
 
1.1.3.1. EP receptors 
 
The EP receptors are divided into 4 distinct classes termed EP1-4 as mentioned 
previously. It was presumed that PGE2 acts through more than one type of EP 
receptor due to its diverse effects. The EP receptors were originally classified by 
their ability to relax and constrict smooth muscle, as well as by the receptor 
pharmacology (Gardiner 1986). The existence of multiple receptor subtypes was 
later confirmed by molecular cloning of these 4 receptors from both human tissue 
(Adam et al. 1994; Bastien et al. 1994; Funk et al. 1993; Regan et al. 1994) and 
from mouse tissue (Honda et al. 1993; Katsuyama et al. 1995; Sugimoto et al. 
1992; Watabe et al. 1993). Molecular cloning has also revealed splice variants of 
the EP3 receptor providing further variation for the actions of PGE2 through these 
EP receptors (Adam et al. 1994). 
 
PGE2 is the most studied of the prostanoids and has the most diverse of known 
physiological effects. Through knockout (KO) mouse studies, a wide range of 
phenotypes dependent on the EP receptors have been identified. Prostanoids and 
the EP receptors have been shown to play a key role in aspects of central nervous 
system function. Fever represents a component of the acute-phase immunological 
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challenge and can be inhibited by non-steroidal anti-inflammatory drugs 
(NSAIDs) such as aspirin. For this reason, it was hypothesised that the EP 
receptors played a role in fever generation and the receptor involved was later 
identified as the EP3 receptor through KO mouse studies (Ushikubi et al. 1998). 
EP3 and EP1 have been shown to play a role in hyperalgesia (Moriyama et al. 
2005; Ueno et al. 2001). The EP4 receptor is involved in facilitating the closure of 
the ductus arteriosus during development (Segi et al. 1998) and both the EP4 and 
EP2 receptors have been shown to play a role in arthritic inflammation (Honda et 
al. 2006). Prostanoids, particularly PGE2 are thought to play a major role in 
inflammation and from KO mouse studies it has been revealed that these actions 
can be pro-inflammatory or anti-inflammatory depending on the expression in 
relevant tissues. These effects will be discussed in more detail later, paying 
particular attention to the role of prostanoids in asthma and Chronic Obstructive 
Pulmonary Disease (COPD). 
 
 The diverse role of PGE2 is due to its ability to activate different receptor 
subtypes coupling to different G-proteins and downstream signalling cascades. 
The schematic in figure 1.2 outlines the signalling pathways of the EP receptors. 
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Figure 1.2: Signalling cascade of EP receptors activated by PGE2. 
The EP1 receptor predominantly couples to Gq, the EP2/EP4 to Gs and the EP3 
receptor to Gi however the EP receptors can all couple to other G proteins. 
Activation of Gq leads to the activation of phospholipase C and an increase in 
calcium/protein kinase C. Gs causes the activation of adenylyl cyclase and an 
increase in cAMP. Gi inhibits adenylyl cyclase thereby decreasing cAMP. PGE2 is 
known to mediate a range of effects via these G proteins however the pathways 
mediating specific effects are largely unknown.   
 
The EP3 and EP4 receptors bind PGE2 with the highest affinity (Kd < 1nM) where 
as the EP1 and EP2 receptors bind PGE2 with a slightly lower affinity (Kd > 10nM) 
(Abramovitz et al. 2000). Although these four receptors bind PGE2 with the 
highest affinity of the prostanoids, the receptors themselves are not as structurally 
homologous when compared to other prostanoid receptors. For example the amino 
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acid homology between EP1 to EP2, EP3 and EP4 is 30, 33 and 28 % respectively 
(Sugimoto & Narumiya 2007). The EP2 receptor is more closely related to other 
Gs-coupled receptors such as the DP and IP receptors rather than the other EP 
receptors. Furthermore, the EP1 receptor shares most homology with TP and FP 
receptors which are both also coupled to Gq (Toh et al. 1995). 
 
1.1.3.2. EP1 receptor  
 
The human EP1 receptor cDNA encodes a 402-amino-acid sequence and the 
mouse and rat EP1 receptor cDNA has also been cloned. There is high receptor 
homology across the species; the rat EP1 cDNA is 96 % homologous to the mouse 
and 83 % homologous to the human sequence (Funk et al. 1993) and is most 
highly expressed in the kidney, stomach and adrenal tissue (Abramovitz et al. 
1995; Guan et al. 1998).  Activation of the EP1 receptor generally leads to an 
increase in Ca
2+
 via Gq (Funk et al. 1993; Watabe et al. 1993) however Narumiya 
and colleagues reported that in mouse EP1 receptors, the increase in Ca
2+
 
correlates to a comparatively small increase in IP3 suggesting that EP1 could 
signal through a pathway independent of Gq (Narumiya et al. 1999). 
 
 
ONO-DI-004 is a non-commercially available agonist by ONO Pharmaceutical 
with a high selectivity for the EP1 receptor (Yamamoto et al. 1999). Other 
agonists at the EP1 receptor include 17-phenyl PGE2, iloprost and sulprostone 
however iloprost and sulprostone are also active at the IP and EP3 receptors 
respectively (Kiriyama et al. 1997). The EP1 receptor antagonists are more 
selective pharmacological tools of which commercially available ligands include 
SC51089 and SC53122. These antagonists have been shown to have analgesic 
properties and to be involved in the regulation of blood pressure (Nakayama et al. 
2002; Stock et al. 2001). AH6809 was originally described as an EP1 receptor 
antagonist (Coleman et al. 1985) however; it is now known that AH6809 has 
almost equal affinity for the human EP1, EP2, DP receptors (Abramovitz et al. 
2000). It has a higher affinity than the EP1 receptor antagonist SC19920 at human 
and guinea-pig EP1 receptors however is only a weak antagonist at the mouse EP1 
receptor (Coleman et al. 1985; Kiriyama et al. 1997). ONO-8711 is a non-
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commercially available antagonist (Watanabe et al. 1999) and a recently 
developed selective EP1 antagonist has been described for the treatment of 
inflammatory pain, GW848687X (Giblin et al. 2007). 
 
 The EP1 receptor has been implicated in a range of physiological processes 
including allodynia (Stock et al. 2001), sensitisation of peripheral nociceptive 
nerves (Moriyama et al. 2005) and urine concentration (Kennedy et al. 2007). In 
the lung, the EP1 receptor, along with the TP receptor, plays a significant role in 
airway smooth muscle contraction (Coleman & Kennedy 1985; Francis et al. 
1991; McKenniff et al. 1988) which will be discussed in more details in section 
1.4. 
 
1.1.3.3. EP2 receptor 
 
The EP2 receptor cDNA encodes a 358-amino-acid polypeptide and has been 
cloned in the human, rat, mouse and rabbit (Boie et al. 1997; Guan et al. 2002; 
Katsuyama et al. 1995; Regan et al. 1994). The amino acid sequences between the 
rat, mouse and human EP2 receptors have been shown to share 98 % homology 
(Boie et al. 1997). Originally the EP2 and EP4 receptors were both cloned in 1994 
and both reported as EP2 as they were positively coupled to adenylyl cyclase via 
Gs (Bastien et al. 1994; Regan et al. 1994). The two clones differed in their 
sensitivities to the synthetic prostanoid butaprost and it was eventually decided 
that the non-sensitive receptor cloned by Bastien et al. would be termed the EP4 
receptor and the „sensitive‟ receptor cloned by Regan et al., termed the EP2 
receptor (Nishigaki et al. 1995). The EP2 receptor is the least expressed of all the 
prostanoid receptors (Narumiya et al. 1999) and has been shown to be expressed 
in relatively low levels in the uterus, lung and spleen (Boie et al. 1997; 
Katsuyama et al. 1995; Regan et al. 1994). 
 
The EP2 receptor was originally characterised by TR4979 (butaprost)-induced 
relaxation of cat trachea (Gardiner 1986) and butaprost is now considered a 
pharmacological tool for investigating the EP2 receptor. Another EP2 receptor 
agonist AH13205 has been described however it appears to be approximately 100 
fold less potent compared to PGE2 in the guinea-pig smooth muscle tissues (Nials 
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et al. 1993). ONO-AE1-259 is an agonist that has high affinity for the EP2 
receptor however this is not commercially available (Yamamoto et al. 1999). 
AH6809 antagonises the EP2 receptor however it is not selective and in humans it 
has equal affinity for the EP1 and DP receptors. In the mouse, AH6809 has the 
highest affinity for the EP2 receptor and is only a low affinity antagonist at the 
murine EP1 and DP receptors (Abramovitz et al. 2000; Kiriyama et al. 1997). 
Although few affinity studies are carried out using guinea-pig receptors, AH6809 
has been shown to inhibit PGE2-induced airway contraction, an action which is 
thought to be mediated through EP1 (Ndukwu et al. 1997). 
 
The EP2 receptor has been shown to have a significant role in the lung. EP2 
mediates relaxation of airway smooth muscle both in human tissue (Norel et al. 
1999) and in animal models (Fortner et al. 2001; Sheller et al. 2000; Tilley et al. 
2003). Furthermore, an anti-inflammatory role of the EP2 receptor in the lung has 
been described using a range of human cell-based assays (Clarke et al. 2004; 
Huang et al. 2007; Kay et al. 2006; Ratcliffe et al. 2007; Sturm et al. 2008; 
Sugiura et al. 2007). This will be described later in more detail. 
 
1.1.3.4. EP3 receptor 
 
The EP3 receptor provides even more scope for the diverse actions of PGE2 due to 
the existence of multiple isoforms in several species investigated to date. The 
human, rat, mouse and bovine receptors have been cloned and these studies 
identified three isoforms of EP3 in the mouse; EP3α, EP3β and EP3γ (Irie et al. 
1993; Sugimoto et al. 1993), four isoforms in the cow; EP3A-D (Namba et al. 
1993), and at least eight isoforms in humans; EP3-I, EP3-II, EP3-III, EP3-IV, EP3-V, 
EP3-VI, EP3-e and EP3-f  (Adam et al. 1994; Kotani et al. 1997; Schmid et al. 1995). 
The differences within species between the multiple splice variants of the EP3 
receptor seem to reside in the unique C-terminal cytoplasmic tails of these 
receptors which could potentially explain differences in receptor phosphorylation, 
signal transduction and desensitisation of the EP3 receptor in different tissues (Bos 
et al. 2004). As mentioned above, the EP3 receptor is thought to predominantly 
inhibit cAMP via Gi however the receptor has been shown to activate other 
signalling pathways such as Gs and Ca
2+
 release (An et al. 1994; Namba et al. 
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1993). The human EP3-I, mouse EP3α, rat EP3 and bovine EP3D share 
approximately 85 % homology (Adam et al. 1994) and studies across species have 
revealed that there is high expression of the EP3 receptors in many tissues 
including kidney, uterus, adrenal gland and stomach (Abramovitz et al. 1995; 
Sugimoto & Narumiya 2007; Yang et al. 1994). 
 
Sulprostone and PGE2 have been shown to have equal affinity for the EP3 
receptors in mouse and human (Abramovitz et al. 2000; Kiriyama et al. 1997). 
However, PGE2 also activates the other EP receptors, and as mentioned 
previously, sulprostone is also an EP1 agonist. ONO-AE-248 is a selective EP3 
agonist (Yamamoto et al. 1999) and ONO-AE3-240, a selective EP3 receptor 
antagonist (Amano et al. 2003). In addition, a family of acylsulfonamide EP3 
selective receptor antagonists, including L-826266, have been recently developed 
(Gallant et al. 2002; Juteau et al. 2001). 
 
The EP3 receptor has a diverse range of effects, possibly enhanced buy the 
existence of multiple receptor isoforms. The EP3 receptor is involved in fever 
generation (Ushikubi et al. 1998) and has been shown to play a role in 
hyperalgesia (Ueno et al. 2001). In the kidney, which highly expresses EP3, PGE2-
EP3 signalling plays a key role in water reabsorption and urinary concentration 
ability (Fernandez-Llama et al. 1999). In contrast to the many beneficial effects of 
the EP2 and EP4 receptors in the lung, the role of EP3 seems to be primarily 
detrimental mediating chemoattraction and degranulation of mast cells (Nguyen et 
al. 2002; Weller et al. 2007).  
 
1.1.3.5. EP4 receptor 
 
The EP4 receptor encodes a 488-amino-acid sequence in humans (Bastien et al. 
1994) and has also been sequenced in the mouse, rat, rabbit and cow (An et al. 
1994; Boie et al. 1997; Breyer et al. 1996; Honda et al. 1993). The sequence 
homology between the rat, mouse and human EP4 receptors has been reported to 
be 89 % (Boie et al. 1997) and the receptor is expressed in tissues such as small 
intestines, lung, kidney, spleen, adrenal glands and thymus (Bastien et al. 1994; 
Breyer et al. 1996; Honda et al. 1993). Although EP4 and EP2 receptors are 
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coupled to Gs, they differ quite markedly in their homology and length of the C-
terminal tail. The EP4 receptor has a much longer C-terminus compared to the EP2 
receptor and in mouse studies it has been suggested that this could be responsible 
for the rapid agonist-induced desensitisation of the EP4 receptor compared to the 
EP2 receptor (Nishigaki et al. 1996). 
 
At the EP4 receptor, PGE2 has the highest affinity of the prostanoid agonists. 
However PGE2 is not selective for the EP4 receptor as it also has high affinity for 
the other EP receptors. The EP4 receptor can be distinguished from the EP1 and 
EP3 by its insensitivity to sulprostone and from the EP2 receptor by its 
insensitivity to butaprost (Boie et al. 1997; Kiriyama et al. 1997). Although not 
commercially available, ONO Pharmaceuticals have developed a highly selective 
EP4 agonist, ONO-AE1-329 (Yamamoto et al. 1999) and an EP4 receptor 
antagonist, ONO-AE3-208 (Kabashima et al. 2002). In addition, a selective EP4 
receptor antagonist, GW627368X, has recently been described (Wilson et al. 
2006). 
 
As mentioned previously, the EP4 receptor is involved in facilitating the closure of 
the ductus arteriosus during development (Segi et al. 1998) and has been shown to 
play a role in arthritic inflammation (Honda et al. 2006). In the lung, as with the 
EP2 receptor, the EP4 receptor has been shown to mediate anti-inflammatory 
effects in a range of cell based assays (Clarke et al. 2004; Okano et al. 2006; 
Ratcliffe et al. 2007; Takayama et al. 2002) which will be discussed later in the 
context of airway inflammatory diseases.  
 
1.1.3.6. FP receptor 
 
The human FP receptor consists of an amino acid sequence of 359 residues 
(Abramovitz et al. 1994) and has also been cloned in the mouse, cow, rat and 
sheep (Kitanaka et al. 1994; Pierce et al. 1997; Sakamoto et al. 1994; Sugimoto et 
al. 1994a). Two splice variants of the FP receptor have been identified in the 
sheep FP receptor; FPA and FPB with the FPA variant C terminal region sharing 
significant homology with the human FP receptor (Pierce et al. 1997). The FP 
 28 
receptor signals through the G-protein Gq (Ito et al. 1994) and is expressed in 
tissues including the kidneys, uterus and placenta (Abramovitz et al. 1994). 
 
The FP receptor is generally associated with luteolysis and uterine contraction. 
Mice deficient in the FP receptor show high progesterone levels in late pregnancy 
compared to wild type mice. This has been shown to cause the impaired 
parturition associated with FP receptor KO mice (Sugimoto et al. 1997). PGF2α 
also has a role in renal function (Breyer & Breyer 2001) and regulating intraocular 
pressure (Camras et al. 1989) and therefore PGF2α analogues are clinically used in 
the treatment of ocular hypertension and glaucoma (Alexander et al. 2002).   
 
The prostanoid PGF2α is most potent at the FP receptor however this receptor is 
the least specific of the prostanoid receptors as it is able to bind both PGD2 and 
PGE2 at nanomolar concentrations (Abramovitz et al. 2000). Furthermore, PGF2α 
does not exhibit a high degree of selectivity for its receptor as PGF2α is also able 
to bind to the EP1 and EP3 receptors with high affinity (Breyer et al. 2001). 
AL8810, an antagonist at the FP receptor was identified by Griffin et al. in 1999 
and is commonly used as a pharmacological tool for the FP receptor (Griffin et al. 
1999). 
 
1.1.3.7. IP receptor 
 
The human IP receptor consists of a sequence of 386 amino acids highly 
expressed in the heart, aorta, lungs, kidney and liver (Boie et al. 1994; Katsuyama 
et al. 1994; Nakagawa et al. 1994). The IP receptor has also been cloned in the 
mouse and is expressed in tissues such as the heart, thymus and spleen (Namba et 
al. 1994). The IP receptor couples to the stimulatory G-protein Gs in most tissues 
which leads to an increase in cAMP (Boie et al. 1994; Katsuyama et al. 1994; 
Nakagawa et al. 1994) however the receptor is also capable of coupling to other 
signalling pathways such as Gi and Gq (Hebert et al. 1998; Katsuyama et al. 1994; 
Namba et al. 1994; Schwaner et al. 1995).  
 
Due to its chemical instability, PGI2 has little experimental use. Iloprost, a 
synthetic IP agonist, is more commonly used experimentally, however this 
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compound also exhibits activity at the EP1 receptor and has a low affinity for the 
EP3 receptor (Abramovitz et al. 2000; Boie et al. 1994). Until recently, selective 
antagonists at the IP receptor were not available which limited the investigations 
into the role of the IP receptor both in vivo and in vitro. A series of selective IP 
receptor antagonists have now been developed; RO1138452 and RO3244794 
(Bley et al. 2005). 
The IP receptor and its prostanoid PGI2 are involved in vascular homeostasis and 
PGI2 is a potent vasodilator and antithrombotic agent (Vane & Botting 1995). 
PGI2 is also involved in mediating oedema and pain accompanying acute 
inflammation (Murata et al. 1997; Ueno et al. 2000). It has been suggested that 
the IP receptor mediates nociceptive pain as the receptor is expressed in dorsal 
root ganglion neurons (Oida et al. 1995). Furthermore, PGE2-IP signalling has 
been implicated in the sensitisation of peripheral sensory nerves (Moriyama et al. 
2005)  More recently, the IP receptor has been shown to play a role in suppressing 
Th2 mediated allergic responses (Nagao et al. 2003; Takahashi et al. 2002) which 
will be discussed later in more detail. 
 
1.1.3.8. TP receptor 
 
The human receptor for TxA2, named TP, was the first eicosanoid receptor to be 
cloned and encodes a protein consisting of 343 amino acids (Hirata et al. 1991). 
Mouse, rat and monkey cDNAs for the TP receptor have also been identified 
(Becker et al. 1998; Hirata et al. 1991; Namba et al. 1992). The human TP 
receptor exists as two alternatively spliced variants; TPα (placental/platelet) and 
TPβ (endothelial) (Raychowdhury et al. 1994; Raychowdhury et al. 1995). 
Despite the isoforms having been named by the tissue/cell they were identified in, 
the mRNAs for each isoform are found in most tissues expressing the TP receptor; 
vascular smooth muscle, platelets, placenta, small intestine, thymus, brain and 
endothelial cells (Hirata et al. 1996; Miggin & Kinsella 1998; Raychowdhury et 
al. 1994). The TP receptor was initially identified as coupling to the G-protein Gq 
leading to an increase in intracellular Ca
2+
 (Shenker et al. 1991) however it is now 
known that the TP receptor can couple to other G-proteins (Becker et al. 1999; 
Offermanns et al. 1994; Walsh et al. 2000). 
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An increase in TxA2 synthesis has been linked to a range of diseases including 
myocardial ischemia, heart failure and renal diseases (Castellani et al. 1997; Oates 
et al. 1988; Spurney et al. 1992). As well as a vast array of cardiovascular effects, 
TxA2 is a stimulant of airway smooth muscle proliferation and is also a potent 
bronchoconstrictor suggesting a role in the pathogenesis of asthma (Devillier & 
Bessard 1997) which will be discussed in more detail later. 
 
As with PGI2, the endogenous ligand at the TP receptor, TxA2, is too unstable to 
be of use experimentally. However there now exist a range of TP agonists (I-BOP 
and U46619) and receptor antagonists (SQ29548, S-145). Ramatroban is also a 
TP receptor antagonist, in clinical use for allergic rhinitis however it is also an 
antagonist of the CRTh2 receptor (Sugimoto et al. 2003).    
 
1.1.3.9. DP receptors  
 
The human DP receptor for PGD2 consists of a polypeptide chain of 359 amino 
acids (Boie et al. 1995) and is expressed at low levels in most tissues. More 
recently, another G-protein coupled receptor has been identified that also binds 
PGD2 and is expressed on Th2 cells, eosinophils and basophils (Hirai et al. 2001). 
This receptor is termed CRTh2 but is also known as DP2 (Boie et al. 1995; Hirai 
et al. 2001). This receptor bears little sequence homology to the DP receptor and 
is more closely related to the other chemoattractant receptors. The DP receptor 
signals predominantly through the G-protein Gs to increase cAMP (Boie et al. 
1995) and the CRTh2 receptor through Gi to inhibit increases in cAMP (Hirai et 
al. 2001). 
 
PGD2, acting through these receptors has been reported to be involved in a range 
of physiological effects such as inhibition of platelet aggregation (Whittle et al. 
1985) and smooth muscle relaxation and contraction (Narumiya & Toda 1985). 
More recently a significant role of the DP and CRTh2 receptors in allergic 
inflammation has evolved (Kostenis & Ulven 2006; Matsuoka et al. 2000) which 
will be discussed in more detail later. 
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PGD2 and the synthetic agonist BW245C are potent agonists at the DP receptor 
however, of these ligands, only PGD2 shares the same potency at the CRTh2 
receptors (Hirai et al. 2001). Furthermore, both of the PGD2 receptors bind the 
PGD2 metabolite, 15d-PGJ2 with equal affinity (Sawyer et al. 2002). BWA868C 
was originally described as a DP receptor antagonist however recent studies have 
suggested that this compound acts as a partial agonist (Liu et al. 1996). The 
antagonist AH6809 mentioned previously is an antagonist at the DP receptor but 
also possesses antagonist activity at the EP1 and EP2 receptors (Abramovitz et al. 
2000). Ramatroban has recently been described as a CRTh2 antagonist however it 
is also a potent TP receptor antagonist (Sugimoto et al. 2003). 
 
The table below summarises prostanoid receptor signalling, expression and 
pharmacology. 
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Receptor 
subtype 
Natural 
ligand 
Agonist Antagonist 
Signalling 
pathway 
Expression 
EP1 
PGE2 
Iloprost, 
sulprostone, 
17-phenyl-
trinor PGE2, 
ONO-DI-004 
SC51322, 
SC51089, 
AH6809, 
GW848687X 
ONO-8711 
Gq? High levels in 
kidney, 
stomach, 
adrenal tissue. 
EP2 
Butaprost, 
AH13205, 
ONO-AE1-259 
AH6809  Gs Low levels in 
uterus, lung, 
spleen. 
EP3 
Sulprostone, 
SC46275,  
ONO-AE-249 
L-826266, 
ONO-AE3-
240 
Gi (also 
possibly 
Gq and Gs) 
High levels in 
many tissues; 
kidney, uterus, 
adrenal gland, 
stomach. 
EP4 
ONO-AE1-329 GW627368X 
ONO-AE3-
208 
Gs Small intestines, 
lung, kidney, 
spleen, adrenal 
gland and thymus 
FP PGF2α 
Fluprostenol AL8810 Gq Kidney, uterus, 
placenta 
IP PGI2 
Iloprost, 
cicaprost 
RO3244794, 
RO1138452 
Gs (also Gi 
and Gq) 
Heart, aorta, lung, 
kidney, liver 
TP TxA2 
I-BOP, U46619 SQ,29548,  
S-145, 
Ramatroban 
Gq 
(isoforms 
can couple 
to other G-
proteins) 
Vascular/airway 
smooth muscle, 
platelets, placenta, 
small intestines, 
thymus, brain, 
endothelial cells 
DP 
PGD2 
BW245C, 
15d-PGJ2 
BWA868C 
(partial 
agonist), 
AH6809 
Gs Low levels in most 
tissues 
CRTh2/ 
DP2 
15d-PGJ2 Ramatroban Gi Th2 cells, 
basophils, 
eosinophils 
 
Table 1.1: Summary of the agonists, antagonists, signalling pathway(s) and 
expression profiles for the prostanoid receptors. 
The table is adapted from (Hata & Breyer 2004) and further summarises the details 
outlined in this section of the thesis. 
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1.2 AIRWAY INFLAMMATORY DISEASES 
 
Chronic inflammation is thought to be central to the pathogenesis of asthma and 
COPD; the two most prevalent airway inflammatory diseases. In 2003, an estimated 
130 million people worldwide were suffering with asthma (Cleland et al. 2003), and 
in the UK alone, around 1200 people per year die from the disease (Asthma UK, 
2009). Chronic asthma causes significant mortality and morbidity in Western societies 
and costs the UK healthcare system more than £2 billion per annum. Furthermore, 
only 10 % of asthmatic patients account for 50 % of this cost (Kochanek et al. 2004). 
COPD and bronchial asthma represent a major problem for world public health as 
they are the 4
th
 leading cause of death in the world after heart disease, cancer and 
stroke (Minino et al. 2007). This is expected to rise and it is predicted that chronic 
airway inflammatory diseases will be the 3
rd
 leading cause of death by 2020 (Lopez et 
al. 2006). 
 
1.2.1. Asthma 
 
Asthma is triggered by a diverse range of factors including viral infection, allergen 
and irritant exposure and exercise. Clinically, asthma is diagnosed by chest tightness, 
wheezing, dyspnoea and cough and these symptoms occur most frequently in the 
early morning and at night (Caramori & Adcock 2003). Allergen exposure is one of 
the most common precipitants of the symptoms of asthma. The atopic individual is 
exposed to the allergen, sensitising the immune system, which leads to the production 
of allergen-specific Immunoglobulin E (IgE). Subsequent exposure to the allergen can 
then produce an asthmatic response characterised by intermittent airflow obstruction, 
which is partially reversible, caused by bronchoconstriction, inflammation and airway 
hyperresponsiveness (Busse & Lemanske, Jr. 2001).  
 
1.2.1.1. Early and late phase reactions 
 
The early phase reaction in asthma, termed the early asthmatic response (EAR) is 
initiated by the presence of allergens in the airways leading to an IgE-mediated 
decrease in airflow. This is characterised by the activation of airway mast cells (Liu et 
al. 1991; Murray et al. 1985) and macrophages (Calhoun et al. 1992; Tonnel et al. 
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1983) expressing the high affinity receptor for IgE, FcεR1. These cells then release 
mediators of smooth muscle contraction such as histamine (Jarjour et al. 1997) and 
eicosanoids (Wenzel et al. 1989) which cause contraction of airway smooth muscle 
and bronchoconstriction, mucus secretion and vasodilatation, all contributing to 
airflow obstruction. 
 
The immediate EAR is often followed by a late-phase reaction termed the late 
asthmatic response (LAR) occurring at 6-9 hours after the initial allergen challenge 
(Bousquet et al. 2000). The late phase involves the recruitment and activation of a 
range of inflammatory cells including eosinophils, basophils, neutrophils, CD4
+
 T 
cells and macrophages (Calhoun et al. 1993; De Monchy et al. 1985; Guo et al. 1994; 
Koh et al. 1993; Montefort et al. 1994; Robinson et al. 1993). The recruitment of 
these cells is controlled by the expression of adhesion molecules on their surface 
(Lassalle et al. 1993) and by the mediator and cytokine release from mast cells in the 
early phase (Smith et al. 1992; Zangrilli et al. 1995). These cytokines include 
Interleukin (IL)-1β, Tumour Necrosis Factor (TNF)-α, IL-8 and granulocyte-
macrophage colony-stimulating factor (GM-CSF) which have been found in tissue 
from asthmatic patients (Broide et al. 1992; Mattoli et al. 1991). Furthermore, T 
helper Type 2 (Th2) cells, which are formed from the CD4
+
 cells, produced additional 
cytokines including IL-4, IL-5 and IL-13. These cytokines, more specific to an asthma 
phenotype, are thought to be involved in increasing eosinophilia, mucus cell 
metaplasia and mucus hypersecretion (Barnes 2001; Brusselle et al. 1994; Gavett et 
al. 1997; Rothenberg et al. 1997; Shakoory et al. 2004). 
 
1.2.1.2. Airway Hyperresponsiveness 
 
The term airway hyperresponsiveness (AHR) describes asthmatics that are more 
sensitive than non-asthmatics to a range of stimuli including pollution, allergens, cold 
air and fog, and to spasmogens including methacholine and histamine (Spina & Page 
2002). AHR is not completely understood although several mechanisms have been 
proposed. It has been suggested that an increase in cytokines, inflammatory cells and 
IgE in the airways leads to hyperresponsiveness in smooth muscle cells thereby 
causing bronchoconstriction (Schmidt & Rabe 2000).  Alternatively, it has been 
suggested that an increase in responsiveness of airway sensory nerves may contribute 
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to AHR as drugs that modulate sensory nerves can also affect bronchoconstriction to 
these agents in vivo (Spina et al. 1998). However, it should be remembered that 
several neurokinin receptor antagonists, have failed in clinical trials, which although it 
does not rule out a contribution for sensory nerves completely, does indicate that local 
axon reflexes may not be important in man (Kraan et al. 2001; Boot et al. 2007). 
Structural changes (remodelling) such as an increased thickness of airway smooth 
muscle layer, resulting from an increase in size (hypertrophy) and number 
(hyperplasia) of smooth muscle cells, hyperplasia of goblet (mucus secreting) cells 
and fibrosis may also contribute to AHR. 
 
1.2.2. COPD 
 
1.2.2.1. Pathology of COPD 
 
COPD is a term used to encompass both chronic obstructive bronchitis and 
emphysema, where the airflow limitation is not fully reversible and usually worsens 
progressively (Rabe et al. 2007). In comparison, the airflow obstruction in asthma is 
usually partially or completely reversible. Pathologically, COPD comprises 
pulmonary emphysema (destruction of the lung parenchyma), respiratory bronchiolitis 
(inflammation of peripheral airways) and inflammation of the central airways 
(Caramori & Adcock 2003; Hogg et al. 1968; Hogg et al. 2004). These disease states 
lead to physiological changes including mucus hypersecretion, gas exchange 
abnormalities, ciliary dysfunction and pulmonary hypertension. Some papers 
hypothesise that mucus hypersecretion causes the first signs of COPD, chronic cough, 
which can be present years before the development of other symptoms (Barnes et al. 
2003). 
 
1.2.2.2. Causes and diagnosis of COPD 
 
Although smoking is a major risk factor in COPD with over 90 % of patients in the 
developed world being smokers, only around 10-20 % of those that smoke develop 
the disease. There are other factors such as occupational risk factors and air pollution 
that are thought to also play a role (Rabe et al. 2007). Diagnosis of COPD is made if 
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the forced expiratory volume (FEV1) to forced vital capacity (FVC) ratio is less than 
70 % (Cazzola et al. 2007). 
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1.3. CURRENT THERAPIES FOR AIRWAY INFLAMMATORY DISEASES 
 
1.3.1. Asthma 
 
Currently, the majority of patients with asthma can be treated with bronchodilators 
and anti-inflammatory agents. Short acting β2-adrenoceptor agonists (e.g. salbutamol) 
are generally used for rescue therapy and longer acting β2-adrenoceptor agonists, 
salmeterol and formoterol, are used to treat symptoms prophylactically. They relax the 
airway smooth muscle thereby leading to bronchodilation. However, these 
bronchodilators have limited anti-inflammatory effects and often fail to relieve 
symptoms of severe asthma (Barnes & Stockley 2005). Recent studies have raised 
concerns over long term use of long acting β2-adrenoceptor agonists as the SMART 
(Salmeterol Multi-centre Asthma Research Trial) study was prematurely halted as 
preliminary data suggested an increased mortality associated with long term use of 
salmeterol. This study therefore prompted the US Food and Drug Administration to 
advise on re-labelling the drug to highlight a “small but significant increase of 
asthma-related death” (Currie et al. 2006). 
 
Glucocorticoids are potent anti-inflammatory agents that influence cells and mediators 
of inflammation in asthma such as mast cells, T-lymphocytes, macrophages and 
eosinophils (Caramori & Adcock 2003). There are however, concerns over the use of 
inhaled corticosteroids as they can lead to long term side effects such as osteoporosis 
and stunted growth (Barnes 2006). 
 
Combination treatment with long acting β2-agonists and glucocorticoids is not 
effective in all patients as approximately 5 % do not respond to therapy (Heaney & 
Robinson 2005; Wenzel 2005). This small percentage however, accounts for a 
significant proportion of the health care costs for treating asthma as they are 
frequently admitted to hospital and take several medications (Barnes 2006). These 
factors therefore represent an unmet clinical need which require novel alternative 
therapeutic targets to treat asthma. 
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1.3.2. COPD  
 
Although smoking is a major risk factor for COPD, smoking cessation strategies have 
a poor success rate. As a patient with COPD becomes more severely affected, 
smoking cessation has a minimal effect on the progression of the disease and it has 
been suggested that smoking cessation fails to reverse the chronic airway 
inflammation (Scanlon et al. 2000; Willemse et al. 2005).  
 
Bronchodilators, also used in asthma therapy, are currently used to treat COPD. The 
bronchodilators can be used on a regular basis to prevent and reduce the symptoms of 
the disease. Commonly used classes of bronchodilators include β-agonists, anti-
cholinergics, and methylxanthines. Although they alleviate the symptoms and lead to 
a reduction in the severity, length and frequency of exacerbation, bronchodilators 
have little effect on the underlying disease progression (Barnes 2000; Barnes 2007; 
Pauwels et al. 2001). 
 
Although anti-inflammatory drugs such as corticosteroids can be beneficial in asthma, 
they are less effective in COPD. Treatment of acute exacerbations of COPD with 
corticosteroids has been shown to relieve the symptoms; however prolonged treatment 
does not modify the progression of the disease and the decline in FEV1 in COPD 
patients (Pauwels et al. 1999; Vestbo et al. 1999). As with asthma, there is a growing 
need to develop novel, safe and effective therapies for the treatment of COPD.  
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1.4. ROLE OF PROSTANOIDS IN AIRWAY INFLAMMATORY DISEASES 
 
A wealth of literature surrounds the role of prostanoids in airway inflammatory 
diseases and it appears that a fine balance exists between the pro-inflammatory and 
anti-inflammatory effects of these endogenous mediators. NSAIDs are now known to 
exert their effects via inhibition of the COX enzymes and thus the production of 
prostanoids. As mentioned previously, prostanoids and their receptors mediate fever 
(Ushikubi et al. 1998), oedema and pain (Murata et al. 1997; Ueno et al. 2000), 
hyperalgesia (Moriyama et al. 2005; Ueno et al. 2001) and arthritic inflammation 
(Honda et al. 2006) which can be treated with aspirin. However, in airway 
inflammatory diseases such as asthma, NSAIDs are contra-indicated and in a subset of 
asthmatic patients aspirin, or other non-selective NSAIDs, can induce 
bronchoconstriction and acute asthma (Kowalski 2007).  
 
The mechanism of aspirin-induced asthma remains controversial. Some researchers 
suggest that by inhibiting COX and the production of prostanoids, a higher proportion 
of arachidonic acid (the precursor) is shunted into the leukotriene pathway, making 
more arachidonic acid available to the enzyme 5-lipoxygenase (5-LO). This therefore 
results in an increase in the production of the bronchoconstrictor agents, leukotrienes. 
Studies have shown that Leukotriene E4 (LTE4) is increased in urine of asthmatic 
patients after aspirin challenge (Christie et al. 1991) and anti-leukotrienes have been 
implicated in the treatment of aspirin-sensitive asthma (Dahlen 2000). However 
lipoxygenase products are not increased in blood from aspirin sensitive asthmatic 
patients (Gray et al. 2002) and furthermore aspirin-tolerant patients do not have an 
increase in leukotrienes when the COX pathway is inhibited (Dahlen & Dahlen 1995). 
An alternative hypothesis has also been proposed by Mitchell & Belvisi suggesting 
that in aspirin-sensitive patients COX-2 predominates which is modified 
biochemically by aspirin (Mitchell & Belvisi 1997). This has been supported by a 
study by Holtzman et al illustrating that aspirin modifies products formed by purified 
COX-2 (Holtzman et al. 1992). The normal production of prostanoids is therefore 
altered and thus facilitates the production of 5-LO products via COX-2. It has been 
shown that endothelial cells expressing COX-2 produced 15-HETE in the presence of 
aspirin. This was then metabolised by 5-LO forming a group of metabolites known as 
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the 15-epilipoxins (Claria & Serhan 1995). However, it is unclear what effect these 
15-epilipoxins have on airway function.  
 
In addition to these two hypotheses proposed above, it could also be suggested that 
prostanoids have a protective role in the airways and prevent the release of mediators 
from airway cells (Clarke et al. 2004; Kay et al. 2006; Pavord & Tattersfield 1995). 
By inhibiting the production of prostanoids, the protective effect is removed and 
asthmatic symptoms exacerbated. It has been shown that COX-2 selective drugs are 
safe for aspirin sensitive asthmatics (Gyllfors et al. 2003; Martin-Garcia et al. 2003; 
Stevenson & Simon 2001; Woessner et al. 2002), which has been supported more 
recently by research suggesting that COX-1 and not COX-2 regulates airway 
contractile function. This would support the previous evidence that inhibition of 
COX-2 does not induce aspirin sensitive asthma and that the adverse effect of aspirin 
in asthmatics is mediated by COX-1 (Harrington et al. 2008).   
 
Despite conflicting theories as to the mechanism of aspirin-sensitive asthma, the fact 
that inhibiting the production of prostanoids can lead to bronchoconstriction and acute 
asthma suggests a role for prostanoids in the control of airway smooth muscle. It is 
clear that prostanoids and prostanoid receptors have important functions in both the 
control of airway smooth muscle contraction/relaxation and inflammation. The 
section below will discuss the bronchoprotective/bronchoconstrictor effects of 
prostanoids as well as the pro- and anti-inflammatory effects. 
 
1.4.1. The control of airway smooth muscle by prostanoids and prostanoid 
receptors 
 
One of the first studies looking at the bronchodilator effects of inhaled prostanoids 
was investigated by Kawakami and colleagues and revealed that in a range of patients 
(normal, asthmatic and chronic bronchitis) PGE2 had a bronchodilator effect 
(Kawakami et al. 1973). Using in vitro preparations of human airways, it has been 
shown that the concentration-response curves to PGE2 were biphasic; relaxing smooth 
muscle at lower concentrations and contracting the muscle at higher concentrations. 
Furthermore, this study also revealed that PGF2α, (FP agonist) 16-16-dimethyl PGE2 
(EP1 agonist) sulprostone (EP1/EP3 agonist) and U46619 (TP agonist) contracted the 
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airway smooth muscle. This contraction was antagonised by a TP receptor antagonist 
suggesting that the contractile response to prostanoids is via the TP receptor (Armour 
et al. 1989; Coleman & Sheldrick 1989). In addition, airway contraction to PGD2 has 
also been shown to be mediated via the TP receptor (Coleman & Sheldrick 1989). In 
further studies, PGE2 has inhibited histamine-induced contraction of human bronchi 
in a dose-dependent manner (Knight et al. 1995). Studies characterising the different 
prostanoid receptors involved in the relaxation of human bronchial preparations 
suggest that IP, EP2 and DP receptors are involved (Norel et al. 1999). This study 
showed that PGE2, misoprostol (EP2 agonist) and PGI2 analogues totally reversed the 
histamine-induced contraction where as agonists at the DP receptor (PGD2 or 
BW245C) only partially reversed this contraction. The PGE2 effect could be 
attenuated by AH6809 (EP1, EP2, DP antagonist) but not by a selective EP4 antagonist 
(Norel et al. 1999). A range of prostanoid receptors have been implicated in the 
contractile responses to PGE2 and more selective agonists and antagonists may be 
required to identify the receptors involved.    
 
Studies using guinea-pig tracheal strips have revealed that PGE2 has the opposite 
effects in guinea-pig compared to human smooth muscle and causes contraction at 
lower concentrations and relaxation at higher concentrations. However, despite these 
contrasting effects, in line with findings in human tissues, the EP1 and TP receptors 
have been implicated in the mediation of prostanoid-induced contraction of the 
guinea-pig trachea (Coleman & Kennedy 1985; Francis et al. 1991; McKenniff et al. 
1988). A bronchoprotective effect of PGE2 has also been observed in animal models. 
One study has shown that increasing the levels of endogenous PGE2, by knocking out 
the gene controlling the catabolic enzyme for PGE2, decreased airway responsiveness 
in mice (Hartney et al. 2006). Using animal models it has been suggested that the EP1 
receptor is responsible for the bronchoconstriction and EP2 receptor is responsible for 
the relaxation of airway smooth muscle. It has been illustrated using EP1, EP2, EP3 
and EP4 KO mice that in EP1 or EP3 receptor KO mice the increase in Penh (an 
indirect measure of airway constriction) to PGE2 is reduced.  Furthermore, although 
PGE2 alone increases Penh, PGE2 protects against methacholine-induced constriction. 
In EP2 KO mice this protection is lost suggesting that the EP2 receptor is involved in 
bronchodilation (Sheller et al. 2000; Tilley et al. 2003). In parallel, Fortner et al. have 
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shown that PGE2 causes relaxation in wild type mice and in EP2 KO mice the relaxant 
effect is significantly decreased (Fortner et al. 2001). 
 
The receptors responsible for PGE2-induced relaxation and contraction of airway 
smooth muscle have been previously investigated as described in this section. 
However, much of the work was carried out with agonists and antagonists that are not 
particularly selective and little or no research investigating the receptor involved in 
the relaxation in guinea-pigs has been carried out. More recently, selective ligands 
have been developed for prostanoid receptors as described in section 1.1 and the use 
of these selective compounds would enable researchers to further dissect out the 
receptors involved. The development of prostanoid receptor KO mice has benefited 
this area of research however it is unknown whether different receptors may be 
involved in different species and furthermore, knocking out one prostanoid receptor 
could possibly impact on the functionality or expression of another receptor. In 
addition, the receptors involved in the control of airway smooth muscle in the disease 
state compared to normal may be different. It has been indicated in a study by Tanaka 
et al. that the EP2 and EP4 receptors are involved in the inhibition of ovalbumin-
induced bronchoconstriction. ONO-AE1-259 (EP2 agonist) and ONO-AE1-329 (EP4 
agonist) mimicked the inhibition of ovalbumin-induced bronchoconstriction observed 
with PGE2 (EP1-4 agonist) (Tanaka et al. 2005). However, further studies would be 
needed to support these initial findings to confirm the role of PGE2 in the control of 
airway smooth muscle. 
 
1.4.2. The control of airway inflammation by prostanoids and prostanoid 
receptors 
 
As described above complete blockade of prostanoids is contra-indicated as this can 
induced symptoms of asthma suggesting that prostanoids possess both detrimental and 
beneficial effects. This section will discuss the pro and anti-inflammatory roles of 
prostanoids and their receptors. 
 
PGD2 has been implicated in airway inflammatory diseases for many years. In 1985, 
PGD2 was shown to be released during acute allergic bronchospasm in man (Murray 
et al. 1985; Murray et al. 1986) and subsequently, it was illustrated that inhalation of 
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aerosolised PGD2 enhanced eosinophilic and lymphocytic airway inflammation in 
mice following allergen challenge (Honda et al. 2003). Furthermore, PGD2 enhances 
leukotriene C4 (LTC4) synthesis by eosinophils during allergic inflammation in vivo 
(Mesquita-Santos et al. 2006). PGD2 has been shown to exert pro-inflammatory 
effects via the CRTh2 receptor by stimulating chemotaxis of eosinophils (Almishri et 
al. 2005; Gervais et al. 2001; Hirai et al. 2001; Monneret et al. 2001; Shiraishi et al. 
2005; Sugimoto et al. 2003), Th2 cells (Honda et al. 2003; Xue et al. 2005) and 
basophils (Hirai et al. 2001; Yoshimura-Uchiyama et al. 2004). Additionally, PGD2 
also mediates some pro-inflammatory effects in the airways via the DP receptor. An 
increase in ovalbumin-induced airway inflammation was observed in wild types 
compared to DP -/- mice (Matsuoka et al. 2000). In addition, PGD2 has been shown to 
mediate inhibition of eosinophil apoptosis via the DP receptor (Gervais et al. 2001). 
In genetic studies in man polymorphisms in the gene encoding the DP receptor have 
been linked to susceptibility to asthma (Oguma et al. 2004; Sanz et al. 2006; Zhu et 
al. 2007). 
 
In contrast to the pro-inflammatory evidence above a small number of studies have 
shown that PGD2 possesses anti-inflammatory properties via the DP receptor and has 
been shown to inhibit activation/migration of eosinophils, basophils, dendritic cells 
and fibroblasts (Angeli et al. 2004; Gervais et al. 2001; Hammad et al. 2003; Hirai et 
al. 2001; Monneret et al. 2001; Yoshimura-Uchiyama et al. 2004). 
 
Although the majority of the studies above suggest that PGD2 is pro-inflammatory in 
the airways, the fact that NSAIDs are not effective treatments for asthma would 
suggest that other prostanoids are having beneficial effects which mask the PGD2 
driven component. For example, the activation of the IP receptor by its endogenous 
prostanoid PGI2 has been shown to inhibit inflammation. In a study by Takahashi et 
al., IP receptor deficient mice demonstrated an increased allergic response in the 
airways (Takahashi et al. 2002). Furthermore, in a more recent study, PGI2-IP 
signalling has been shown to be anti-inflammatory by inhibiting the recruitment of 
Th2 cells to the airways (Jaffar et al. 2007). In addition, Nagao et al. suggested that 
PGI2 plays an inhibitory role in the development of allergen-induced airway 
remodelling and moreover, PGI2 has also been shown to have an inhibitory role on 
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IgE production, Th2 cytokine production and inflammatory infiltrates associated with 
allergic asthma (Nagao et al. 2003). 
 
The prostanoid PGE2 has received the most interest in relation to inflammatory 
diseases. It is commonly considered to be a pro-inflammatory mediator involved in 
the pathogenesis of several inflammatory disease states including UVB-mediated 
cutaneous inflammation and rheumatoid arthritis (McCoy et al. 2002; Wilgus et al. 
2002). In such diseases, there is a correlation between disease progression and levels 
of PGE2 in the tissue and furthermore, COX inhibitors can reduce the progression of 
the disease. In contrast to these inflammatory diseases, PGE2 in the lung is normally 
much higher than in plasma and evidence suggests that increased levels of PGE2 in 
the lung may be therapeutically beneficial (Vancheri et al. 2004). 
 
Using a range of cell based assays, researchers have shown that PGE2 possesses a 
range of anti-inflammatory properties and suggest that these effects may be mediated 
via the EP2 and/or the EP4 receptor. A study by Kay et al. revealed that PGE2 inhibits 
mast cell degranulation via the EP2 receptor (Kay et al. 2006). Furthermore, PGE2 has 
been shown to inhibit the release of various cytokines and chemokines from human 
airway smooth muscle cells and macrophages via the EP2/EP4 receptors (Clarke et al. 
2004; Ratcliffe et al. 2007; Takayama et al. 2002). In fibroblasts, PGE2 inhibits 
collagen proliferation and protects against cigarette-induced apoptosis via the EP2 
receptor (Huang et al. 2007; Sugiura et al. 2007). Additionally, PGE2 suppresses Th1 
and Th2 polarization via the EP2 and/or EP4 receptors (Okano et al. 2006). Eosinophil 
trafficking can be inhibited by activation of the EP2 receptor (Sturm et al. 2008). In 
contrast, PGE2 has been shown to act as a chemoattractant for mouse mast cells via 
the EP3 receptor (Weller et al. 2007). The EP3 receptor has also been implicated in 
PGE2-induced degranulation of mast cells, contrary to the anti-inflammatory effects 
described above (Nguyen et al. 2002). 
 
In these cell based assay systems, PGE2 has been shown to be predominantly anti-
inflammatory, exerting its effects via the EP2 and EP4 receptors. The latter study 
showing PGE2 as a chemoattractant would suggest that PGE2 has some pro-
inflammatory properties, but through a different receptor.  
 
 45 
From in vivo models, PGE2 has been shown to be anti-inflammatory in a rat 
ovalbumin model (Martin et al. 2002). In contrast to the data described in cell-based 
assays, Kunikata et al. have shown that the activation of the EP3 receptor suppresses 
inflammation and the EP3 KO mice had an increased inflammatory response 
compared to the wild types (Kunikata et al. 2005). This would suggest that the EP3 
receptor could be involved in the anti-inflammatory effects of PGE2. The majority of 
studies linking PGE2 with an anti-inflammatory effect have been performed in cell-
based assays. As such, the limited numbers of in vivo studies suggest that more 
research would be needed to further investigate the receptors involved in the anti-
inflammatory effects of PGE2. As described earlier, the improved range of 
pharmacologically selective agonists and antagonists that are now available will 
enable the researcher to dissect further the receptors involve in these processes.  
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1.5. PROSTANOIDS AS A THERAPY FOR AIRWAY INFLAMMATORY 
DISEASES 
 
Despite discrepancies as to the receptors responsible for the bronchodilator and anti-
inflammatory effects of PGE2, there is clear evidence that PGE2 is beneficial to the 
lungs. In addition to the in vitro and in vivo studies described above, the beneficial 
potential of PGE2 as a therapy has long been recognised. In 1973, Kawakami et al. 
showed that inhaled PGE2 was a bronchodilator in normal subjects and in patients 
with asthma and chronic bronchitis (Kawakami et al. 1973). This was supported in 
subsequent studies showing that inhaled PGE2 could act as a bronchodilator agent in 
both normal subjects (Walters et al. 1982) and in exercise induced asthmatics (Melillo 
et al. 1994). In addition to the bronchodilator effects, PGE2 has been shown to 
attenuate an allergen-induced fall in FEV1, methacholine-induced airway 
hyperresponsiveness and increases in sputum eosinophils (Gauvreau et al. 1999; 
Pavord et al. 1993). 
 
Despite the benefits of inhaled PGE2 described in the previous section, the 
development of prostanoid agonists for the treatment of airway inflammatory diseases 
has been hindered as prostanoids induce irritancy of the upper airway resulting in a 
reflex cough. PGE2 has been shown to excite airway afferent nerves (Coleridge et al. 
1976; Mohammed et al. 1993) which concurs with the transient cough observed in 
both normal and asthmatic patients during studies of inhaled PGE2 (Costello et al. 
1985; Gauvreau et al. 1999; Kawakami et al. 1973; Melillo et al. 1994; Pavord et al. 
1993). If the receptor responsible for the sensory irritant effects of PGE2 could be 
identified, a therapy could be developed that is anti-inflammatory and a 
bronchodilator but devoid of cough as a side effect. The following section will give a 
general overview of cough and the cough reflex and outline how prostanoids can 
modulate the cough reflex.  
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1.6. COUGH AND SENSORY NERVES 
 
1.6.1. The cough reflex 
 
The cough reflex is a vital defence mechanism to remove or expel foreign materials 
and excess secretions from the airways. In addition to the protective function, cough 
can also occur as an unwanted side effect of airway diseases (Irwin & Madison 2000; 
Morice et al. 2004) or as a result of pharmacological activation of airway sensory 
nerves. 
 
Cough can be initiated by a range of irritants including dust, cigarette smoke (Bergren 
2001; Joad et al. 2007; Salo et al. 2004), chemical fumes, a change in osmolarity of 
the airway surface (Joad et al. 2007; Koskela et al. 2005), airway obstruction or 
mechanical irritation (Canning et al. 2004). Cough can also be initiated in animals and 
humans by a wide variety of pharmacological stimuli such as capsaicin (Collier & 
Fuller 1984; Trevisani et al. 2004), a low pH solution (for example citric acid) 
(Bickerman & Barach 1954; Lalloo et al. 1995; Usmani et al. 2005), hypertonic saline 
(Gatti et al. 2006; Lalloo et al. 1995; Lowry et al. 1988), bradykinin (Bergren 2001; 
Canning et al. 2004; Fuller & Choudry 1987) and as mentioned above, prostaglandins 
(Costello et al. 1985; Gardiner & Browne 1984; Kawakami et al. 1973). These stimuli 
activate specific receptors on sensory nerves which are located in or under the airway 
epithelium. Stimulation of these receptors activates sensory nerves, carried in the 
vagus nerve, which relays information to the Central Nervous System (CNS), in 
particular to the Nucleus Tractus Solitarius (NTS). Second order neurones relay the 
messages to the respiratory pattern generator which changes the signals to the 
inspiratory and expiratory motor neurons leading to contraction of skeletal respiratory 
muscles and cough (Reynolds et al. 2004). 
 
1.6.2. Introduction to airway sensory nerves 
 
It is widely accepted that cough occurs as a reflex response to activation of airway 
sensory nerves which have their endings located in or under the airway epithelium. 
Sensory afferent nerves represent the most abundant nerve type that innervates the 
guinea-pig airways. The majority of these fibres have their cell bodies in the nodose 
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or jugular vagal nerve ganglia (Riccio et al. 1996a). These ganglia have distinct 
embryological origins; the jugular ganglion is neural crest derived and the nodose 
ganglion is epibrachial placode derived. A small population of fibres innervating the 
lungs originate from spinal afferents with the cell bodies in the dorsal root ganglion 
(Plato et al. 2006).  
 
Airway sensory nerves can be classified in many different ways.  Commonly, they are 
classified by the functionality i.e. by the physiological response. However, other 
classifications of subtypes can be based on their origin, location in the airways, 
neurochemistry, type of reflex evoked or their electrophysiological properties.  
 
The cough reflex is under the control of at least two classes of sensory afferent nerve 
fibres that innervate the lungs via the vagus nerve. These include the myelinated, 
rapidly adapting receptors (RARs or Aδ fibres) and the nonmyelinated C-fibres with 
bronchial or pulmonary endings (Coleridge & Coleridge, 1984; Sant‟ Ambrogio, 
1987; Lalloo et al., 1995).  
  
C-fibres are a group of nerves contributing to a large proportion of the nerve endings 
seen in the airway epithelium and are chemosensitive especially to capsaicin. They are 
defined as small afferent nerves with unmyelinated axons and conduct action 
potentials at relatively low velocities (0.1-2m/s) (Canning et al. 2006a; Fox et al. 
1993; Mazzone 2005; Riccio et al. 1996a). A-fibres are larger myelinated axons and 
conduct action potentials at relatively higher velocities (3-50m/s).These nerves can be 
broadly classified into low threshold mechanosensors (which respond to light touch 
but are often less sensitive to chemical stimuli) and chemosensors/nociceptors (which 
are sensitive to stimuli such as citric acid or capsaicin but require more mechanical 
force to cause firing) (Coleridge & Coleridge 1984; Riccio et al. 1996a; Undem et al. 
2004). 
 
There are two classic types of low threshold mechanosensors; rapidly adapting 
receptors (RARs) and slowly adapting receptors (SARs). RARs and SARs both 
originate in the nodose ganglia and conduct action potentials rapidly thereby 
classifying both types as A-fibres (Mazzone 2005).  RARs may be classified as 
„irritant receptors‟ and are sensory receptors that adapt to a maintained mechanical 
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stimulus, undergoing bursts of irregular activity. They are located throughout the lung 
but are mainly concentrated in the larger airways, decreasing towards the smaller 
airways (Belvisi, 2003). A third type of low threshold mechanosensor has been 
recently described in the guinea-pig airways which originate from the nodose and 
project fibres primarily to the extrapulmonary airways; larynx, trachea and large 
bronchi. These fibres are A-fibres but conduct action potentials at a lower velocity 
than the RARs (Aδ range ~5 m/s) (Canning et al. 2004) and do not express the 
capsaicin receptor TRPV1 (Transient receptor potential cation channel, subfamily V, 
member 1) (Mazzone 2004; Riccio et al. 1996a).  
 
Chemosensors, or nociceptors, are often defined as C-fibres that are sensitive to 
capsaicin however there are exceptions in that some C-fibres are capsaicin-insensitive 
(Kollarik et al. 2003). Conversely, a small population of fibres that are sensitive to 
capsaicin can conduct action potentials in the Aδ-fibre range (Kajekar et al. 1999). 
However, C-fibres can be distinguished from other airway afferent nerves as they 
synthesise and release neuropeptides (Hunter & Undem 1999). Additionally, C-fibres 
can be subdivided by their ganglionic origin and sites of termination in the airways. 
Jugular C-fibres innervate both intra and extra pulmonary C-fibres where as nodose 
C-fibres are almost exclusively innervating the intrapulmonary airways (Canning et 
al. 2006b). 
 
1.6.3. Airway sensory nerves and the cough reflex 
 
It is currently debated as to which airway sensory nerves mediate the cough reflex, 
though it is likely that all sensory nerves innervating the lung contribute to some 
degree. Differences in experimental set-up, species investigated and conscious or 
anaesthetised subjects all contribute to the debate (Mazzone 2005). 
 
The TRPV1 receptor is expressed on C-fibres and Aδ-fibres (Kollarik & Undem 
2004; Undem et al., 2004; Watanabe et al., 2006) and it is widely proposed that these 
capsaicin-sensitive chemosensors are involved in the cough reflex. Furthermore, 
activators of these fibres are potent tussive stimuli; capsaicin, resiniferatoxin, 
bradykinin and citric acid (Choudry et al. 1989; Forsberg & Karlsson 1986; Laude et 
al. 1993). Arguments against a primary role for C-fibres in cough stem from studies in 
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anaesthetised animals. Despite the definite tussive response of capsaicin in conscious 
animals and the fact that cough can be initiated in anaesthetised animals via 
mechanical probing, electrical stimulation or exposure to acid (Canning et al. 2004; 
Canning et al. 2006a; Tatar et al. 1994), it still remains to be demonstrated that 
capsaicin induces cough in anaesthetised animals.  
 
RARs were originally believed to play a key role in the cough reflex however much of 
this early work originated from studies in anaesthetised animals (Tatar et al. 1988; 
Tatar et al. 1994). Stimuli thought to activate RARs, such as LTC4 and LTD4, 
histamine and neuropeptides have been ineffective in conscious studies (Barnes et al. 
1984; Canning et al. 2004; Joos et al. 1987). It could therefore be suggested that a 
sub-set of RARs mediate the cough reflex, or perhaps more than one pathway is 
required to synergistically initiate cough (Mazzone 2004). Studies in guinea-pigs have 
shown that bronchodilators may inhibit capsaicin and bradykinin-induced activation 
of RARs suggesting that activation of C-fibres, which causes bronchoconstriction, 
may stimulate mechanosensitive RARs (Bergren 1997). SARs are not thought to be 
involved in the cough reflex and cannot be activated by capsaicin, a known tussive 
agent (Ho et al. 2001). 
 
As described above, a third type of low threshold mechanosensor has recently been 
described (Canning et al. 2004) which has been proposed as a “cough receptor”. 
These are distinct from RARs, SARs and C-fibres but are sensitive to mechanical 
stimulation and acid. Their location in the upper airways provides additional support 
for a role in the cough response. These distinct nerve sub-types could be responsible 
for activation of afferent nerves induced by mechanical irritation and acidic conditions 
observed in previous studies (Kollarik & Undem 2002; Riccio et al. 1996a; Wong et 
al. 1999). The cough receptor has been characterised in the guinea-pig, a species that 
possesses a cough response, but is not found in mice and rats which are not thought to 
have a cough reflex (Canning et al. 2004; Mazzone 2005). This interesting finding 
could be key to identifying the afferent nerves responsible for the cough reflex and 
further research is needed to confirm whether this receptor exists in man. 
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1.6.4. Modulation of the cough reflex by prostanoids 
 
I have described above the wealth of literature illustrating that PGE2 can cause cough. 
In addition to directly eliciting cough in subjects, prostanoids can also modulate the 
cough reflex in response to other stimuli. Studies have demonstrated that PGE2 is able 
to sensitise C-fibre endings in peripheral tissue to various chemical and mechanical 
stimuli (Martin et al. 1987; Mense 1981). In human subjects, inhalation of prostanoids 
has been shown to increase the sensitivity of the capsaicin-induced cough reflex 
(Choudry et al. 1989; Ishiura et al. 2007; Stone et al. 1992). Stone et al. showed that 
both PGF2α and PGE2 sensitised the cough reflex to stimulation by capsaicin in man 
(Stone et al. 1992). In a more recent study, Ishiura et al. showed that another 
prostanoid, PGI2, also increased the sensitivity of the cough reflex to capsaicin 
(Ishiura et al. 2007). In a study by Choudry et al. it was illustrated that inhalation of 
PGE2 prior to inhalation of capsaicin enhances the response to capsaicin. This 
suggested that an enhanced cough reflex sensitivity in man could be as a result of 
endogenously produced PGE2 (Choudry et al. 1989). This suggestion is supported by 
a study by Fujimura et al. who illustrated that the cough threshold to capsaicin is 
increased following administration of the COX inhibitor, indomethacin (Fujimura et 
al. 1995). Additionally, it has been shown using an in vivo rat model that PGE2 
sensitises pulmonary C-fibres to chemical (capsaicin, lactic acid, and adenosine) and 
mechanical (lung hyperinflation) stimuli (Ho et al. 2000). In vitro, whole cell voltage 
clamp recordings in cultured rat nodose and jugular sensory neurons have shown that 
pre-treatment with PGE2 amplified the whole cell current induced by capsaicin 
(Kwong & Lee 2002). 
 
It is unclear as to the mechanism of PGE2-induced sensitisation of airway afferent 
nerves and cough. As PGI2, PGF2α and PGE2 all sensitise the cough response to 
capsaicin, it could be suggested that the EP receptor, IP receptor and FP receptor may 
all play a role. Alternatively, as both iloprost (PGI2 analogue) and PGF2α have affinity 
at the EP1 receptor, it could also be hypothesised that the EP1 receptor is involved in 
these effects. Kwong & Lee showed that PGE2 sensitisation of cultured rat nodose and 
jugular sensory neurons is mediated by the EP2 receptor (Kwong & Lee 2002). This 
evidence presumes that butaprost only activates EP2 however it also has affinity for 
the other EP receptors (Boie et al. 1997). Further investigation to identify whether the 
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same receptor is involved in guinea-pig and humans is needed and to identify whether 
the receptor responsible for the cough is the same as the receptor involved in the 
sensitisation of the cough reflex to other stimuli. 
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1.7. IN VIVO AND IN VITRO MODELS OF COUGH 
 
1.7.1. Assessment of cough in man 
 
There are number of methodologies now available to assess cough in the clinic. These 
include cough questionnaires, objective cough monitoring with recently developed 
devices and measurement of cough sensitivity with capsaicin/citric acid challenge.  
 
Cough questionnaires measure the impact of the cough on daily life and score the 
patients social, physical, and psychological state. Cough questionnaires have been 
developed in several clinic across the country including the Leicester Cough 
Questionnaire (Birring et al. 2003) . In addition to questionnaires, there are now 
monitors that record the occurrence and frequency of cough and assess the 
effectiveness of any antitussive therapies prescribed.  A range of technologies have 
been developed by various cough clinics which provide robust, non-invasive and 
unbiased monitoring of the cough response. These include the Manchester Cough 
Diary (Smith 2007), the Vivometrics Lifeshirt (Coyle et al. 2005), the Leicester 
Cough Monitor (Matos et al. 2007) and the Hull Automatic Cough Counter (Barry et 
al. 2006) 
 
In the clinic agents can be assessed for their tussive activity or sensitisation of the 
cough reflex to other stimuli. For example, Costello et al. measured the direct effects 
of an aerosol of PGE2 (Costello et al. 1985), where as Ishiura et al. investigated the 
effects of an aerosol of PGI2 on the sensitivity of the cough reflex to capsaicin (Ishiura 
et al. 2007). Sensitivity of the cough reflex is often measured by the cough threshold, 
determined by the C2 and C5 values. These values are defined as the concentration of 
tussive stimuli that initiate 2 (C2) or 5 (C5) coughs per inhalation (Ishiura et al. 2007; 
Doherty et al. 2000; Kastelik et al. 2002; Singapuri et al. 2008). 
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1.7.2. In vivo models of cough 
 
Cough studies have previously been conducted to investigate physiological and 
pharmacological modulation of the cough reflex and specific neural pathways in 
health and disease. These studies have been conducted in a range of species including 
guinea-pig, cat, dog, rabbits and rodents (Gardiner & Browne 1984; Kamei et al. 
2006; Mutolo et al. 2008; Patel et al. 2003; Tsubouchi et al. 2008). Guinea-pigs are 
the most common species of choice for cough studies and a range of studies have been 
conducted using this species (Belvisi & Hele 2003). A small number of studies have 
been carried out using mice (Kamei et al. 2006; Kamei et al. 2003), however 
researchers remain sceptical as to whether the tussive effects observed in these studies 
represent a cough similar to that in man.  
 
The most common in vivo model of cough involves a conscious guinea-pig being 
placed in a perspex chamber where an aerosol can be delivered directly into the 
chamber and the cough sound amplified by a microphone within the box.   The cough 
response is recorded by the computer and confirmed by observing the characteristic 
opening of the mouth, the stance and posture of the animal, the sound produced and 
the flow recordings (Patel et al. 2003). Previously, cough had to be counted manually 
by a trained observed meaning that one or maybe two animals could be challenged at 
the same time. Recent advances in technology mean that multiple animals can be 
challenged in parallel increasing throughput and minimising bias or operator error 
(Battram et al. 2005). 
 
The use of anaesthetised animals has been described in cats, dogs and guinea-pigs 
(Canning et al. 2004; Canning et al. 2006a; Tatar et al. 1988; Tatar et al. 1994). This 
method allows direct neural response to be assessed within the physiological 
environment in vivo. Stimuli to evoke cough include electrical stimulation, 
mechanical probing or administration of a tussive stimulus and can be identified by 
pressure changes and by direct observations.   
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1.7.3. In vitro measurement of sensory nerve activity 
 
In vitro and ex vivo models of sensory nerve activity represent an effective alternative 
to in vivo experiments as they allow measurement of specific nerve fibres innervating 
the lung. Furthermore, they are often higher throughput and more cost effective as, in 
the case of the isolated whole vagus nerve system, more than one experiment can be 
carried out using tissue from one animal. 
 
The isolated vagus nerve system represents a way of measuring depolarisation in 
response to pharmacological agents in vitro. These tussive agents are applied directly 
to the isolated vagus nerve which has been dissected out of the animals and mounted 
in a grease-gap chamber. Electrodes are placed at both ends and the nerve electrically 
isolated in the centre of the nerve. Stimuli are applied to one end of the nerve and 
depolarisation is recorded (Birrell et al. 2002; Fox et al. 1995). The isolated whole 
vagus nerve preparation has been used in many studies and has been effective in 
showing pharmacological proof of concept before profiling compounds in the in vivo 
cough model. Compounds that are able to inhibit sensory nerve depolarisation in the 
isolated whole vagus preparation have then also been shown to be anti-tussive in vivo 
(Patel et al. 2003; Usmani et al. 2005). Furthermore, an important advantage of the 
isolated whole nerve preparation is that human vagus nerves can be studied and the 
predicted effects of any compound in man can be obtained. The responses to tussive 
stimuli in isolated nerves from humans have been previously shown to represent the 
effects observed in the clinic (Belvisi et al. 2008; Belvisi et al. 1998; Usmani et al. 
2005). However, when studying the whole vagus nerve, the depolarisation represents 
a summation of the change in membrane potential of all the axons in the nerve. As 
only some of these nerve fibres are innervating the airways, this may not represent the 
true effect of the compound on the airway afferent nerve endings (Patel et al. 2003).  
 
To further investigate specific afferent fibre subtypes, isolated tissue preparations 
have been developed that allow distinct afferent fibres to be identified. Fox et al. 
isolated guinea-pig trachea with the vagus nerve attached and measured parameters 
such as conductance velocities, location and sensitivity to mechanical or chemical 
stimuli of the afferent fibres (Fox et al. 1993; Fox et al. 1995). Alternatively, a 
technique has been developed using isolated guinea-pig trachea with the vagus nerve 
 56 
and nodose and jugular ganglia attached. An electrode is inserted into the ganglia and 
if firing of a fibre can be detected, by electrical and/or mechanical stimulation of a 
receptor field on the surface of the trachea/bronchi, the electrode is successfully 
positioned. When effectively recording from a single nerve fibre, the effects of 
mechanical, electrical or pharmacological manipulation can be investigated (Carr & 
Undem 2003; Riccio et al. 1996b; Riccio et al. 1996a; Undem et al. 2004). Both 
techniques are advantageous as they allow distinct afferent nerve subtypes and 
receptive fields to be studied in response to mechanical or chemical stimulation. 
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1.8. THESIS PLAN 
 
As described in this thesis introduction, current drugs for airway inflammatory 
diseases are not effective in all patients and alternative therapies are therefore 
required. PGE2 has been shown to be a bronchodilator and anti-inflammatory in a 
range of cell based assays, in vivo models and clinical trials in normal subjects and 
asthmatic patients. However, during these studies, inhaled PGE2 has been shown to 
cause sensory nerve irritation and cough. The aim of this thesis is to use a multi-
disciplinary approach to identify the receptor(s) involved in PGE2-induced cough. If 
this receptor is different to the receptor(s) responsible for the beneficial effects, an 
agonist could be developed that is a bronchodilator and anti-inflammatory but devoid 
of tussive side effects. The receptor(s) responsible for the tussive response to 
prostanoids will be identified by: 
 
 Comparing the depolarisation of PGE2 to other tussive stimuli in an isolated 
vagus nerve system in a range of species. 
 
 Utilising a range of prostanoid receptor agonists and antagonists to identify the 
receptor involved in PGE2-induced sensory nerve activity in mouse, guinea-pig 
and human isolated vagus nerves. 
 
 Using isolated nerves from KO mice to investigate differences in responses to 
tussive stimuli to parallel the pharmacological experiments above. 
 
 Exploiting gene and protein expression techniques to identify prostanoid 
receptors expressed in sensory nerve tissue. 
 
 Antagonising the PGE2-induced cough using a specific prostanoid receptor 
antagonist in an in vivo model of cough. 
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CHAPTER 2 
 
Methodology 
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2.1. INTRODUCTION 
 
This chapter outlines the general methodology for the in vivo and in vitro techniques 
used in this thesis. Details of individual experimental protocols and statistical analysis 
employed are given in the methods section of each chapter. Drugs/reagents and 
appropriate vehicles used in this thesis are listed in the appendix.  
 
2.2. IN VIVO COUGH EXPERIMENTS 
 
2.2.1. Measurement of cough 
 
Conscious, unrestrained guinea-pigs (250-350 g, Charles River, France) were placed 
in individual Perspex closed chambers (Buxco USA). The apparatus consisted of two 
chambers, linked to a single nebuliser, allowing two guinea-pigs to be exposed to the 
same aerosol simultaneously. Guinea-pigs were exposed to a nebulised aqueous 
solution of vehicle (0.1 M phosphate buffer) or PGE2. The aerosol was generated with 
an Aerogen nebuliser (Buxco, USA). The coughs were counted for a total of 10 
minutes. Each chamber was fitted with a microphone, which was connected to an 
external speaker, allowing the cough sounds to be magnified. Coughs were counted 
by a trained observer and recognised by the characteristic opening of the mouth, the 
stance and posture of the animal, the sound produced and the flow recordings.  
 
2.2.2. Pharmacokinetic analysis of the levels of L826266 
 
During studies analysing the antagonism of PGE2-induced cough, heparinised blood 
samples were taken via cardiac puncture immediately following overdose with 
sodium pentobarbitone. Plasma was separated from blood samples and analysed for 
L826266 by Liquid Chromatography - Mass Spectrometry/Mass Spectrometry (LC-
MS/MS) analysis at Merck Frosst, Canada. 
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2.3. BREEDING OF KO MICE  
 
Breeding pairs of mice devoid of one of the following genes; Ptger1 (EP1), Ptger2 
(EP2), Ptger3 (EP3) (Ushikubi et al. 1998), Ptgdr (DP) (Matsuoka et al. 2000), Ptgfr 
(FP) (Sugimoto et al. 1997), Ptgir (IP) (Murata et al. 1997), Tbxa2r (TP) (Kabashima 
et al. 2003) had been backcrossed at least 8 times onto the C57bl/6 background. 
Ptger4
-/-
 (EP4) mice do not survive on the C57bl/6 background due to patent ductus 
arteriosus (Nguyen et al. 1997; Segi et al. 1998) and so they were backcrossed on a 
mixed background of 129/Ola X C57bl/6. Mice were kindly provided by Dr S 
Narumiya, Kyoto University, and breeding colonies maintained at Imperial College, 
London. In parallel to these colonies of prostanoid receptor deficient mice, a wild type 
colony was also required. The 129/Ola x C57bl/6 wild type mice were provided by 
Kyoto University however C57bl/6 wild type mice were purchased from Harlan, UK. 
It is important to breed wild type controls alongside the knock out mouse colonies so 
they are exposed to the same diet, housing conditions and environment. Ideally, 
littermate controls would be used in experiments. This would require heterozygous 
pairs to be bred, selecting the wild type and KOs from the offspring. However, this 
would require an increased number of breeding pairs and, with the higher numbers of 
breeding colonies, would vastly increase the number of cages, the costs and the 
number of mice surplus to requirement. Because of this, wild type controls were bred 
in a separate colony alongside the KOs.      
 
Animals were housed in cages within an isolator on arrival and were placed on a 
transgenic diet and provided with food and water ad libitum. Pairs were mated and 
subsequent offspring were set up in harems containing 2 females and 1 male. 
Throughout the breeding, the genotype of the animals was monitored to ensure that 
the disrupted gene remained through the generations. 
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2.4. GENOTYPING OF KO MICE 
 
2.4.1. DNA extraction and quantification 
 
DNA was extracted from tail tips of wild type and prostanoid receptor KO mice using 
a non-chloroform mouse tail kit (Tepnel Life Sciences). Briefly, 0.5 – 1 cm of mouse 
tail was removed. The tissue was placed in a 1.5 ml centrifuge tube and lysed 
overnight at 55 °C in 175 μl reagent M1 and 20 μl proteinase K solution (10 mg/ml in 
nuclease-free water). On removal from the incubator, 65 μl reagent M2 and 100 μl 
Nucleon Resin was added. The tubes were then mixed and centrifuged at 2000 g for 
10 minutes. Without disturbing the Nucleon Resin/debris layer, the aqueous phase 
was transferred to a clean 1.5 ml centrifuge tube. Following this, 1 volume of 100 % 
isopropanol was added and the tube was inverted several times until the DNA was 
visible. Samples were then centrifuged at 2000 g for 5 minutes to pellet the DNA. The 
supernatant was discarded without disturbing the pellet. The DNA pellet was then 
washed with 70 % ethanol and the tube contents mixed ensuring the pellet was 
dislodged from the bottom of the centrifuge tube. The samples were re-centrifuged at 
2000 g for 2 minutes and again the supernatant discarded. The pellet was air-dried at 
room temperature for 10 minutes. The DNA was re-suspended in 100 μl nuclease-free 
water and left at room temperature for 3 hours to re-hydrate. Samples were stored at -
80°C until required.  
 
The purity and integrity of the DNA samples was assessed by A260/A280 
spectrophotometry on the GeneQuant RNA/DNA quantifier (Amersham Pharmacia 
Biotech, U.K.).  
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2.4.2. Primer Design 
 
Primer sequences were kindly provided by ONO Pharmaceuticals with the exception 
of the EP4 primers which were available in the literature (Segi et al. 1998). Using the 
EP1 receptor gene as an example, a description of how primers are designed is given 
below.  
The EP1 KO has a Neomycin (Neo) cassette inserted into exon 2 as shown in figure 
2.1 below. Primers can therefore be designed to identify the wild type (EP1 forward 
and EP1 reverse) and the KO (Neo forward and EP1 reverse). 
 
 
 
     
 
 
 
 
 
Figure 2.1: Schematic Showing the disruption of the EP1 receptor gene. 
The schematic shows the disruption of exon 2 of the EP1 gene. A neomycin cassette 
(neo), contained in the vector, is inserted into the genome using restriction enzymes. 
Restriction sites are indicated by letters X, E and K adapted from (Ushikubi et al. 
1998).  
 
Primers were designed such that the wild type amplicon would span the disrupted site 
of the EP1 gene. This ensures that the wild type and KO can be easily differentiated 
based on the amplicon size. The diagram below shows the approximate position of the 
primers in the EP1 gene (Figure 2.2). The wild type primers for the EP1 were designed 
resulting in an amplicon size of 1000 bp. To create the disrupted gene, the neomycin 
cassette was inserted into a position between this primer pair. As a result, the primers 
for the wild type also produce an amplicon in the disrupted gene. However, this 
amplicon is now much larger (2100 bp) as the primers span the neomycin cassette. To 
avoid any discrepancy as to the target gene being amplified, a separate PCR reaction 
is also carried out using a forward primer that binds within the neomycin sequence. 
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This provides additional assurance that the particular animal is a KO as the wild type 
primers could be amplifying two separate genes. The primers for the disrupted gene 
produce an amplicon of approximately 1100 bp. Because of the similarities in product 
size, separate reactions were carried out.  
 
       
(a) 
 
 
 
 
 
 
(b) 
 
 
 
Figure 2.2: Primer positions within the EP1 wild type and disrupted genes.  
(a) Primers amplify part of the wild type gene producing an amplicon of 1000 bp. (b) 
These same primers used for the wild type gene also produce an amplicon in the 
disrupted gene of 2100 bp. A separate pair of primers, specific to the disrupted gene, 
was also designed to be carried out in a separate PCR producing an amplicon of 
1100 bp. Adapted from (Ushikubi et al. 1998) 
 
In many situations, the wild type primers only produce an amplicon in a wild type 
gene and so therefore, primers for the wild type and disrupted gene can often be added 
to the same PCR. The primer sequences and combinations are described in Chapter 3. 
 
2.4.3. PCR 
 
PCR is used to exponentially amplify the sections of DNA in between the primer pair. 
The PCR contained 1x Green GoTaq Flexi Buffer, 0.2 mM dNTPs, 2 mM MgCl2, 
1.25 u enzyme, 10 pmol forward and 10 pmol reverse primers, and a volume of DNA 
(50 ng) or Nuclease-free water for control, made up to 25 μl with Nuclease-free water 
(Promega U.K. Ltd). The samples were heated to 94
o
C for 2 minutes followed by 40 
Exon 1 Exon 2 Exon 3
Wild 
type
Exon 1 Exon 2 Exon 3
Wild type
KO
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cycles of denaturing, annealing and extension steps. More than 40 cycles can reduce 
the polymerase specific activity, increase nonspecific amplification, and deplete 
available nucleotides (Kramer & Coen 2001). All samples were denatured at 94
o
C for 
30 seconds as this is dependent on the enzyme rather than the primer pairs. The 
annealing temperature is specific to the primer pair and depends on factors such as 
melting temperature and GC content. The annealing temperatures are between 58-
65
o
C for 30 seconds. The temperature of the extension step is also primer dependent 
and the length of time that the reaction is held for depends on the product size i.e. the 
larger the expected product size, the longer the time needed (approximately 1 minute 
per 1000 bp). This was followed by a final extension step for 10 minutes at the same 
temperature as the extension step to ensure that all products were full length. The 
reaction was then stopped by cooling to 4
o
C. PCR reactions were carried out using the 
ABI PRISM 7000 (Applied Biosystems, Warrington, Cheshire, U.K).  
 
2.4.4. Visualisation of PCR products 
 
The PCR products and DNA ladder (Hyperladder II or IV, Bioline Ltd, London) were 
run on a 2 % agarose gel in Tris Borate EDTA (TBE) buffer containing 0.05 μl/ml 
Safeview (NBS Biologicals Ltd, Huntingdon, U.K.)  at 80 V for 1 hour. The gel was 
then visualised under ultra-violet light and photographed. 
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2.5. MEASUREMENT OF DEPOLARISATION IN THE ISOLATED VAGUS 
NERVE SYSTEM 
 
2.5.1. Mouse and guinea-pig vagus nerves 
 
Male C57bl/6j mice (Bred in-house, 18-20 g) or prostanoid receptor KO mice (Bred 
in-house 18-20 g) were sacrificed using 200 mg/kg sodium pentobarbitone. Male 
Dunkin Hartley guinea-pigs (350 g) were sacrificed by cervical dislocation. The neck 
was opened by mid-line incision to expose the trachea and thorax.  Segments of vagus 
nerve, caudal to the nodose ganglion were removed with fine forceps and placed in 
modified Krebs solution (mM): NaCl - 118; KCl – 5.9; MgSO4 - 1.2; NaH2PO4 – 1.2; 
CaCl2 - 2.5; Glucose – 6.6; NaHCO3 – 25.5; and bubbled with 95 % O2/5 % CO2.  
The nerve was then cleared of connective tissue and carefully desheathed (guinea-pig 
only) under a dissecting microscope. Throughout, care was taken to ensure that the 
nerve trunks remained in Krebs solution (bubbled with oxygen) and that they were not 
stretched or damaged. 
 
2.5.2. Human vagus 
 
Human trachea, with branches of the cervical vagus still attached, was removed from 
donor patients for heart or heart/lung transplants performed at The Royal Brompton or 
Harefield Hospital. 
 
The epineural and perineural sheath surrounding the vagus nerve in human airways is 
much tougher compared to that of guinea pig nerves and is consequently harder to 
remove. Thus, where possible, fine nerve branches of the recurrent laryngeal nerves 
were used since they were easier to desheath. Additionally, it was certain that these 
nerve sections would contain fibres supplying the airways. Segments of nerve, 
approximately 20 - 30 mm long were prepared as described for guinea pig vagi. The 
availability of human vagus nerve is scarce and therefore limits the number of 
experiments that can be performed. However, where possible I have performed key 
experiments.  
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2.5.3. Measurement of nerve depolarisation 
 
Immediately after dissection, the desheathed nerve trunk was mounted in a 
„grease-gap‟ recording chamber as described previously (Birrell et al. 2002) and 
shown diagrammatically below in figure 2.3.The nerve was drawn longitudinally 
through a narrow channel (2 mm diam., 10 mm. length) in a Perspex block. A larger 
channel was available for human vagus nerves. The centre of the channel was slowly 
injected with petroleum jelly to create an area of high resistance and electrically 
isolating the extracellular space between the two ends of the nerve. One end of the 
nerve was constantly superfused with Krebs solution with a flow rate of 
approximately 2 ml/min. Depolarisation of the nerve was measured using Ag/AgCl 
electrodes (Mere 2 Flexible reference electrodes, World Precision Instruments (WPI)) 
filled with Krebssolution at each end of the nerve and recorded D.C. potential via a 
DAM 50 differential amplifier (WPI). D.C. voltages were amplified x 10, filtered at 
1000 Hz and sampled at 5 Hz.  During each experiment, simultaneous recordings 
were made from 2 nerves. The temperature of the perfusate was maintained at 37C 
by means of a water bath. The pen-recorder was calibrated such that 1 cm was 
equivalent to 0.1 millivolts (mV). 
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Figure 2.3: Diagrammatic representation of the isolated vagus nerve 
preparation. 
The isolated vagus nerve is drawn through the Perspex channel. Vaseline is injected 
into the middle of the nerve isolating the two ends. Electrodes make contact with one 
end of the nerve (Left of diagram) and the other electrode is placed in Krebs at the 
other end of the nerve. Krebs or drugs are applied to one end of the nerve at a set drip 
rate (2 ml/min) and the depolarisation recorded on a chart recorder.    
 
Vagus nerves were prepared for measurement of extracellular recording as described 
previously (section 2.5.1 and 2.5.2). The superfusing medium could be quickly 
changed with little artefact, by means of a tap and the new solution reaching the 
recording site with a delay of approximately 20 seconds. Drugs were applied at 
known concentrations into the perfusing solution and depolarising responses recorded 
onto a chart recorder (Lectromed Multi-Trace 2).  Agonists were applied for 2 
minutes, after which the tissue was washed.  An interval was allowed between 
compound incubations, or until the baseline response of the nerve was regained.  In 
between drug applications, perfusion of the nerve with oxygenated Krebs was 
maintained. Specific compounds used in experiments will be described in the results 
chapters.  
 
 
 
chart   
recorder
krebs/drugs vaseline
nerve
electrode
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2.6. MEASUREMENT OF GENE EXPRESSION 
 
2.6.1. RNA extraction 
 
Guinea-pig tissue was dissected and immediately flash-frozen in liquid nitrogen and 
stored at -80ºC. The frozen tissue was crushed using a pestle and mortar and the 
resulting powder transferred to a 2 ml centrifuge tube containing 1 ml TRI Reagent. 
TRI Reagent is a mixture of guanidine thiocyanate and phenol which dissolved DNA, 
RNA and protein on lysis of the sample. Samples were then centrifuged at 12,000 rpm 
in a microcentrifuge for 10 minutes at 4°C. This separates the sample into three 
layers; the top aqueous phase (containing RNA) interphase (containing DNA) and an 
organic phase (containing protein). The clear supernatant (top layer) was transferred 
to a new 2 ml centrifuge tube and left to stand for 5 minutes at room temperature to 
ensure complete dissociation of nucleoprotein complexes. After this, 0.2 ml 
chloroform was added to each tube and mixed and left to stand for 15 minutes at room 
temperature. Samples were centrifuged at 12,000 rpm for 15 minutes at 4°C, the 
aqueous phase removed and placed in a clean 1.5 ml centrifuge tube. A 1/10 volume 
isopropanol was added, mixed and left at room temperature for 5 minutes. Samples 
were centrifuged at 12,000 rpm for 10 minutes at 4°C, supernatant transferred to 
another 1.5 ml tube and remaining amount of isopropanol added to a total of 0.5 ml 
isopropanol per 1 ml TRI Reagent. The samples were then mixed and left to stand at 
room temperature for 5 minutes causing precipitation of RNA in the sample. Samples 
were centrifuged at 12,000 rpm for 10 minutes at 4°C and this time the supernatant 
discarded leaving an RNA pellet. The pellet was washed with 70 % ethanol, vortexed 
and centrifuged at 12,000 rpm for 5 minutes at 4°C. The ethanol was removed, 
without disturbing the pellet and the pellet left to dry for 5-10 minutes. The samples 
were then resuspended in 50 μl nuclease-free water.  
 
The purity and integrity of the
 
RNA samples was assessed by A260/A280 
spectrophotometric measurements
 
on the GeneQuant RNA/DNA quantifier 
(Amersham Pharmacia Biotech,
 
UK).  
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2.6.2. Reverse Transcription 
 
RNA samples (1 μg) were reverse-transcribed to complementary deoxyribonucleic 
acid (cDNA) using a master mix (TaqMan reverse transcription reagents, Applied 
Biosystems, Warrington, Cheshire, U.K.) containing 1x TaqMan RT buffer, 5,5 mM 
MgCl2, deoxyNTPs mixture (500 μM per NTP), 2.5 μM random hexamers, 0.4 U/μl 
RNase inhibitor and 1.25 U/μl Multiscribe reverse transcriptase, in a final reaction 
volume of 50 μl. The RNA samples were incubated in a Perkin Elmer 480 thermal 
cycler (Boston M.A., U.S.A.) at 25°C for 10 minutes and then reverse transcribed at 
48°C for 30 minutes and denatured at 95°C for 5 minutes. Samples were then stored at 
-80°C until required. 
 
2.6.3. Real Time Polymerase Chain Reaction 
 
Real time PCR was carried out using TaqMan chemistry on the ABI Prism 7000 
(Applied Biosystems, Warrington Cheshire U.K.) using a flurogenic probe to enable 
the detection of a specific PCR product as it accumulates during PCR cycles. The 
TaqMan chemistry works as follows. An oligonucleotide probe is constructed 
containing a reporter fluorescent dye at the 5‟ end and a quencher dye at the 3‟ end. 
While the probe is intact, the proximity of the quencher dye greatly reduces the 
fluorescence emitted by the reporter dye. If the target sequence is present, the probe 
anneals downstream from one of the primer sites and is cleaved by the 5‟ nuclease 
activity of Taq DNA polymerase enzyme as the primer is extended. The cleavage of 
the probe separates the reporter dye from the quencher dye and increases the signal of 
the reporter dye. The cleavage also removes the probe from the target strand, allowing 
primer extension to continue to the end of the template strand. Additional reporter dye 
molecules are cleaved from their respective probes with each cycle. This causes an 
increase in fluorescence intensity, which is proportional to the amplicon produced. In 
TaqMan chemistry the amplicon is typically 50-150 bp. The process is shown 
diagrammatically in Figure 2.4 below. 
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Figure 2.4: TaqMan chemistry. 
(A) Following denaturation, the primers and probe anneal to the target. Fluorescence 
emission does not occur due to the close proximity of the flurophore and the 
quencher, as the probe is still intact. (B) During the extension phase of the PCR 
reaction, the probe is cleaved by the 5’ to 3’ activity of Taq polymerase. This causes 
the fluorophore and quencher to become separated allowing the emission of the 
fluorescence from the reporter dye. F = flurophore, Q = quencher, FW = forward, 
RV = reverse (Overbergh et al. 2003) 
 
This method has many advantages over conventional PCR. In conventional PCR, 
once the samples have been amplified in the thermal cycler, they then must be run out 
on a gel with an appropriate carrier dye. Compared to TaqMan real time PCR, this 
method allows less samples to be analysed at the same time and furthermore, the gel 
must be photographed and subject to densiometric measurements to compare 
expression levels of particular genes resulting in semi-quantitative measurements. 
Taqman chemistry is particularly good for tissues with low expression of a gene as the 
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TaqMan machine measures the fluorescence emitted by the cleaved probe, cycle by 
cycle, thereby improving specificity and sensitivity.  
 
Primers and probes were designed for the target gene of interest, or pre-developed 
assays were purchased from Applied Biosystems. TaqMan primers are designed to 
span two different exons (and therefore one intron) of the target gene in order to avoid 
amplification of contaminating genomic DNA. Pre-developed assays contain the 
primers and probe, designed by Applied Biosystems in one reaction. For custom 
assays, the forward primer, reverse primers and probe are purchased separately, again 
from Applied Biosystems. The TaqMan probe has a fluorescent reporter dye, FAM, 
which is covalently linked to its 5‟ end and a downstream quencher dye, TAMRA, 
linked to the 3‟ end. Reactions were internally controlled with 18s rRNA internal 
control (Applied Biosystems, Warrington, Cheshire, U.K.). 18s uses VIC as its 
quencher dye so that both reporter signals in the reaction can be measured.  
 
PCR reactions were performed in a 25 μl reaction containing 3 μl sample cDNA (2.5 
ng/μl), the designed forward primer, reverse primer and probe, or pre-developed assay 
of the target gene, 2x TaqMan universal master mix and 18s internal control (Applied 
Biosystems). Amplification and detection of products were carried out in the ABI 
Prism 7000 Sequence Detection System (Applied Biosystems, Warrington, Cheshire, 
U.K.) using an amplification protocol of 1 cycle at 50°C for 2 minutes, 1 cycle at 
95°C for 10 minutes, 40 cycles at 95°C for 15 seconds, and 60°C for 1 minute.  
 
2.6.4. Analysis of Real time PCR results 
 
Results were analysed using the Sequence Detection Software (Applied Biosystems) 
and the relative amount of target gene transcript was normalised to the amount of 18s 
internal control transcript in the same cDNA sample. The critical threshold cycle (ct), 
defined as the cycle at which the fluorescence from the TaqMan probe become 
detectable above background, is inversely proportional to the logarithm of the initial 
number of template molecules. Therefore the higher the target concentration, the 
lower the number of amplification cycles required to increase above the baseline. The 
Ct will always occur during the exponential phase of amplification and will therefore 
 72 
be unaffected by reaction components becoming limited in the plateau phase 
potentially leading to false results. 
 
As the PCR reaction is exponential, data in this thesis are expressed as arbitrary 
values taking into account the exponential reaction, using the following equation 2
-delta 
ct
  i.e. 2
-(target ct – 18s ct)
, written as 2
-Δct
. This allows levels or mRNA expression to be 
compared in different tissues, relative to the expression of the endogenous control.  
 
2.6.5. Validation of TaqMan assays 
 
The most significant advantage that TaqMan real time PCR has over traditional PCR 
is that multiplex reactions can be run. Both the target gene and the internal control 
(ribosomal 18s RNA) can be run in parallel in the same well, making this method 
more quantifiable and more accurate. Applied Biosystems guarantee that single 
reactions are 100 % efficient however multiplex PCR was carried out in this thesis. 
Multiplex PCR is the use of more than one primer pair in the same tube and can be 
used for relative quantification where one primer pair amplifies the gene of interest 
and one amplifies the internal control. To do Multiplex PCR, it is necessary to 
validate the assays to ensure that both the target and internal control reactions were 
running with equal efficiency.     
 
A target rich gene sample was identified from a panel of tissues. A standard curve was 
then constructed by diluting cDNA from the most abundant tissue. The concentrations 
of cDNA used were 25, 8.333, 2.788, 0.926, 0.309, 0.103, 0.034 and 0.011 ng/25μl. 
The slope value should double every 3.3 cycles and so the slope value should be close 
to -3.3. The R
2
 value should greater than 0.98. This must be true for both the target 
gene and the 18s ct values otherwise one or both of the reactions are not running 
efficiently over a range of cDNA concentrations and the assays could be interfering 
with each other. Further analysis of the delta ct values for the target gene stipulate that 
the R
2
 value should be less than 0.1, indicating that the delta Ct values on the standard 
curve form a straight line, providing further proof than the assays are equally efficient 
in a multiplex reaction.  
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2.7. IMMUNOHISTOCHEMISTRY 
 
Histological processing and assessment was carried out 24 hours after the kidney 
(positive control), nodose and jugular ganglia were dissected from guinea-pigs and 
immersion fixed in formalin. The nodose and jugular ganglia were processed as 
separate wax tissue blocks. Using a closed tissue processor, the samples were 
processed to paraffin wax and then embedded in fresh paraffin wax. The sections, 
embedded in paraffin wax, were cut to 9 μm, fixed onto Polysine slides and dried 
overnight at 37ºC. Sections were dewaxed in xylene and rehydrated. In order to block 
endogenous peroxidase in the sections, slides were incubated with 3 % hydrogen 
peroxide for 30 minutes at room temperature. Slides were washed in PBS buffer (1 % 
BSA and 0.1 % Tween 20 in PBS) and goat serum applied for 30 minutes to prevent 
non-specific binding of the secondary antibody. Sections were incubated with the 
rabbit polyclonal EP3 antibody (SantaCruz sc20676 dilute 1:50) or rabbit isotype 
control, for one hour at room temperature. The rabbit polyclonal PGP 9.5 antibody 
(Diluted 1:3000) and corresponding rabbit isotype control were incubated overnight at 
4ºC. Sections were washed in PBS buffer and incubated for 1 hour at room 
temperature with a goat anti-rabbit biotinylated secondary antibody (Dako E-0432, 
diluted 1:300 in PBS buffer). After washing the slides, avidin and biotinylated 
horseradish peroxidise was applied to the sections for 30 minutes at room temperature 
(Vectastain Elite ABC kit PK-6100). Finally, sections were incubated with the 
chromagen DAB for 5 minutes and the nuclei were counterstained with haematoxylin. 
Sections were dehydrated using increasing concentrations of alcohol, cleared with 
xylene and coverslipped. Images were acquired using an Olympus BX51 system 
microscope equipped with a Quicam Q-imaging Fast1394 camera, linked to a 
computer with Image Pro-plus Version 5.1 image analysis software (Media 
Cybernetics, UK). 
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CHAPTER 3 
 
 Characterisation of models and techniques for 
investigating the receptor responsible for PGE2-
induced cough 
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3.1. RATIONALE 
 
PGE2 has been shown to be anti-inflammatory and a bronchodilator in asthmatic 
patients (Gauvreau et al. 1999; Kawakami et al. 1973; Melillo et al. 1994; Pavord et 
al. 1993) however PGE2 causes cough as a side effect. In order to investigate the 
receptor responsible for PGE2-induced cough, it was initially necessary to characterise 
models of sensory nerve irritation and cough in response to PGE2. The tussive 
response to PGE2 has been well documented in man (Costello et al. 1985; Gauvreau 
et al. 1999; Kawakami et al. 1973) however small animal models of PGE2-induced 
cough have not previously been published. Guinea-pigs, unlike rats and mice, possess 
a cough reflex and would therefore be the species of choice for in vivo models of 
cough. The first aim of this chapter was to confirm that, like humans, guinea-pigs 
cough in response to PGE2, which will then enable me to investigate the hypothesis. 
 
The second aim of this chapter was to characterise depolarising responses to PGE2 in 
an in vitro model of sensory nerve activation. It is neither ethical nor cost effective to 
investigate the role of all 9 prostanoid receptors in an in vivo model of cough. 
Furthermore, in vivo profiling of prostanoid receptor agonists and antagonists may be 
complicated by differences in pharmacokinetic profiles. The isolated vagus nerve 
system provides an ideal opportunity to carry out comprehensive pharmacological 
assessment of prostanoid receptor agonists and antagonists in vitro avoiding potential 
pharmacokinetic issues. Moreover, lesser quantities of compound are required for in 
vitro compared to in vivo experiments. Thus, an in vitro model of sensory nerve 
activation that is representative of cough was vital. I used human and guinea-pig 
isolated nerves because these species both possess a cough reflex. Furthermore, using 
human and guinea-pig isolated nerves in parallel allows confirmation that the findings 
in animal translate into man. In addition to guinea-pig and human nerves I have 
characterised depolarising responses in wild type mice. Breeding pairs of prostanoid 
receptor knockout mice (EP1, EP2, EP3, EP4, DP, FP, IP and TP) were kindly donated 
by Kyoto University, Japan. Although mice do not possess a cough reflex per se, the 
KO mice provide an invaluable tool for this research and seem to behave similarly to 
guinea-pig and human vagus nerves with regard to the response to tussive agents. As 
well as characterising the responses to PGE2 in isolated nerves from wild type mice, 
the third aim of this chapter was to develop a method of genotyping the colonies of 
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KO mice. Confirmation of the genotype of each individual animal was imperative so 
that any future experiments carried out were reliable and sufficiently controlled. 
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3.2. METHODS 
 
3.2.1. PGE2-induced cough in the guinea-pig model 
 
Conscious, unrestrained guinea-pigs (250-350 g, Charles River, France) were placed 
in a closed chamber. Animals were exposed to a 10 minute aerosol of vehicle (0.1 M 
phosphate buffer), 10, 100 or 1000 µg/ml PGE2 and the number of coughs recorded as 
previously described in section 2.1. 
 
3.2.2. Sensory nerve activation in the isolated vagus nerve preparation 
 
Vagus nerves from male C57bl/6j mice (18-20 g) and male Dunkin-Hartley guinea-
pigs (250-350g) were dissected free and placed in Krebs‟s solution as described in 
Chapter 2. Human vagus nerve was removed from donor patients for heart or 
heart/lung transplants performed at The Royal Brompton or Harefield Hospital. 
Approval was obtained from the Royal Brompton and Harefield ethics committee. 
PGE2 (0.1 % ethanol vehicle, 10 or 30 μM), capsaicin (0.1 % DMSO vehicle, 0.1, 1, 
10 and 100 μM) or a low pH solution (pH 5.0, composition in mM: NaCl – 118.5; 
KCl – 1.7; KH2PO4 – 6.6; MgSO4.7H2O – 1.2; NaH2PO4 – 0.1; glucose – 10; CaCl2 – 
2.5), were applied to guinea-pig, mouse or human nerves in a random order for 2 
minutes each, washing the tissue in between. No more than 5 concentrations were 
applied to each section of nerve. 
 
3.2.3. Genotyping KO mice 
 
3.2.3.1. Animals 
 
 Breeding pairs of mice devoid of one of the following genes; Ptger1 (EP1), Ptger2 
(EP2), Ptger3 (EP3), Ptgdr (DP), Ptgfr (FP), Ptgir (IP), Tbxa2r (TP) had been 
backcrossed at least 8 times onto the C57bl/6 background. Ptger4
-/-
 (EP4 KO) mice do 
not survive on the C57bl/6 background due to patent ductus arteriosus (Nguyen et al. 
1997; Segi et al. 1998) and so they were backcrossed on a mixed background of 
129/Ola X C57bl/6. Mice were kindly provided by Dr S Narumiya, Kyoto University, 
and breeding colonies maintained at Imperial College, London.  
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3.2.3.2. Confirmation of DNA extraction 
 
DNA was extracted from tail tips as described in section 2.4.1. To confirm the 
presence of DNA in the samples, a PCR reaction was carried out using mouse 
genomic DNA primers that had been previously optimised and validated. Primer 
sequences were forward 5‟-GTTGAGTAGTGAGTCAGTC-3‟ and reverse 
5‟-CGTGGCTGGTGATTTCTG-3‟ with an expected product size of 250 bp. The PCR 
reaction contained 1x Green GoTaq Flexi buffer, 0.2 mM dNTPs, 2 mM MgCl2, 1.25 
u enzyme, 10 pmol forward and 10 pmol reverse primers, and a volume of DNA (50 
ng) or nuclease-free water for control, made up to 25 μl with nuclease-free water. The 
samples were heated to 95
o
C for 2 minutes followed by 40 cycles of 95
o
C for 30 
seconds (denaturing) 55
o
C for 30 seconds (annealing), 75
o
C for 45 seconds 
(extension). Amplified DNA was then electrophoresed on a 2 % agarose gel and 
visualised under UV light. 
 
3.2.3.3. Optimisation of PCR reactions 
 
Primers were designed as describes in section 2.4.2. and the primer sequences used 
are shown in Table 1 below. Initially, the FP heterozygous/KO colony was used to 
optimise the concentration of Mg
2+
 which depends on the polymerase enzyme used. 
Annealing and extension temperatures were then adjusted for each set of primers to 
identify the optimum conditions.  
 
3.2.4. Statistical analysis 
 
The concentration response curve of PGE2-induced cough was analysed using the 
Kruskal-Wallis test for multiple groups followed by the Dunn‟s post-hoc test 
comparing all groups to vehicle. Significance was denoted by *P<0.05. For isolated 
vagus nerve experiments, depolarising responses to tussive stimuli were plotted as 
mean ± s.e.m.  
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Primer name Sequence 
EP1 forward 5'-TGA GCC TAG CGG ATG AGG CAG C-3' 
EP1 reverse 5'-GCG GAG AGT CCG GCT AGA GAA G-3' 
EP1 neomycin 5'-CCT GGG TGG AGA GGC TTT TT-3' 
EP2 forward 5'-CTG GCC ATT ATG ACC ATC ACC TTC GCC A-3' 
EP2 reverse 5'-CTG AGC AAC ACC CAT GTT TCT ATC CTG G-3' 
EP2 neomycin 5'-TGA TAT TGC TGA AGA GCT TGG CGG CGA A-3' 
EP3 forward 5'-AAA GTG ACT AGC ACC CAG AAT TCC TGC C-3' 
EP3 reverse 5'-GAG TCC TCC ACT TTG GTG TAC ACA GTA C-3' 
EP3 neomycin 5'-TGC CGA ATA TCA TGG TGG AAA ATG GCC G-3' 
EP4 forward 5'-TCT ACT TGC TCC CAG TGG ACA TAG A-3' 
EP4 reverse 5'-GAA CAG ACT CCT GAA CTG GGT ATG G-3' 
EP4 neomycin 5'-TGC CGA ATA TCA TGG TGG AAA ATG G-3' 
DP forward 5'-TCG GTC TTT TAT GTG CTC GTG-3' 
DP reverse 5'-GGA TCA TCT GGA TGA AAC ACC-3' 
DP neomycin 5'-CCC GTG ATA TTG CTG AAG AGC-3' 
FP forward 5'-GCC CAT CCT TGG ACA CCG AGA TTA TCA A-3' 
FP reverse 5'-AGA GTT GGC AAG CTG TGA CTT CGT CTT T-3' 
FP neomycin 5'-TGA TAT TGC TGA AGA GCT TGG CGG CGA A-3' 
IP forward 5'- GAG CAG AAA AAT TCC CAG AGG CTT –3' 
IP reverse 5'- GTA TCT TTC AGT ACC TGA GGA CTG –3' 
IP neomycin 5'- TGA CCG CTT CCT CGT GCT TTA C –3' 
TP forward 5'- ACT TCA TGG GGT CAG AAG CA -3' 
TP reverse 5'- ACA TGG CTC CTA AGC CTG AC-3' 
TP neomycin 5'- CTC GTC CTG CAG TTC ATT CA -3' 
 
Table 3.1: Primer sequences used to genotype prostanoid receptor KO mice.  
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3.3. RESULTS 
 
3.3.1. Characterisation of PGE2-induced cough 
 
During studies of inhaled PGE2 in man, this potentially beneficial drug caused a reflex 
cough in a significant proportion of the participants (Costello et al. 1985; Gauvreau et 
al. 1999; Kawakami et al. 1973; Melillo et al. 1994). In order to investigate the 
receptor responsible for the cough, it was necessary to develop a technique to 
investigate PGE2-induced cough in small animals. The guinea-pig is the most suitable 
species for this investigation as guinea-pigs, like humans, possess a cough reflex. The 
concentration range for PGE2 was based on human studies with inhaled PGE2 where 
concentrations between 100 and 500 μg/ml were used to elicit cough (Costello et al. 
1985). 
 
A concentration-response had been carried out to inhaled PGE2 in guinea-pigs (Figure 
3.1). The vehicle elicited no coughs. A concentration of 10 μg/ml caused one animal 
to cough and at 100 and 1000 μg/ml PGE2 a significant number of coughs were 
observed compared to vehicle.  As both 100 and 1000 μg/ml caused a significant 
number of coughs, 100 μg/ml will be used in future experiments. The use of this 
concentration also offers a considerable reduction in cost. 
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Figure 3.1: Concentration-response to PGE2 in a guinea-pig model of cough. 
Guinea-pigs were exposed to vehicle or 10, 100, 1000 μg/ml PGE2 for 10 minutes and 
the number of coughs recorded. N=8 in each group and data plotted as (a) a scatter 
graph and (b) a bar chart showing mean ± s.e.m.. Statistical significance when 
compared to vehicle is denoted as * P<0.05. 
 
It should also be noted that PGE2-induced cough differs from the classically studied 
capsaicin or citric acid-induced cough. Capsaicin and citric acid both cause single, 
loud coughs (Figure 3.2) where as the cough response in guinea-pigs to PGE2 is 
distinctly different. During inhaled PGE2, the cough occurs almost always as bouts of 
coughs (Figure 3.2) consisting of 10 to 30 coughs, with multiple bouts often occurring 
during one 10 minute exposure. Despite the cough in response to PGE2 occurring in 
bouts, the coughs were counted as individual coughs rather than bouts. This was 
because of the variation that occurs in the number of coughs in each bout. In some 
cases only one or two bouts occurred in each animal and by only counting the bouts 
may mask any measureable differences in the effects of PGE2. Furthermore, 
individual coughs were easily recognisable by the sound and posture of the animal 
and there were no discrepancies of the number of coughs in each bout.     
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                                              4 seconds 
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                 Flow  
                 16 ml/s 
 
                 4 seconds 
 
Figure 3.2: An example trace of guinea-pig cough in response to capsaicin and 
PGE2. 
Inhaled capsaicin causes single loud coughs (a) whereas PGE2 causes smaller coughs 
which always occur in bouts (b). Images were acquired by screen capture during real 
time data replay.  
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3.3.2. Characterisation of PGE2-induced sensory nerve activation 
 
Once it was established that PGE2 was able to induce cough in the in vivo model, I 
then went on to characterise responses to PGE2 in isolated nerves from human, 
guinea-pig and mouse. In these species, I compared responses to PGE2 and common 
tussive agents, capsaicin and low pH (Lalloo et al. 1995; Usmani et al. 2005). Citric 
acid is commonly used in vivo to cause cough however a low pH solution of pH 5, 
similar to citric acid, was used on the isolated nerve as it is more physiological 
suitable for these experiments as it allows the vagal tissue to be preserved for the 
duration of the experiment (Fox et al. 1995).  Our group has previously published that 
the responses to capsaicin, low pH and PGE2 are remarkably similar in guinea-pig and 
human isolated nerves (Belvisi et al. 2008), however to be able to utilise the KO mice 
in the future, it was also necessary to compare responses in mice to guinea-pig and 
human.  
 
Depolarisation, which is a measure of sensory nerve activity, was recorded over a 2 
minute period while perfusing the nerve with different concentrations of PGE2, 
capsaicin or a low pH solution. Representative traces of the responses to these tussive 
stimuli in mouse are shown in Figure 3.3. All stimuli cause depolarisation and the 
maximum depolarisation achieved to each concentration was recorded. PGE2 and 
capsaicin caused a concentration-dependent increase in depolarisation with the 
vehicles (0.1 % DMSO and 0.1 % ethanol) having no effect on the nerves themselves 
(Figure 3.4).  
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Figure 3.3: Example depolarisation to PGE2 in an isolated nerve from wild type 
mice. 
The isolated nerve was incubated with PGE2, or other tussive stimuli, causing 
depolarisation. After 2 minutes, the nerve section was washed with Krebs until the 
response returns to baseline. The depolarising response is expressed as change in mV 
from baseline. 
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Figure 3.4: Comparison of the depolarising responses to PGE2, capsaicin and low 
pH in human, mouse and guinea-pig isolated nerves. 
Capsaicin (0 - 100 μM), low pH (a) and PGE2 (0 - 100 μM) (b), were applied to 
mouse (n=4-6), guinea-pig ( n=4-6) and human (n=1-5) isolated nerves for 2 minutes 
in a random order. Depolarisation (mV) was recorded and data were plotted as mean 
± s.e.m. 
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3.3.3. Development of a genotyping technique for knockout mice 
 
Breeding pairs of mice, each with a prostanoid receptor gene knocked out (EP1, EP2, 
EP3, EP4, TP, IP, FP or DP) were received as kind donations from Kyoto University, 
Japan. As shown in Figure 3.4, isolated vagus nerves from wild type mice display a 
remarkably similar depolarising response to PGE2, capsaicin and low pH when 
compared to guinea-pig and human nerves. Therefore, even though mice do not 
cough, the sensory nerve irritation is representative of guinea-pig and human tissue.  
In order to fully utilise these KO mice to investigate the role of the prostanoid 
receptors in PGE2-induced sensory nerve irritation, it was necessary to first develop a 
method to confirm the genotype.  
 
All of the KO mice had been bred on a C57bl/6 background with the exception of the 
EP4 KO mice. These mice were bred on a mixed background of C57bl/6 x 129/Ola as 
most offspring from parents with a C57bl/6 background did not survive for more than 
72 hours after birth (Segi et al. 1998). We were therefore also provided with breeding 
pairs of C57bl/6 x 129/Ola wild type mice as controls. 
 
The FP breeding pair consisted of a heterozygous female and a homozygous male. A 
homozygous female cannot be used for breeding purposes and she is unable to deliver 
the foetus at full term (Sugimoto et al. 1997). In order to expand our breeding colony, 
these mice required genotyping to identify heterozygous females and homozygous 
males for breeding purposes and then later to identify male homozygous KOs for 
experimentation. 
 
DNA was extracted from 13 mice from the FP receptor deficient mouse colony. To 
confirm that the extraction had been successful, a PCR reaction was carried out using 
mouse genomic DNA primers that had been previously optimised and validated. A 
band at the expected primer size (approx 250 bp) was observed in all of the DNA 
samples (Figure 3.5).  
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Figure 3.5: Verification of genomic DNA in the extracted samples. 
A gel showing genomic DNA present in tail digests of 3 wild-type animals and the 13 
FP receptor deficient offspring. Expected product size of 250 bp. 
 
Using the FP and neomycin primers, conditions were optimised for the MgCl2 
concentration and annealing temperatures. One wild type DNA and three random FP 
heterozygous/homozygous DNA samples were profiled (FP4, 5, 11). The reaction was 
effective at all 3 temperatures tested. Reactions containing 1.5 and 2 mM MgCl2, at 
the 65
o
C annealing temperature, are shown in Figure 3.6.  
 
 
 
 
 
 
 
 
 
Figure 3.6: Optimisation of PCR conditions. 
Gel shows the required conditions of the FP primers at 1.5 and 2 mM MgCl2 with an 
annealing temperature of 65 ºC. Negative control with water (control), positive wild 
type control (W.T.) and FP samples are shown. Expected wild type band at 750 bp 
and disrupted gene at 500 bp. No bands were observed with 1.5 mM MgCl2.    
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A concentration of 2.0 mM MgCl2 was found to produce a suitable band under these 
reaction conditions. The reaction was effective at all 3 temperatures tested and 65
o
C, 
producing the brightest band, was chosen for genotyping of DNA samples from the 
FP receptor heterozygous or KO mice (Figure 3.7). Male and female samples were 
identified and a double band indicated that the animal was heterozygous for the FP 
receptor gene and a single band at 500 bp indicated that the animal was a homozygous 
KO. From these results, heterozygous females and homozygous KO males were 
chosen for breeding pairs. 
 
 
 
 
 
 
 
 
 
Figure 3.7: Genotyping of 13 DNA samples extracted from FP deficient mice. 
The gel shows DNA extracted from wild type (positive controls) and FP receptor 
deficient mice (FP1-13). The primers for the wild type FP gene produce a band at 750 
bp and the primers for the disrupted FP gene produced a band at 500 bp. The positive 
control wild types contain both FP alleles. Double bands indicate heterozygous 
animals and the single band at 450 bp shows a homozygous KO mouse. Male (M) and 
Female (F) mice are indicated and heterozygous/homozygous animals are produced 
in a 50:50 ratio.     
 
Although the genotyping of the FP receptor deficient mouse colony was necessary to 
continue breeding, I also wanted to have a method of genotyping all of the different 
prostanoid receptor KO mice to ensure that the mice used for experimentation did 
have the particular gene disrupted. Therefore, using a similar approach to above, I 
designed and tested all of the primer pairs for each receptor KO.  Optimum conditions 
for each set of primers are shown in the table below (Table 3.2). All of the reactions 
included an initial step of 94°C for 2 minutes. This was then followed by 40 cycles of 
denaturing, annealing and extension. The denaturing step was constant for all 
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reactions (94°C for 30 seconds) and the annealing and extension temperatures and 
durations are shown in the table for each set of primers. After the 40 cycles, a final 
extension step was carried out for 10 minutes at the same temperature as the primer 
specific extension step. The reaction was stopped by cooling the samples to 4°C for 5 
minutes.  It was necessary to add DMSO to some of the GC-rich primer reactions to 
prevent secondary structure formation (Filichkin & Gelvin 1992). Furthermore, due to 
primer-primer interactions and the need for different annealing temperatures, some of 
the reactions for a particular receptor had to be carried out separately for wild type 
and KO product amplification. 
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Receptor Primers Annealing Extension  Product size 
(bp) °C secs °C secs 
EP1 (w.t.) EP1 for/rev 59 30 68 120 w.t. = 1000 
KO = 2100 
EP1 (KO) EP1 neo/rev 60 30 68 90 KO = 1000 
EP2 (w.t.) EP2 for/rev 58 30 68 60 w.t.=650 
EP2 (KO) EP2 neo/rev 65 30 75 60 KO = 470 
EP3 EP3 for/rev/neo 65 30 75 60 w.t. = 350 
KO = 550 
EP4 EP4 for/rev/neo 65 30 75 60 w.t. = 450 
KO = 700 
DP (w.t.) DP for/rev 60 30 75 90 w.t. = 400 
KO = 1500 
DP (KO) DP neo/rev 62 30 72 45 KO = 340 
FP FP for/rev/neo 65 30 75 45 w.t. = 750 
KO = 500 
IP IP for/rev/neo 58 30 68 90 w.t. = 1350 
KO = 900 
TP TP for/rev/neo 65 30 75 45 w.t. = 250 
KO = 650 
  
Table 3.2: Optimised PCR conditions for the genotyping of prostanoid receptor 
KO mice 
The table shows primer combinations to identify a particular w.t. or KO allele. 
Annealing and extension temperatures and durations are indicated. The final column 
shows the number of base pairs of the product, indicating the expected position of the 
band on the gel.  
 
Once the optimum conditions for each primer set were established, the genotypes of 
all of the animals in each colony were confirmed. Subsequently, animals used for 
experimentation were always genotyped using this technique.   
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3.4. DISCUSSION 
 
This chapter outlines the development of a model of PGE2-induced guinea-pig cough 
and PGE2-induced sensory nerve activation to enable investigation of the receptor 
responsible for the effects of PGE2. Furthermore, breeding colonies of each of the 
prostanoid receptor KO mice are a valuable asset to the research and in order to use 
these mice for experimentation I established a genotyping technique to confirm that 
each animal did have the assumed gene knocked out. 
 
In several studies of inhaled PGE2 in man, cough has been observed either as a 
primary end point or as a side effect. In a study by Costello et al., prostaglandin-
induced cough was characterised. Healthy subjects were repeatedly challenged with 
100-500 μg/ml and the coughs counted. The concentration of PGE2 used concurs with 
that chosen in this study to induce cough in guinea-pigs (100 μg/ml). In a separate 
group of subjects, inhaled PGE2 was compared to PGF2α, citric acid and acetylcholine 
and it was determined that PGF2α and PGE2 were, respectively, 1000 and 10000 times 
more potent than acetylcholine and citric acid, suggesting that PGE2 has significant 
tussive activity in man (Costello et al. 1985). Prior to these experiments in man, the 
only in vivo investigations of prostaglandin-induced cough had been carried out in the 
cat (Gardiner et al. 1978; Gardiner & Browne 1984) however no published literature 
is available in a guinea-pig model of PGE2-induced cough. 
 
As well as eliciting cough in healthy human subjects, PGE2 has also been shown to 
cause cough as a side effect during studies of PGE2-mediated bronchodilation and 
anti-inflammatory actions (Gauvreau et al. 1999; Kawakami et al. 1973; Melillo et al. 
1994; Pavord et al. 1993). While investigating prostaglandins as bronchodilators, 
Kawakami et al. noted cough and irritancy as a side effect. In this study, normal 
subjects as well as those with asthma and chronic bronchitis were investigated. Cough 
and irritancy occurred in a proportion of the subjects in each group, indicating that 
PGE2 induces cough in both normal subjects and disease patients. Prostaglandins can 
also sensitise the cough response in man to other tussive stimuli such as capsaicin. 
PGE2 (Choudry et al. 1989; Stone et al. 1992), PGF2α (Stone et al. 1992) and PGI2 
(Ishiura et al. 2007) have all been shown to sensitise the cough reflex and in parallel 
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to other studies of inhaled prostaglandins, these trials all noted that the prostaglandin 
induced cough in a proportion of patients.  
 
In this chapter I have described the development of a guinea-pig model of cough 
which will be used to investigate the receptor involved in the tussive effects of PGE2. 
Previously, in vivo investigations of PGE2-induced cough had been done using the cat 
as the species of choice (Gardiner et al. 1978; Gardiner & Browne 1984) however 
developing a model of guinea-pig cough provides a more cost effective in vivo model. 
Furthermore, in previous experiments with cats, although conscious measurements 
were taken, the animal was restrained causing undue stress and potential adverse 
effects on the cough response leading to unreliable results. In our model of cough in 
the guinea-pig, the animals remained conscious and unrestrained. Conscious 
unrestrained guinea-pigs allow analysis of the cough to incorporate stance and posture 
as well as sound produced during the cough reflex. Automated systems are in place 
for capsaicin and citric acid-induced cough as they occur as individual, distinct 
coughs. As PGE2-induced cough occurs in bouts of coughs and are smaller and 
quieter than capsaicin or citric acid-induced cough, an automated system has not yet 
been established using the Buxco software. Because of the inability of the Buxco 
software to recognise alternative types of cough, only 2 animals can be challenged at 
once rendering this model relatively lower throughput. Despite this, coughs counted 
by trained observers are unbiased and reproducible. Moreover, if required, the 
computer recording can be re-run to confirm the number of coughs.    
 
Our system for measuring sensory nerve activation in the isolated vagus nerve has 
previously been shown to be predictive of tussive effects of other ligands in vivo 
(Birrell et al. 2002; Patel et al. 2003; Usmani et al. 2005).The vagus nerve supplies 
the majority of the sensory nerve fibres to the airway and therefore depolarisation of 
the isolated vagus nerve from the guinea-pig was characterised using various tussive 
stimuli that have previously been shown to cause cough; capsaicin (Midgren et al. 
1992), PGE2 (Costello et al. 1985), and low pH (Laude et al. 1993). The guinea-pig 
species was initially chosen as they are capable of evoking a cough reflex in response 
to tussive stimuli (Patel et al. 2003). Furthermore, it has already been established that 
the guinea-pig vagus nerve responds in a similar manner to that of man (Belvisi et al. 
2008; Belvisi et al. 1998). The mouse vagus nerve was also characterised to responses 
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induced by the tussive stimuli. The mouse, guinea-pig and human vagus nerves 
produced a similar profile in the magnitude of their responses illustrating that the 
effects of these stimuli are translated across species. Although mice do not cough per 
se, these translational responses mean that future work will be able to incorporate 
parallel experiments using isolated vagus nerves from human, guinea-pig and wild 
type/KO mice.  
 
In vitro assessment of sensory nerve depolarisation provides a reliable alternative to in 
vivo cough experiments which are expensive and pose complex pharmacokinetic 
issues. The isolated vagus nerve preparation allows the PGE2-induced depolarisation 
to be investigated with antagonists that may not have an ideal pharmacokinetic profile 
in vivo. Furthermore, a much lesser quantity of agonist or antagonist is required to 
carry out an experiment using the isolated vagus nerve preparation compared to cough 
in vivo. However, the data from the isolated vagus nerve should be interpreted with 
some caution as the tussive stimuli and compounds are applied to the trunk of the 
isolated vagus nerve. Therefore the signal that is recorded extracellularly in these 
experiments represents a summation of the changes in membrane potential of all of 
the axons within the vagus nerve. Furthermore, the expression and transduction 
mechanisms of the receptors situated on the membrane of the axon may not 
necessarily represent their behaviour in the peripheral endings (Patel et al. 2003). An 
alternative method could be the single fibre technique where agents are applied 
directly to the nerve ending in the airway and action potentials can be recorded from a 
single fibre in the nerve trunk (Fox et al. 1997). This technique is, however, lower 
throughput and requires more specialised equipment. Nevertheless, agents that 
activate the nerve using either the isolated vagus nerve technique or the single fibre 
technique have also been shown to induce cough in vivo (Birrell et al. 2002; Fox et al. 
1997; Patel et al. 2003; Usmani et al. 2005) suggesting that the two models do 
translate. 
 
The final aim of this chapter was to develop a method of genotyping the prostanoid 
receptor KO mice. These mice are an extremely valuable tool for the project and so 
confirming that a particular animal has the assumed gene knocked out was crucial. As 
guinea-pigs are the only small animals with a cough reflex, knockout guinea-pig 
would be the ideal subject for an in vivo cough model as the effects of a particular 
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gene on PGE2-induced cough could be directly assessed. However these are not yet 
available as the full guinea-pig genome sequence has not yet been published. 
Furthermore, the smaller litter size and longer gestation period are also not optimal 
conditions for a KO breeding colony. Mice have been the preferred species for the 
production of transgenic animals and their genome can be altered to knockout, or up- 
or down-regulate the expression of a particular gene. Mice have a similar number of 
genes to humans, 40 % of the nucleotide sequence can directly align with the human 
genome and furthermore, 80 % of human genes have a corresponding gene in the 
mouse (Mouse Genome Sequencing Consortium 2002). An alternative to genotyping 
would be phenotyping. It may be possible, using a selective agonist to show that the 
agonist has an effect in the wild type and no effect in the KO mouse therefore 
confirming that the animal is a KO. This method, however, should be used with 
caution as we do not know the effect of disrupting one gene on other genes. For 
example if one of the prostanoid genes is knocked out, it could be possible, in theory, 
that other receptors may be inactivated. Therefore, in one KO, several selective 
agonists may not have affinity at their receptors rendering it difficult to confirm which 
gene is knocked out. Furthermore, prostanoid ligands that are available are not 
completely selective and so even if the targeted gene is knocked out, an agonist may 
still have an effect, but not through the assumed receptor.  
 
In summary, I have shown here that PGE2 causes cough in an in vivo guinea-pig 
model and this effect is translated into the isolated vagus nerve preparation where 
PGE2 caused depolarisation in nerves from human, guinea-pig and mouse. 
Furthermore, a genotyping technique has been established for all of the prostanoid 
receptor KO colonies allowing these mice to be available for future experimentation.  
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CHAPTER 4 
 
 Investigating the prostanoid receptor mediating 
PGE2-induced nerve activation 
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4.1. RATIONALE 
 
In Chapter 3, it was demonstrated that PGE2 causes cough in guinea-pigs which 
concurs with the reported tussive effects in man. Furthermore, I also characterised the 
responses to PGE2 in an isolated vagus nerve preparation. In this chapter, the aim is to 
utilise the isolated vagus nerve preparation and profile a range of prostanoid receptor 
antagonists in the system against PGE2 and therefore identify the receptor involved in 
PGE2-induced depolarisation of the isolated nerve. Until recently, the availability of 
prostanoid receptor antagonists had been limited and those that were available lacked 
selectivity at a particular receptor. After contacting pharmaceutical companies, in 
addition to purchasing commercially available antagonists, I managed to accumulate a 
range of pharmacological tools. 
 
In parallel to the antagonist experiments, isolated vagus nerves from prostanoid 
receptor KO mice are another valuable tool to probe the receptor responsible for 
PGE2-induced depolarisation. After developing a genotyping technique for each of the 
prostanoid receptor KOs, vagal nerves from the animals were then available for use in 
experiments. Although mice do not cough per se, I illustrated in Chapter 3 that PGE2, 
as well as other tussive agents, capsaicin and low pH, were able to depolarise the 
isolated nerves from wild type mice. By comparing the depolarisation induced by 
PGE2 in the wild type and KO mice, I aim to identify the receptor involved in PGE2-
induced sensory nerve activation in this system.     
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4.2. METHODS 
 
4.2.1. Antagonism of PGE2-induced depolarisation. 
 
Vagus nerves from male C57bl/6j mice (18-20 g, Bred in-house) and male Dunkin-
Hartley guinea-pigs (250-350 g, Harlan, Bicester, UK) were dissected free and placed 
in Krebs‟s solution as described in section 2.5.1. Human vagus nerve was removed 
from donor patients for heart or heart/lung transplants performed at The Royal 
Brompton or Harefield Hospital. Approval was obtained from the Royal Brompton 
and Harefield ethics committee.  
 
A concentration of 10 μM PGE2 was selected from the range of concentrations 
investigated in Chapter 3 and the effect of a range of receptor antagonists was 
investigated in the guinea-pig and mouse; 0.1 % DMSO vehicle, 1 μM GW848687X 
(EP1) (Giblin et al. 2007), 0.2 μM L826266 (EP3) (Gallant et al. 2002; Juteau et al. 
2001), 1 μM GW627368X (EP4) (Wilson et al. 2006), 10 μM AL8810 (FP) (Griffin et 
al. 1999), 10 μM AH6809 (EP1/2DP) (Keery & Lumley 1988), 1 μM SQ29548 (TP) 
(Ogletree et al. 1985) and 1 μM RO3244794 (IP) (Bley et al. 2005). Concentrations of 
antagonists were selected at approximately 100-fold pA2 value as is common practice. 
Information regarding the affinity/potency and selectivity of the antagonists is 
described below in table 4.1.Where possible, agonists (10 μM) which have a 
preference for a certain prostanoid receptor were profiled in parallel to PGE2: PGF2α 
(FP), PGD2 (DP), Iloprost (IP) and U46619 (TP). Agonists were applied to the nerve 
for 2 minutes and washed. A second response was elicited to ensure the response was 
reproducible. The antagonist was then perfused onto the nerve for 10 minutes and 
immediately after, PGE2 (or agonist) in the presence of antagonist was applied and the 
inhibition recorded. The nerve was then washed and the agonist response repeated to 
ensure the nerve was still viable. Any antagonists that inhibited the PGE2-induced 
depolarisation were then investigated in the human vagus nerve. 
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Prostanoid 
antagonist 
Affinity/Potency Selectivity 
GW848687X 
(EP1) 
pA2 of 9.1 (a) 
pIC50 at human recombinant EP1 
= 8.6±0.1 (a) 
>400-fold selectivity for EP1 
over other EP receptors (a)  
L826266 (EP3) Ki = 0.002 at rat EP3 receptor (b) 3000-fold more selective at EP3 
compared to EP4 and >7500-
fold compared to EP1 and EP2 
receptors (b) 
GW627368X 
(EP4) 
human EP4 receptors pKb = 7.9 ± 
0.4 (c) 
pre-contracted piglet saphenous 
vein pKb = 9.2 ± 0.2 (c) 
>10000 fold selectivity for EP4 
over other prostanoid receptors 
(c) 
AH6809 (EP1, 
EP2, DP) 
Antagonist of anti-aggregatory 
effects of PGD2 at the DP receptor 
pA2 = ~6 (d) 
~ equal selectivity a the DP, 
EP1 and EP2  (e) 
AL8810 (FP) Inhibition of FP agonist in A7r6 
cells and 3T3 cells with pA2 
values of 6.68 and 6.34 (f) 
TP antagonism > 100µM 
No activity at other prostanoid 
receptors (f) 
RO3244794 
(IP) 
Inhibition of carbaprostacyclin 
cAMP accumulation pA2 = 8.5 ± 
0.11 (g) 
>1000 fold selectivity for the IP 
receptor over the other 
prostanoid receptors (g) 
SQ29548 (TP) Inhibition of guinea-pig trachea 
contraction by a thromboxane A2 
mimetic. pA2 = 7.8 (h) 
Ki at the TP receptor = 4.1nM 
Ki at other prostanoid receptors 
= >100000 nM (h) 
 
Table 4.1: Information about the affinity/potency and selectivity of the 
prostanoid receptor antagonists used in this thesis. 
a) Giblin et al. 2007, b) personal communication, c) Wilson et al. 2006, d) Keery & 
Lumley 1988, e) Kiriyama et al. 1997, f) Griffin et al. 1999, g) Bley et al. 2005, h) 
Ogletree et al. 1985. 
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4.2.2. Dose response of the EP3 receptor antagonist on PGE2 and sulprostone-
induced depolarisation 
 
Vagus nerves from male Dunkin-Hartley guinea-pigs (250-350 g, Harlan, Bicester, 
UK) were dissected free and placed in Krebs‟s solution as described in section 2.5.1. 
A dose response of the EP3 antagonist L826266 (0.02, 0.2, 2 and 20 μM) in response 
to depolarisation by 10 μM PGE2 was investigated. A concentration of 2 μM L-
826266 was also profiled against sulprostone (10 μM), an agonist with some 
selectivity for the EP3 receptor.  
 
4.2.3. Effect of EP3 receptor antagonist on prostanoids and tussive stimuli  
 
Vagus nerves from male Dunkin-Hartley guinea-pigs (250-350 g, Harlan, Bicester, 
UK) were dissected free and placed in Krebs‟s solution as described in section 2.5.1. 
The effect of 2 μM L826266 (EP3 receptor antagonist) on responses to PGE2, PGD2, 
PGF2α, Iloprost, U46619 (all 10 μM), capsaicin (1 μM) and low pH was recorded as 
described above. 
 
4.2.4. The effects of tussive stimuli on isolated nerves from prostanoid receptor 
KO mice 
 
Vagus nerves from wild type or prostanoid receptor KO mice (18-20 g) were 
dissected free and placed in Krebs‟s solution as described in section 2.5.1. PGE2 (0.1, 
1, 10 or 100 μM), another example prostanoid PGD2 (10 μM), capsaicin (1 μM) or 
low pH were applied to the nerves for 2 minutes and the depolarisation recorded.  
 
4.2.5. Statistical analysis 
 
Antagonism of prostanoid agonists was analysed using a two-tailed paired t-test 
comparing responses to agonist (in the same piece of vagus nerve) in the absence and 
presence of antagonist. Responses to PGE2 in the KO mice were analysed using the 
Kruskal-Wallis test for multiple comparisons followed by a Dunn‟s post-hoc test, 
comparing responses in each prostanoid receptor KO to the corresponding wild type 
control. Data are presented as mean ± s.e.m., *P<0.05. 
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4.3. RESULTS 
 
4.3.1. Antagonism of PGE2-induced depolarisation of isolated vagus nerves 
 
After confirming that PGE2-induces depolarisation in isolated vagus nerves, I then 
proceeded to investigate the receptor mediating this response in guinea-pig isolated 
nerves using an extensive range of prostanoid receptor agonists and antagonists. 
Antagonists at FP (AL8810), EP1/2DP (AH6809), TP (SQ29548) and IP (RO3244794) 
inhibited corresponding receptor agonists (PGF2α, PGD2, U46619 and Iloprost 
respectively) but did not inhibit PGE2-induced depolarisation (Figure 4.1a). Vehicle 
or antagonists at EP1 (GW848687X) and EP4 (GW627368X) had no effect on PGE2; 
however the EP3 antagonist (L826266) attenuated depolarisation to PGE2 in the 
guinea-pig vagus nerve (Figure 4.1b). 
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(a) 
 
 
 
 
 
 
 
 
 
  (b) 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: The effect of prostanoid receptor antagonists on PGE2-induced 
depolarisation of the guinea-pig vagus nerve. 
(a) Inhibition of PGE2 (black bars) or selective agonists (open bars; 10 μM PGF2α 
(FP), PGD2 (DP), U46619 (TP) and Iloprost (IP)) by antagonists 10 μM AL8810 
(FP), 10 μM AH6809 (EP1/2DP), 1 μM TP (SQ29548) and 1 μM IP (RO3244794) 
respectively. (b) Inhibition of PGE2-induced depolarisation (10 μM) by vehicle (0.1 % 
DMSO) and antagonists at EP1 (1 μM GW848687X), EP3 (0.2 μM L826266) and EP4 
(1 μM GW627368X). Data represent mean ± s.e.m., n=4, *p<0.05 comparing 
response in the same nerve before and after antagonist.  
 
 
 102 
In order to illustrate antagonism of a prostanoid agonist in the isolated vagus nerve, an 
example trace is shown in Figure 4.2. The example shows that the FP antagonist, 
AL8810, inhibited the responses to PGF2α by 60 % but did not attenuate the 
depolarisation elicited by PGE2 (Figure 4.2). Two reproducible responses to the 
agonist were acquired. The antagonist was then incubated for 10 minutes and the 
agonist perfused onto the nerve in the presence of the antagonist to measure 
depolarisation. Once the nerve had recovered, the nerve was washed with Krebs and 
again perfused with the agonist. This was to ensure that the decreased response to the 
agonist was due to the antagonist rather than a decline in the responsiveness of the 
nerve. It must be noted that in all antagonist experiments, data was only included if 
the agonist responses were recovered after antagonist incubation.  
 
     (a)                              
 
 
 
 
 
 
 
 
    (b) 
 
 
 
 
 
 
Figure 4.2: AL8810 inhibits PGF2α but not PGE2 in the isolated guinea-pig vagus 
nerve. 
Representative traces showing the effects of the FP antagonist AL8810 on PGF2α (a) 
and PGE2 (b). AL8810 inhibited PGF2α by 60 % but did not inhibit PGE2. “w” 
indicates where the nerve was washed with Krebs following the 2 minute incubation. 
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The same range of antagonists was then investigated in wild type mice and the effects 
were mirrored in both species. The EP3 antagonist significantly inhibited PGE2-
induced depolarisation of the mouse vagus nerve, whereas no inhibition by the other 
antagonists was observed (Figure 4.3). 
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Figure 4.3: The effect of prostanoid receptor antagonists on PGE2-induced 
depolarisation of the mouse vagus nerve. 
(a) Inhibition of PGE2 (black bars) or selective agonists (open bars; 10 μM PGF2α 
(FP), PGD2 (DP), U46619 (TP) and Iloprost (IP)) by antagonists 10 μM AL8810 
(FP), 10 μM AH6809 (EP1/2DP), 1 μM SQ29548 (TP) and 1 μM RO3244794 (IP) 
respectively. (b) Inhibition of PGE2-induced depolarisation (10 μM) by vehicle (0.1 % 
DMSO) and antagonists at EP1 (1 μM GW848687X), EP3 (0.2 μM L826266) and EP4 
(1 μM GW627368X). Data represent mean ± s.e.m., n=4, *p<0.05 comparing 
response in the same nerve before and after antagonist.  
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I then went on to further investigate the effects of the EP3 antagonist on PGE2-induced 
depolarisation. Using isolated guinea-pig vagus nerves, L826266 concentration-
dependently inhibited PGE2 (Figure 4.4). L826266 also completely abolished 
depolarisations induced by sulprostone, an EP3 agonist, confirming that L826266 is an 
EP3 antagonist (Figure 4.4). The EP3 antagonist had a remarkably similar effect in the 
human vagus nerve, inhibiting PGE2 by 80 % (Figure 4.5) suggesting that the receptor 
responsible for PGE2-induced sensory nerve activation is the same in guinea-pigs, 
mice and humans. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Dose response of EP3 receptor antagonist on PGE2 and sulprostone-
induced depolarisation in guinea-pig isolated vagus nerves. 
Percentage inhibition of 10 μM PGE2 (black bars) by 0.1 % DMSO or L826266 (0.02, 
0.2, 2 and 20 μM). Percentage inhibition of 10 μM Sulprostone (grey bar) by 2 μM 
L826266. Data are expressed as mean ± s.e.m. (n=4), *p<0.05 comparing responses 
in the same nerve before and after antagonist. 
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Figure 4.5: Inhibition of PGE2 by the EP3 receptor antagonist in an isolated 
human vagus nerve. 
A copy of an original trace in which a concentration of 0.2 μM EP3 antagonist 
inhibited PGE2-induced depolarisation in the human vagus nerve by 80 %. “w” 
indicates where the nerve was washed following the 2 minute incubation. 
 
After identifying that the PGE2-induced depolarisation was attenuated by the EP3 
receptor antagonist in all three species, it was then necessary to investigate whether 
the EP3 antagonist specifically inhibits PGE2-induced depolarisation or if the 
antagonist can inhibit depolarisation induced by other tussive stimuli (Figure 4.6). A 
concentration of 2 μM L826266 inhibited PGE2 by 100 % however the antagonist did 
not inhibit capsaicin, low pH or other prostanoids; PGD2, U46619, or Iloprost. 
L826266 did however partially inhibit depolarisation induced by PGF2α. 
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Figure 4.6: The effect of an EP3 receptor antagonist on prostanoid agonists, 
capsaicin and low pH in the isolated guinea-pig vagus nerve. 
Percentage inhibition of PGE2 (10 μM), capsaicin (1 μM), low pH (pH 5) PGD2 (10 
μM), U46619 (10 μM), PGF2α (10 μM) by L826266 (2 μM) in guinea-pig vagus 
nerves. Data are expressed as mean ± s.e.m. (n=4), *p<0.05 comparing responses in 
the same nerve before and after antagonist. 
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4.3.2. The effects of PGE2 in isolated nerves from prostanoid receptor KO mice 
 
Prostanoid receptor KO mice are a valuable tool to investigate the receptor involved 
in PGE2-induced activation of sensory nerves. Although a comprehensive range of 
antagonists have been acquired, not all receptor antagonists are completely selective. 
For example, the antagonist AH6809 has been shown to act as an antagonist at the 
EP1, EP2 and DP receptors. However, a number of selective antagonists have been 
acquired and furthermore, the prostanoid receptor KO mice are available to profile in 
parallel. Although mice do not cough, it was shown in Chapter 3 that the magnitude 
of depolarisation to PGE2 in mice was similar to that in guinea-pig and human nerves 
illustrating that PGE2 can activate nerves in mice, despite the absence of a cough 
reflex. 
 
To investigate the responses to PGE2 in the mice, isolated nerves were dissected from 
wild type and KO mice and the responses to 10 μM PGE2 were compared. The EP1, 
EP2, EP3, DP, FP, IP and TP KO mice were compared to the C57bl/6 wild type mice 
and the EP4 KO mice were compared to the C57bl/6 x 129/Ola mice according to the 
background that the KO was bred on. The EP3 KO mice had a significantly decreased 
response to PGE2 compared to the corresponding wild types suggesting that the EP3 
receptor is required for PGE2-induced depolarisation of the nerve (Figure 4.7).  An 
example trace showing the responses to PGE2 in wild types and EP3 KO mice is 
shown in Figure 4.8. PGE2 caused depolarisation in the wild type mice eliciting a 
change of 0.11 mV whereas a significantly smaller depolarisation was seen in the 
isolated nerves from the EP3 KO mice (Figure 4.8). All of the mice used for 
experimentation were genotyped using the methods developed and optimised in 
Chapter 3. As an example, a gel is shown confirming disruption of the gene encoding 
the EP3 receptor in EP3 KO mice. Using the EP3 primers, PCR products were run on a 
gel allowing the wild type and EP3 KOs to be confirmed (Figure 4.9). 
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Figure 4.7: The effects of PGE2 in isolated nerves from wild types and prostanoid 
receptor KO mice. 
Responses to 10 μM PGE2 in isolated vagus nerves from wild type or prostanoid 
receptor knockout mice. EP1, EP2, EP3, DP, FP, IP and TP KOs were compared to 
C57bl/6 (w.t.) and EP4KO to C57bl/6 x 129Ola (EP4w.t.). Data are expressed as 
mean ± s.e.m. (n=4-6) and *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: An example trace showing the effects of PGE2 in isolated nerves from 
wild type and EP3KO mice. 
Representative trace showing the depolarisation to 10 μM PGE2 in the wild type mice 
(left) and no effect of PGE2 in the  EP3 KO mice (right). “w” indicates where the 
nerve was washed following the 2 minute incubation. 
0
0.05
0.1
0.15
mV
0
0.05
0.1
0.15
mV
2min 2min
C57bl/6 EP3KO
PGE2 PGE2
w
w
w
 110 
Vehicle 0.1 1 10 100
0.000
0.025
0.050
0.075
0.100
0.125
0.150
0.175
Vehicle/PGE2 (M)
D
ep
ol
ar
is
at
io
n 
(m
V
)
350bp
550bp
C57BL/6 Ptger3 -/-
 
 
 
 
 
Figure 4.9: An example gel showing the PCR products of DNA extracted from 
wild type and EP3 KO mice. 
Representative gel showing PCR products using the EP3 primers. Product size in wild 
type was 350 bp and EP3 KO 550 bp. 
 
Once it was established that a concentration of 10 μM PGE2 caused depolarisation in 
the wild type mice and that this response was virtually abolished in the EP3 KO mice, 
a dose response to PGE2 was then carried out. It is possible that a higher concentration 
of PGE2 may induce depolarisation in the EP3 KO mice and so concentrations of 
PGE2 (0.1, 1, 10 and 100 μM) were compared in the wild type and EP3 KO mice 
(Figure 4.10). Depolarisation to PGE2 in the wild type mice concentration-
dependently increased where as a small depolarisation, seen in one animal in the 10 
μM group was the only effect of PGE2 in the EP3 KO mice. The absence of a response 
to PGE2 was maintained in the EP3 KO mice using 100 μM PGE2. 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Concentration response of PGE2 in isolated nerves from wild types 
and EP3 KO mice. 
Depolarisation to Vehicle (0.1 % ethanol), 0.1, 1, 10 and 100 μM PGE2 in wild type 
(open bars) and EP3 KO mice (black bars). Data are expressed as mean ± s.e.m. 
(n=4). 
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4.3.3. The effect of other tussive stimuli on isolated nerves from KO mice. 
 
It has been established so far that PGE2-induced depolarisation of the isolated vagus 
nerve is virtually abolished in the EP3 KO mice. I then went on to investigate whether 
the response to another prostanoid is still present in the EP3 KO mice (Figure 4.11). 
Using PGD2 as an example, I have shown that the response to PGE2 was abolished in 
the EP3 KO mice however PGD2 induced depolarisation in these mice suggesting that 
the EP3 receptor-mediated response is not responsible for all prostanoid-induced 
depolarisation.    
 
 
 
 
 
 
 
 
 
 
Figure 4.11: The effect of PGE2 and PGD2, in isolated vagus nerves from EP3KO 
mice.  
Depolarisation in response to PGE2 and PGD2 (10 μM) in isolated vagus nerves from 
EP3KO mice. Data expressed as mean ± s.e.m. (n=4). 
 
The response to PGE2 was abolished in the EP3 KO mice however the response to 
PGD2 is still present, suggesting that the PGD2-induced depolarisation occurs through 
a different mechanism to PGE2. Further investigation aimed to identify whether the 
depolarisation to other non-prostanoid tussive stimuli is altered in any of the isolated 
vagus nerves from prostanoid receptor KO mice (Figure 4.12). The depolarisation to 
both capsaicin and low pH appear to be increased in the isolated vagus nerves from 
EP3 KO mice when compared to the responses in the wild type mice. However this 
effect was not statistically significant.     
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Figure 4.12: The effect of capsaicin and low pH in isolated nerves from 
prostanoid receptor KO mice. 
Responses to (a) 1 μM capsaicin and (b) low pH in isolated vagus nerves from wild 
type or prostanoid receptor KO mice. EP1, EP2, EP3, DP, FP, IP and TP KOs were 
compared to C57bl/6 (wild type) and EP4 KO to C57bl/6 x 129Ola (EP4 wild type). 
Data are expressed as mean ± s.e.m. (n=4-6). 
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4.4. DISCUSSION 
 
It has been established that PGE2 causes cough in guinea-pigs and can depolarise the 
isolated vagus nerve from mouse, guinea-pig and man. The aim of this chapter was to 
investigate the receptor responsible for the PGE2-induced depolarisation using the 
isolated vagus nerve preparation. Prior to the start of my PhD, the range of prostanoid 
receptor agonists and antagonists available was limited and so after contacting several 
pharmaceutical companies and receiving breeding pairs of prostanoid receptor KO 
mice, I was then in a position to address the hypothesis.  
 
In Chapter 3, it was established that a concentration of 10 μM PGE2 induced 
depolarisation in all three species and so I then proceeded to investigate whether the 
PGE2-induced depolarisation could be inhibited by any of the available prostanoid 
receptor antagonists. Antagonists at the FP (AL8810), EP1/2/DP (AH6809), TP 
(SQ29548) and IP (RO3244794) receptors inhibited their corresponding receptor 
agonists; PGF2α (FP), PGD2 (DP), U46619 (TP) and Iloprost (IP) respectively but did 
not inhibit PGE2. Based on this data it could be suggested that the FP, DP, TP and IP 
receptors are all expressed on the vagus nerve, but do not mediate the effects of PGE2. 
Given that PGE2 has the highest affinity at the EP receptors (Abramovitz et al. 2000; 
Coleman et al. 1994), it is likely that one or more of the EP receptors could be 
involved in PGE2-induced depolarisation. Unfortunately, no selective antagonists at 
the EP2 receptor were available. Antagonists at EP1 (GW848687X) and EP4 
(GW627368X) had no effect on PGE2 however the EP3 antagonist, L826266 
attenuated the PGE2-induced depolarisation in guinea-pig, human and mouse isolated 
nerves. To illustrate that the effects were not just seen at the concentration of 
antagonist used, a concentration response of the antagonist against PGE2 was carried 
out and L826266 concentration-dependently inhibited PGE2-induced depolarisation. 
Repeated stimulation of the isolated vagus nerve with the same tussive stimuli gives 
rise to potential modulatory effects such as desensitisation. This does not occur with 
PGE2 in this system. For example, in the antagonist dose response, the responses to 
PGE2 were reproducible (n=12) regardless of the concentration of antagonist used; 
0.099 ± 0.005 mV (first stimulation), 0.108 ± 0.005 mV (second stimulation) and 
0.093 ± 0.004 mV (after antagonist recovery). Taken in combination, this data 
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provided substantial evidence that the EP3 receptor plays a significant role in this 
response to PGE2 and that furthermore, the effect is translated across species.  
 
Although significant pharmacological evidence that the EP3 receptor is responsible for 
PGE2-induced sensory nerve activity has been produced, this data was further 
supported using isolated nerves from prostanoid receptor KO mice. The receptor 
antagonists used in the study were not all completely selective; for example, AH6809 
has been shown to act as an antagonist at the EP1, EP2 and DP receptors (Coleman et 
al. 1985; Keery & Lumley 1988; Woodward et al. 1995). Although mice do not 
cough per se, these KO mice can be used in parallel to the antagonist studies to 
identify the receptor involved in PGE2-induced depolarisation.  The EP3 KO mice had 
a diminished response to 10 μM PGE2 whereas responses in nerves from other 
prostanoid receptor deficient mice; EP1, EP2, EP4, DP, FP, IP, TP depolarised the 
nerve to the same magnitude as wild types. A dose response in wild type and EP3 KO 
mice was carried out to investigate whether the diminished response with 10 μM 
PGE2 was maintained at higher and lower concentrations of PGE2.  Responses to 
PGE2 in EP3 KO mice were completely abolished at 0.1, 1 and 100 μM illustrating 
that this was not just an effect at one concentration of PGE2. 
 
PGE2 causes depolarisation via the EP3 receptor however it was unknown whether the 
receptor mediated all prostanoid-induced depolarisation or if it is specific to PGE2. 
Where the response to PGE2 was abolished in the EP3 KO mice a response to PGD2 
was still attained suggesting that the EP3 receptor does not play a role in all 
prostanoid-induced depolarisation. In the guinea-pig isolated vagus nerves, a 
concentration of 2 μM L826266 completely abolished the depolarisation induced by 
PGE2 and sulprostone, an EP3 agonist. PGE2 has affinity at all four EP receptors 
(Breyer et al. 2001; Coleman et al. 1994; Narumiya et al. 1999) and sulprostone has 
been show to have affinity at both the EP1 and EP3 receptors (Kiriyama et al. 1997). 
As L826266 can inhibit both PGE2 and sulprostone by 100 % it could be suggested 
that depolarisation induced by these agonists is only mediated by the EP3 receptor and 
not by other EP receptors. Other tussive agonists were also profiled against the same 
concentration of L826266 and depolarisation induced by capsaicin, low pH, PGD2, 
U46619, and Iloprost was not inhibited by L826266. The antagonist did, however, 
significantly inhibit the response to PGF2α. Previously in this chapter; it was shown 
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that the FP receptor antagonist, AL8810, inhibited PGF2α-induced depolarisation by 
59 ± 10.6 %. Here it was shown that the EP3 antagonist L826266 also partially 
inhibited PGF2α. One possible suggestion could be that L826266 is not completely 
selective for the EP3 receptor. However unpublished data has shown that L826266 is 
25,000 times more potent at the EP3 receptor than it is at the FP receptor (Ki = 0.001 
nM EP3, 25 nM FP) (Personal Communication (Slipetz 2007)). An alternative, and 
more likely, suggestion would be that PGF2α is causing depolarisation of the isolated 
vagus nerve through both the FP and the EP3 receptors. Published literature would 
support this theory as PGF2α has been previously been shown to cause contraction of 
airway smooth muscle via the EP3 receptor (Kiriyama et al. 1997). 
 
The isolated nerves from EP3 KO mice had a significantly decreased response to PGE2 
and the EP3 antagonist inhibited PGE2, but not capsaicin or low pH. Because highly 
selective antagonists are not available for all receptors, the responses to capsaicin and 
low pH were profiled in isolated nerves from the prostanoid receptor KO mice.  No 
significant differences were observed, however the responses to both capsaicin and 
low pH in the EP3 KO mice were greater when compared to vehicle. More n-numbers 
would be required to confirm whether this is indeed a true effect. As described in 
Chapter 1, capsaicin and low pH are thought to depolarise nerves through activation 
of the TRPV1 receptor (Fox et al. 1995). The fact that the responses to these stimuli 
were increased in EP3 KO mice, but were not inhibited by the EP3 receptor antagonist 
may suggest that this is not a direct effect on the EP3 receptor. One explanation could 
be that altering the expression of the EP3 receptor may impact on the TRPV1 receptor, 
possibly upregulating the number of TRPV1 receptors expressed on the membrane. 
This would then result in more TRPV1 receptors present on the membrane to cause an 
increase in the depolarisation response to capsaicin and low pH. 
 
In summary this chapter has confirmed, in vitro, that the EP3 receptor antagonist 
L826266 inhibits PGE2-induced depolarisation of the guinea-pig, mouse and human 
vagus nerves and that the response to PGE2 is virtually abolished in EP3 KO mice. 
Taken in combination, this would suggest that the EP3 receptor mediates PGE2-
induced depolarisation of isolated vagus nerves from human, mouse and guinea-pig 
and could potentially mediate PGE2-induced cough. 
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CHAPTER 5 
 
 The EP3 receptor in vagal nerve ganglia and cough 
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5.1. RATIONALE 
 
It has been shown so far that PGE2 causes cough in guinea-pigs. Furthermore, PGE2 
depolarises isolated vagus nerves from guinea-pig, mouse and human and the EP3 
antagonist inhibits this response in all three species. Responses to PGE2 in the vagus 
from EP3KO mice are virtually abolished when compared to isolated vagus nerves 
from wild type mice. Taken in combination, this data provides key evidence that the 
EP3 receptor is central to PGE2-induced depolarisation and could therefore be 
responsible for PGE2-induced cough.  
 
The first aim of this chapter was to confirm that the EP3 receptor is expressed in nerve 
cell bodies carried in the vagus nerve. The cell bodies of vagal nerve fibres are 
contained in jugular and nodose ganglia. Using TaqMan real-time PCR and 
immunohistochemical techniques I aimed to identify the EP3 receptor expression, at 
the gene and protein level, in both guinea-pig nodose and jugular ganglia. 
 
The second aim of this chapter was to show that the EP3 receptor antagonist can 
inhibit PGE2-induced cough in vivo. It has been shown that the EP3 antagonist inhibits 
PGE2-induced depolarisation in guinea-pig, mouse and human isolated nerves 
suggesting that the mechanism of PGE2-induced depolarisation translates to man. This 
evidence is further supported as PGE2 causes cough in both man and guinea-pig. 
Using a model of PGE2-induced cough in the guinea-pig, I aim to show the 
involvement of the EP3 receptor in PGE2-induced cough.  
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5.2. METHODS 
 
5.2.1. Gene expression of the EP3 receptor measured by Taqman Real Time-PCR 
 
Expression of the EP3 receptor was measured as previously described in section 2.6. 
Briefly guinea-pig tissue samples were dissected and immediately flash-frozen. The 
tissue was crushed and RNA extracted. Human RNA was purchased from Clontech 
Laboratories. RNA was reverse-transcribed and amplification of the cDNA and 
detection of the target PCR product was carried out by real-time PCR involving a 5‟-
nuclease assay with fluorescent labelled Taqman probes (Applied Biosystems, 
Warrington, UK). Human primers and probes for the EP3 receptor were purchased as 
an assay-on-demand from Applied Biosystems (See Table 5.1). Sequences for the 
guinea-pig assay were kindly designed by GlaxoSmithKline and the primers and 
probe for the EP3 receptor custom-made by Applied Biosystems (Table 5.1). 
Reactions were internally controlled by 18S rRNA internal control (Applied 
Biosystems). Amplification and detection of the 18S and EP3 products were carried 
out using the ABI PRISM 7000 sequence detection system (Applied Biosystems). 
Sequence Detection Software was used for data analysis and amounts of target gene 
was normalised to the amount of 18S rRNA internal control in the same reaction. 
Data was converted from the exponential form into linear data using the calculation 2
-
(target ct – 18S ct)
 where ct is the number of threshold cycles. The numbers were changed 
into whole numbers by multiplying by 10
6
. 
 
Assay PubMed 
accession number 
Primer and probe sequences. 
Human EP3  NM_198712 Hs00168755_m1 Applied Biosystems assay ID 
Guinea-pig EP3 N/A Forward primer 5‟-ATGCGAGCCACATGAAGACG-3‟ 
Reverse primer 5‟-CAGTGTACTGACCCACGCCC-3‟ 
Probe 5‟-GTGCTGCTCGGCGTGTGGCTG-3‟ 
 
Table 5.1: Table showing the primer and probe sequences or the assay number 
for the human and guinea-pig EP3 receptor TaqMan assays. 
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5.2.2. Immunohistochemical staining of guinea-pig tissue sections 
 
Sections were prepared as describer in section 2.7. Kidney (positive control), jugular 
ganglia or nodose ganglia sections were incubated with a rabbit polyclonal EP3 
receptor antibody (SantaCruz sc20676, 1:50) or rabbit isotype control for one hour at 
room temperature. The rabbit polyclonal PGP 9.5 antibody (Abcam 1:3000) was 
incubated overnight at 4ºC.   Sections were washed and a goat anti-rabbit biotinylated 
secondary antibody (Dako 1:300) was applied for one hour at room temperature. An 
avidin and biotinylated horseradish peroxidise complex was applied to the sections 
followed by DAB chromagen and nuclei counterstained with haematoxylin. Image 
acquisition was carried out as previously described in section 2.7.    
 
5.2.3. Pharmacokinetic analysis of orally administered L826266 
 
The jugular vein of each guinea-pig was cannulated prior to L826266 administration, 
to allow serial blood sampling. Guinea-pigs were dosed with 30 mg/kg L826266 in 
methylcellulose in water (p.o.). Serial blood samples (150µl) were removed at 0, 15, 
30, 60, 120, 240, 360 and 1440 minutes after administration of L826266. An equal 
volume of heparinised saline was administered to the animal after removal of each 
blood sample. Plasma was separated from blood samples and analysed for L826266 
by Liquid Chromatography - Mass Spectrometry/Mass Spectrometry (LC-MS/MS) 
analysis by Merck Frosst, Canada. 
 
5.2.4. Antagonism of the PGE2-induced cough in vivo 
 
In the first study, male guinea-pigs were dosed i.p. with vehicle (0.5 % 
methylcellulose + 0.2 % Tween 80 in saline), 0.3, 3 or 30 mg/kg L826266 in 
suspension (5ml/kg at 2 sites) one hour prior to cough challenge. Guinea-pigs were 
then exposed to an aerosol of 100 μg/ml PGE2 for 10 minutes and the coughs counted 
as previously described. 
 
In the second study, male guinea-pigs were dosed i.p. with vehicle (0.5 % 
methylcellulose + 0.2 % Tween 80 in saline) or 300 mg/kg L826266 (5 ml/kg at 2 
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sites) 40 minutes prior to cough challenge. Guinea-pigs were exposed to 300 μg/ml 
PGE2 for 10 minutes and the coughs counted as detailed in section 2.2.1. 
 
In each study, following cough challenge, animals were given an overdose of 
pentobarbitone and a blood sample taken via cardiac puncture. Plasma was separated 
from blood samples and analysed for L826266 by LC-MS/MS analysis by Merck 
Frosst, Canada.  
 
5.2.5. Statistical analysis 
 
A concentration-response curve to PGE2-induced cough was analysed using Kruskal-
Wallis test for multiple groups followed by Dunn‟s post-hoc test comparing all groups 
to vehicle. Antagonism of the PGE2-induced cough was analysed using a Mann 
Whitney U test for non-parametric data and plotted as mean ± s.e.m.  
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5.3. RESULTS  
 
5.3.1. Expression of the EP3 receptor in vagal nerve ganglia 
 
To investigate the expression of the EP3 receptor, a human tissue RNA panel was 
initially used to identify tissues that express the EP3 receptor. This tissue could then be 
used to validate the assay, as described in section 2.6.5, and also as a positive control 
in future experiments. The expression of the EP3 receptor in a range of RNA samples 
extracted from human tissue were profiled (Figure 5.1). The EP3 receptor was shown 
to express high levels of the EP3 mRNA in the kidney, with the liver, heart, brain and 
skeletal muscle having low or undetectable levels of the EP3 receptor mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Expression of the EP3 receptor mRNA in RNA extracted from 
human tissue.  
mRNA levels of the EP3 receptor in human liver, kidney, heart, brain and skeletal 
muscle (n=1). 
 
To parallel the expression of the EP3 receptor mRNA in human tissue (above), RNA 
was extracted from guinea-pig liver, kidney, heart, brain and skeletal muscle. Using 
guinea-pig primers and probes for Taqman RT-PCR, expression of the EP3 receptor 
was quantified (Figure 5.2). As with the human tissue panel, the guinea-pig kidney 
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had the highest expression of the EP3 receptor mRNA. The assay was validated using 
the guinea-pig kidney, as described in section 2.6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Expression of the EP3 receptor mRNA in RNA extracted from 
guinea-pig tissue.  
mRNA levels of the EP3 receptor in guinea-pig liver, kidney, heart, brain and skeletal 
muscle (n=3). 
 
 
The expression pattern of the EP3 receptor in guinea-pig and human tissue was similar 
and illustrated that the EP3 receptor was highly expressed in the kidney of both 
species. Using expression of the EP3 receptor in the kidney as a positive control, EP3 
receptor mRNA was quantified in the guinea-pig nodose and jugular ganglia (Figure 
5.3). The EP3 receptor was highly expressed in the guinea-pig kidney, and expression 
of the EP3 receptor was detected at slightly higher levels in the jugular compared to 
the nodose ganglia. 
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Figure 5.3: Expression of the EP3 receptor in guinea-pig kidney, jugular ganglia 
and nodose ganglia. 
Expression of the EP3 receptor in untreated guinea-pig kidney, jugular and nodose 
ganglia (n=3). 
 
 
Using Taqman RT PCR, it has been shown that the EP3 receptor is expressed in the 
nodose and jugular ganglia and confirmed using the kidney as a positive control from 
both human and guinea-pig. I then went on to use a second technique, 
immunohistochemical staining, to identify the EP3 receptor protein in kidney, jugular 
and nodose ganglia. A series of antibody dilutions was carried out using guinea-pig 
kidney and the optimum concentration chosen for future studies was 1:50. I then went 
on to stain sections of guinea-pig ganglia using a 1:50 antibody dilution (Figure 5.4). 
The kidney was again used as the positive control and staining can be seen in distal 
convoluted tubules as expected (Morath et al. 1999; Sugimoto et al. 1994b). 
Expression of the EP3 receptor protein can also be observed in the jugular and nodose 
ganglia. The protein expression seems to concur with the gene expression data as the 
jugular ganglia has a higher expression of the receptor protein compared to the nodose 
ganglia (Figure 5.4). Consecutive sections were incubated with IgG instead of 
primary antibody to show that the staining is specific to the EP3 antibody and the 
secondary antibody does not bind to proteins other than the EP3 receptor antibody. 
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Figure 5.4: Expression of EP3 receptor protein by immunohistochemical staining 
in untreated guinea-pig kidney, nodose ganglion and jugular ganglion.  
Guinea-pig kidney, jugular ganglia and nodose ganglia were dissected and fixed in 
formalin and processed into sections. Sections were stained for the EP3 receptor 
protein (a) and IgG control (b) in consecutive sections. Sections are representative of 
at least three animals. Scale bars is 100 μm.  
 
To confirm that the EP3 receptor is expressed on nerve cells, subsequent sections of 
ganglia were stained for the EP3 receptor protein and PGP 9.5, a neuronal marker. 
PGP 9.5 stains all nerve cells in the ganglia and a consecutive section shows that a 
proportion of these nerve cells express the EP3 receptor protein (Figure 5.5). 
 
 
 
 
 125 
 
              (a)            (b) 
 
       
  Jugular ganglion 
 
 
 
 
Figure 5.5: Confirmation that the EP3 receptors are expressed on guinea-pig 
nerve cell bodies using PGP 9.5. 
Expression of EP3 receptor protein (a) and PGP 9.5 (b) in the jugular ganglion. PGP 
9.5 is a neuronal marker and stains all nerve cells. The EP3 receptor is expressed in 
the jugular ganglion on a subset of the nerve cell bodies stained by PGP 9.5 (brown 
staining). Nuclei were counterstained with haematoxylin (blue). Sections are 
representative of at least 3 guinea-pigs. Scale bar is 100 μm. 
 
 
5.3.2. Antagonism of PGE2-induced cough  
 
The expression of the EP3 receptor in vagal nerve ganglia has been confirmed by 
Taqman RT PCR and immunohistochemical staining. Furthermore, PGE2-induced 
depolarisation can be inhibited by the EP3 receptor antagonist in guinea-pig, mouse 
and human isolated nerves. These findings suggest that the EP3 receptor could be 
involved in PGE2 induced cough. The EP3 antagonist, L826266, was used to inhibit 
PGE2-induced cough in vivo. Initially an experiment was carried out dosing the 
guinea-pigs with 0.3, 3 and 30 mg/kg L826266 one hour prior to challenge with 100 
μg/ml PGE2. These doses of antagonist were selected based on unpublished data from 
Merck Frosst, the source of L826266. Data was available in guinea-pigs illustrating 
that when given orally at 30 mg/kg, the mean plasma concentration at one hour was 
9.1 μM (Table 5.2 & Figure 5.6). Given that a concentration of 2 μM L826266 
completely abolished PGE2-induced depolarisation in isolated nerves, it was thought 
that 30 mg/kg may be sufficient to inhibit PGE2-induced cough.    
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Time post 
dose 
(minutes) 
L826266 concentration (μM) Mean SD 
Subject 1 Subject 2 
0 0 0 0 0 
15 2.64 1.09 1.86 1.09 
30 4.19 7.02 5.60 2.00 
60 5.19 13 9.10 5.52 
120 5.14 3.02 4.08 1.50 
240 0.52 0.29 0.40 0.16 
360 0.21 0.024 0.12 0.13 
1440 0.15 0 0.075 0.11 
 
Table 5.2: Plasma concentrations of L826266 following oral administration in 
guinea-pigs.  
Guinea-pigs were orally dosed with L826266 (30 mg/kg, 5 ml/kg). The vehicle was 0.5 
% methylcellulose in water. Serial blood samples were taken at 0, 15, 30, 60, 120, 
240, 360 and 1440 minutes after oral administration of L826266. Plasma was 
separated from blood samples and analysed for L826266 by LC-MS/MS analysis. 
N=2 in each group. 
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Figure 5.6: Concentration-time profile of the plasma concentration of L826266 
following oral administration in guinea-pigs. 
Guinea-pigs were orally dosed with L826266 (30 mg/kg, 5 ml/kg). The vehicle was 0.5 
% methylcellulose in water. Serial blood samples were taken at 0, 15, 30, 60, 120, 
240, 360 and 1440 minutes after oral administration of L826266. Plasma was 
separated from blood samples and analysed for L826266 by LC-MS/MS analysis. 
N=2 in each group. 
 
Based on the pharmacokinetic analysis in Table 5.2 and Figure 5.6, an in vivo guinea-
pig study was carried out to investigate the inhibition of PGE2 induced cough (Figure 
5.7). The i.p. dosing route was chosen instead of oral dosing as previous studies in 
house have revealed that the stress that the animals are subjected to for oral dosing, 
one hour prior to challenge, impacts on the cough response to tussive stimuli.  
Guinea-pigs were dosed i.p. with 0.3, 3 or 30 mg/kg L826266 one hour prior to 
challenge with 100 μg/ml PGE2. There were no significant differences between the 
vehicle dosed group and the antagonist dosed groups. At 3 mg/kg it appeared that the 
response to PGE2 was decreased as only 1 out of 12 animals coughed. However this 
was not observed at 30 mg/kg. Furthermore, there were 7 out of 12 animals in the 
vehicle group that did not cough in response to PGE2 (Figure 5.7) 
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Figure 5.7: Effects of 0.3, 3 and 30 mg/kg EP3 antagonist on PGE2-induced 
cough. 
EP3 antagonist, L826266, was dosed (0.3, 3 and 30 mg/kg in 0.5 % methylcellulose + 
0.2 %  Tween 80 in saline, i.p.) one hour prior to challenge with 100 μg/ml PGE2 for 
10 minutes. Coughs were counted and data are depicted as (a) scatter plot and (b) 
bar graph and expressed as mean ± s.e.m. (n=12). 
 
Blood samples were taken from each of the animals 10-15 minutes following 
challenge with PGE2 (approximately 90 minutes following administration of 
L826266). Animals were overdosed with sodium pentobarbitone and blood was taken 
via cardiac puncture. The plasma was separated and samples were sent to Merck 
Frosst for analysis of plasma concentration of L826266. There were low 
concentrations of L826266 in the groups of animals dosed at 0.3 and 3 mg/kg. In this 
study, at 30 mg/kg i.p., similar plasma concentrations were observed to those recorded 
at 1-2 hours after oral administration of L826266. Plasma concentrations following 30 
mg/kg L826266 (i.p.) were 4.3 ± 1.9 μM (Table 5.3). In table 5.3, I also compared the 
number of coughs occurring in each animal with the plasma concentration of L826266 
however no correlation was observed (Table 5.3). 
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Vehicle 0.3 mg/kg 3 mg/kg 30 mg/kg 
Coughs Plasma 
levels 
(μM) 
Coughs Plasma 
levels 
(μM) 
Coughs Plasma 
levels 
(μM) 
Coughs Plasma 
levels 
(μM) 
15 N/A 0 0.000 0 0.058 19 6.55 
0 N/A 71 0.000 0 0.081 24 4.34 
0 N/A 0 0.000 0 0.013 0 3.87 
19 N/A 0 0.000 0 0.000 17 5.25 
0 N/A 0 0.037 0 0.000 0 3.07 
19 N/A 0 0.000 0 0.040 0 5.60 
0 N/A 20 0.000 0 0.083 0 7.28 
19 N/A 18 0.000 0 0.067 17 6.23 
44 N/A 35 0.000 39 0.051 17 3.12 
0 N/A 0 0.000 0 0.034 0 3.62 
0 0.000 17 0.000 0 0.015 0 1.10 
0 0.000 24 0.000 0 0.088 25 1.63 
 
Table 5.3: Plasma concentrations of L826266 following i.p. administration in 
guinea-pigs.  
Guinea-pigs were dosed i.p. with L826266 (0.3, 3 or 30 mg/kg, 5 ml/kg). The vehicle 
was 0.5 % methylcellulose, 0.2 % Tween 80 in saline. Terminal blood samples were 
taken at approximately 90 minutes following i.p. administration of L826266. Plasma 
was separated from blood samples and analysed for L826266 by LC-MS/MS analysis. 
The numbers of coughs were compared in individual guinea-pigs to the plasma 
concentration of L826266. N=12 in each group. 
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Due to the unusually high number of non-responders in the vehicle group of Figure 
5.7, it was decided to repeat the concentration-response curve to PGE2. PGE2 at 
concentrations of 30, 100 and 300 μg/ml were delivered by aerosol and in this study, 
only 300 μg/ml elicited a significant number of coughs compared to vehicle. At a 
concentration of 100 μg/ml (the concentration shown previously to cause a significant 
number of coughs), only one out of the group of 12 animals coughed (Figure 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Concentration-response to PGE2 in a guinea-pig model of cough. 
Guinea-pigs were exposed to vehicle or 30, 100, 300 μg/ml PGE2 for 10 minutes and 
the number of coughs recorded. N=8 in each group and data plotted as a scatter 
graph. Statistical significance is denoted as * P<0.05. 
 
Despite the lower PGE2 concentrations, the previous antagonist study (Figure 5.7) did 
not appear to inhibit cough. In a subsequent study, it was decided to increase the 
concentration of PGE2 to 300 μg/ml, but also use an antagonist concentration of 300 
mg/kg. Furthermore, the time between dosing and cough challenge was decreased to 
40 minutes as, from Figure 5.6, the plasma concentration appears to decrease between 
1 and 2 hours. 
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Guinea-pigs were dosed with vehicle or 300 mg/kg L826266 40 minutes prior to 
challenge with 300 μg/ml PGE2. Coughs were counted and 300 mg/kg L826266 
significantly inhibited the number of coughs to PGE2 (Figure 5.9). 
 
 
(a)              (b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Inhibition of PGE2-induced cough by L826266. 
Guinea-pigs were dosed (i.p.) with vehicle (0.5 % methylcellulose + 0.2% Tween 80 
in saline, n=5) or 300 mg/kg L826266 (n=6) 40 minutes prior to cough challenge 
with 300 μg/ml PGE2. Data are represented as mean ± s.e.m. and depicted as (a) bar 
chart and (b) scatter plot. *p<0.05. 
 
As with previous studies, following challenge with PGE2, guinea-pigs were culled 
with an overdose of sodium pentobarbitone and heparinised blood samples taken via 
cardiac puncture. Again plasma samples were kindly analysed by Merck Frosst and it 
was found that the plasma concentration, approximately 70 minutes following i.p. 
administration of 300 mg/kg L826266, was 135.6 ± 12.71 μM (Figure 5.10). 
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Figure 5.10: Plasma concentration of L826266 following i.p. administration in 
guinea-pigs. 
Scatter plot showing the plasma concentration of L826266 (a) 90 minutes following 
i.p. administration of 0.3, 3 and 30 mg/kg L826266 (n=12) and (b) 70 minutes 
following i.p. administration of 300 mg/kg (n=6). Following cough challenge, 
terminal blood samples were taken and the plasma separated. Samples were analysed 
for L826266 by LC-MS/MS analysis. 
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5.4. DISCUSSION 
 
After identifying the EP3 receptor as the receptor involved in PGE2-induced 
depolarisation of guinea-pig, mouse and human vagus nerves, this chapter aimed to 
confirm the presence of the EP3 receptor in vagal nerve ganglia and illustrate that the 
cough response to PGE2 can be attenuated by the EP3 receptor antagonist L826266.  
 
In vivo doses of L826266 were initially chosen based on pharmacokinetic data 
supplied by Merck Frosst, Canada. Pharmacokinetic studies are often carried out by 
oral and/or i.v. dosing; however the preferred route of dosing for cough studies is i.p. 
Previous studies in-house have shown that oral dosing prior to cough challenge can 
impact on the cough response. Oral dosing can induce stress on the animal which then 
reduces the cough response to tussive stimuli. The pharmacokinetic studies were 
carried out using 30 mg/kg L826266 and a plasma concentration of 9.1 μM was 
achieved at 60 minutes following oral administration. In the first cough study, at 30 
mg/kg i.p., a plasma concentration of 4.3 μM was achieved at around 90 minutes 
following i.p. administration suggesting that the oral and i.p. dosing produce similar 
plasma concentrations. From in vitro studies in the isolated vagus nerve, a 
concentration of 2 μM L826266 completely inhibited depolarisation induced by PGE2. 
Based on this data, it was possible that the top concentration used in this study, 30 
mg/kg, could have inhibited PGE2-induced cough. However, little previous in vivo 
data with the antagonist was available. L826266 has been used in an in vivo study 
however the antagonist was injected directly into the paw of the mouse and so would 
be less influenced by the pharmacokinetic profile of the antagonist (Claudino et al. 
2006). Furthermore, the concentration of L826266 that is free or plasma-bound was 
also unknown. Following this experiment, data was available from Merck Frosst 
revealing that L826266 was highly shifted in the presence of protein. The Ki of 
L826266 on the EP3 receptor was 0.76 nM and in the presence of only 0.05 % Human 
Serum Albumin (HSA) the Ki was shifted to 8.7 nM (Personal communication, 
(Gallant 2008)). Although whole plasma binding has not been assessed, HSA is the 
most abundant blood plasma protein and provides a good indication of the 
pharmacokinetic profile of the antagonist. Based on the relatively large shift seen with 
a low concentration of HSA, it could be predicted that the plasma binding would be 
high and so a significantly higher plasma concentration would need to be achieved to 
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provide enough unbound L826266 to have an effect in vivo. This data provided by 
Merck Frosst suggests a 1 log loss in potency in the presence of 0.05 % HSA and so it 
was predicted that 10 times more compound would be required to achieve inhibition 
in vivo based on in vitro data. With no effect at 30 mg/kg L826266, the dose was 
increased in a subsequent study to 300 mg/kg L826266. Another possible reason for 
the lack of antagonism of the PGE2-induced cough at 30 mg/kg L826266 could be the 
proximity of the target receptors. L826266 was administered i.p. and the tussive 
response is initiated via activation of a nerve ending protruding into the airways 
between the epithelial cells. For L826266 to antagonise PGE2 at the EP3 receptor, the 
drug is required to be transported from the blood into the tissue surrounding the 
airways to reach the nerve endings. 
 
Despite obtaining no inhibition of PGE2-induced cough to 30 mg/kg L826266, a 
substantial set of data suggesting a role for the EP3 had been produced. L826266 
inhibits PGE2-induced depolarisation in human, mouse and guinea-pig and it has also 
been shown in this chapter that the EP3 receptor is expressed at both the gene and 
protein level in guinea-pig vagal nerve ganglia and expression of the EP3 receptor in 
mouse and rat sensory ganglia has been previously published (Nakamura et al. 2000; 
Sugimoto et al. 1994c). Furthermore, expression of the EP3 receptor on vagal nerve 
cells contained within the ganglia was confirmed by staining consecutive section of 
jugular ganglia and showing that staining for the EP3 receptor and the neuronal 
marker PGP9.5 are in similar areas of the ganglion.  Because of the data suggesting 
that the affinity of L826266 at the EP3 receptor could be shifted in the presence of 
protein, I carried out a second in vivo cough study using a higher dose of the 
antagonist L826266.  We were kindly supplied with sufficient quantities of the 
antagonist and so based on the shift in potency in the presence of HSA, the amount of 
compound was increased 10-fold to a dose of 300 mg/kg. At this dose, the number of 
coughs was decreased by approximately 50 % and this result was statistically 
significant. Ideally, a dose response of the antagonist would have been investigated, 
using higher doses of L826266. However, this would require huge amounts of 
compound which were not available and issues could be raised due to the selectivity 
of the compound at higher doses in vivo which would be difficult to assess. 
Furthermore, in vivo studies are costly in terms of the reagents and animals required, 
and in addition, large numbers of animals would be needed for each study.       
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The concentration of PGE2 challenge was based on initial development studies of the 
PGE2-induced cough in Chapter 3. A concentration of 100 μg/ml PGE2 was chosen 
for studies as a significant number of coughs were achieved when compared to 
vehicle. In the first study, investigating inhibition by 0.3, 3 and 30 mg/kg L826266, 
there were an unusual number of animals that did not cough in response to PGE2. 
Although a significant number of animals coughed during a 10 minute aerosol of 100 
μg/ml PGE2 in the development studies, responses may differ between batches of 
animals from the same supplier or differences in holding conditions. Due to the low 
number of animals that coughed in response to PGE2, a concentration response was 
repeated using 30, 100 and 300 μg/ml PGE2. During this experiment significant 
numbers of coughs were only observed at 300 μg/ml PGE2. The second antagonist 
study therefore used a challenge concentration of 300 μg/ml PGE2 which induced a 
cough response in all animals (vehicle and drug treated group) allowing the effects of 
the antagonist to be observed. It should be noted that in the second antagonist study, a 
greater number of coughs were observed in both groups (vehicle and animals dosed 
with 300 mg/kg L826266) when compared to the same concentration during the 
concentration-response experiment. We have previously seen that the responsiveness 
to PGE2 can differ between batches of animals from the same supplier. To control the 
experiment, studies were always carried out using animals from the same batch to 
account for differences in responses to tussive agents.  
 
To summarise, it has been shown in this chapter that the EP3 receptor is expressed in 
both human and guinea-pig kidney using both RT PCR and immunohistochemical 
staining. Furthermore, the expression of the EP3 receptor in nodose and jugular 
ganglia has been confirmed with the jugular ganglia appearing to express more EP3 
receptors at both the gene and protein level. In the antagonist cough studies, it was 
shown that 300 mg/kg L826266 inhibited PGE2-induced cough confirming the role of 
the EP3 receptor in PGE2-induced cough.            
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CHAPTER 6  
 
Discussion and Future Investigations 
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6.1 SUMMARY AND DISCUSSION 
 
Asthma and COPD represent a major problem for world public health as chronic 
respiratory diseases are currently the 4
th
 leading cause of death (Minino et al. 2007). 
Bronchodilators, such as long acting β2-adrenergic receptor agonists (e.g. salmeterol),  
are the mainstay treatment however these drugs often fail to relieve symptoms of 
COPD and severe asthma (Barnes & Stockley 2005) and prolonged use of salmeterol 
has been associated with an increased risk of death in a sub population of patients 
(Currie et al. 2006). Furthermore, inhaled corticosteroids are effective in many 
asthmatic patients but are of little benefit to patients with severe asthma (Barnes 2000; 
Wenzel 2005). These factors therefore represent a significant need to develop safe, 
new therapies for airway inflammatory diseases.  
 
PGE2 is a potential therapy that has previously been shown to be anti-inflammatory 
and a bronchodilator in asthmatic patients (Gauvreau et al. 1999; Kawakami et al. 
1973; Melillo et al. 1994; Pavord et al. 1993). Despite these benefits, PGE2 has not 
been developed for the treatment of airway inflammatory diseases as prostanoids 
induce irritancy of the upper airways resulting in a reflex cough (Costello et al. 1985; 
Gauvreau et al. 1999; Kawakami et al. 1973). The aim of the thesis was to therefore 
identify the receptor responsible for the PGE2-induced cough, representing a key step 
in the development of an agonist profile that confers bronchodilator and anti-
inflammatory effects but is devoid of the tussive side effects.  
 
To approach this research question, I initially characterised models of sensory nerve 
irritation and cough. Although PGE2-induced cough has been well documented in 
man, there is no published literature characterising the tussive response in small 
animals. I established that guinea-pigs, like humans, possess a cough response to 
PGE2, and that furthermore, the number of coughs increase with the dose of PGE2. 
This model of PGE2-induced cough thus provided a basis on which to investigate the 
receptor responsible for PGE2-induced cough. However, given that there are 9 
different prostanoid receptors, it was not practical to carry out multiple experiments to 
attempt to attenuate the PGE2-induced cough with different antagonists. I therefore 
initially utilised an in vitro isolated vagus nerve preparation to identify the receptor 
involved in PGE2-induced vagus nerve depolarisation. In vitro assays are often used 
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for pharmacological proof of concept studies prior to evaluating the effects of a 
potential therapy in vivo as they are more cost effective, often higher throughput and 
require the use of fewer animals. However, results obtained in vitro should be 
interpreted with some caution as the effects may not completely represent what would 
happen in a far more complex in vivo system. Nevertheless, the isolated vagus nerve 
preparation is a well-established, valuable model in the study of sensory nerve 
activation, and previous studies have shown that the ligands that inhibit the 
depolarisation in vitro also inhibit cough in the conscious guinea-pig (Patel et al. 
2003; Usmani et al. 2005). Using this isolated vagus nerve preparation I characterised 
the responses to PGE2 in parallel with capsaicin and low pH, in guinea-pig, mouse 
and human vagus nerves. Guinea-pigs were employed because they are the only small 
animal with a cough reflex and it had already been shown that guinea-pigs cough in 
response to aerosolised PGE2. Although mice do not cough per se, isolated vagus 
nerves from mice do respond to PGE2 and other tussive stimuli. This therefore 
provided a means of investigating responses to tussive stimuli in isolated nerves from 
mice that had been genetically modified to knock out one of the prostanoid receptor 
genes (EP1, EP2, EP3, EP4, DP, FP, IP, and TP). Furthermore, the availability of 
human vagus nerve from lung transplant patients offered a way of translating the 
findings in this system into man. Capsaicin, low pH and PGE2 caused depolarisation 
in all three species, suggesting that responses in the guinea-pig and mouse translate 
into man. 
 
Using this model of sensory nerve activation, I showed that antagonists at the EP1, 
EP2, EP4, FP, DP, IP, and TP receptors had no effect on PGE2-induced depolarisation. 
However, an EP3 antagonist (L826266) inhibited PGE2-induced depolarisation in 
guinea-pig, mouse and human isolated vagus nerve suggesting that the EP3 receptor 
plays a prominent role in the response to PGE2 and is translated across species. 
Furthermore, L826266 significantly inhibited the depolarisation induced by 
sulprostone, an EP1/EP3 agonist, supporting the evidence that the EP3 receptor is 
involved in sensory nerve activation. 
 
The prostanoid receptor KO mice proved to be extremely important and beneficial 
tools to investigate the receptor involved in the tussive repsonse to PGE2. A 
considerable amount of time was spent developing and optimising a genotyping 
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method for these mice as confirmation that the animal did in fact have the assumed 
gene KO was considered crucial. The genotyping was necessary for the FP KO 
animals as they are bred as heterozygous females and homozygous males. From these, 
KO animals were selected for experimentation and future breeding stocks were 
identified. The other KO colonies were established from pairs of receptor KOs 
provided by Kyoto University, Japan. Although genotyping was not absolutely 
necessary, I felt it was an important control in these studies to have confirmation that 
the assumed gene was knocked out. It is always a possibility in breeding programs 
that animals can become mixed up or breeders mistakenly paired. Breeding colonies 
were therefore routinely screened and tissue from animals used for experimentation 
was always taken for DNA extraction and genotyping. Investigating responses in 
isolated nerves from the KO mice revealed that PGE2 causes a significantly decreased 
response to PGE2 in the EP3 KO mice supporting evidence already obtained that the 
EP3 receptor plays a role in PGE2-induced depolarisation of the isolated nerves. 
 
Findings from experiments using isolated vagus nerves suggest a role for the EP3 
receptor in the activation of sensory nerves by PGE2. This could therefore suggest that 
the EP3 receptor is also involved in the tussive response to PGE2. To test this 
hypothesis, I used the EP3 receptor antagonist L826266 in an in vivo guinea-pig model 
and 300mg/kg L826266 significantly inhibited the response to PGE2. This dose of 
L826266, although a significant decrease, did not completely abolish the cough 
response and future experiments are discussed in section 6.2 below. 
 
The role of the EP3 receptor in functional experiments such as activation of isolated 
sensory nerves and cough were supported by gene and protein assays. Guinea-pig 
primers and probes for TaqMan RT PCR were kindly provided by GlaxoSmithKline 
as the guinea-pig genome is not publically available and it would therefore not have 
been possible to design primers and probes myself. An abundant source of the guinea-
pig gene encoding the EP3 receptor (Ptger3) was identified in the kidney providing a 
positive control and it was confirmed that the EP3 receptor was expressed in both the 
nodose and jugular ganglia. Unfortunately, it was not possible to acquire human vagal 
nerve ganglia, however using available tissues, the expression profile of the human 
EP3 receptor followed a similar pattern to that of the guinea-pig suggesting that 
distribution of EP3 receptor expression could be translated between species. 
 140 
Expression of the EP3 receptor protein was also investigated in guinea-pig kidney and 
vagal nerve ganglia. There are currently no commercially available antibodies that are 
raised against the guinea-pig EP3 receptor protein. Therefore, using a human EP3 
receptor antibody suitable for immunohistochemistry, I stained sections of the kidney, 
nodose ganglia and jugular ganglia. As a positive control, expression of the EP3 
receptor was observed in expected areas of the guinea-pig kidney (distal convoluted 
tubules) suggesting that the antibody was suitable for use in the guinea-pig. The EP3 
receptor antibody stained areas of the nodose and jugular ganglia. Subsequently, 
consecutive sections of jugular ganglia were stained for EP3 and PGP 9.5 indicating 
that the EP3 receptor is expressed in areas of the ganglia containing neuronal tissue. 
More extensive investigations, outlined in section 6.2 below, would be needed to 
confirm that the EP3 receptors are indeed expressed on vagal nerves innervating the 
airways. 
 
6.1.1 Limitations of the thesis 
 
The experimental techniques used in this thesis have provided evidence that the EP3 
receptor is involved in the isolated nerve activation and cough in response to PGE2. 
However, there are limitations associated with these techniques. As discussed 
previously, the isolated vagus nerve preparation provides a relatively high throughput 
in vitro system that has been shown to reflect the responses seen in guinea-pig in vivo. 
As mice do not possess a cough reflex, they cannot be used for in vivo cough 
experiments however the effect of the tussive stimuli on the isolated vagus nerves 
seem to parallel the responses in guinea-pig. It may be that mice do possess the 
sensory nerves mediating irritation but just do not possess the central cough reflex 
and/or the appropriate motor responses. In addition, the isolated vagus nerve contains 
parasympathetic nerves and sensory nerves innervating other organ systems such as 
the heart and GI tract. Furthermore, the effect on the isolated nerve trunk does not 
necessarily represent what happens at the nerve terminal in the airways. Despite this, 
the advantage of this system is that our group has access to human tissue from donor 
transplant patients surplus to requirement for heart/lung transplant with branches of 
the vagus nerve attached. With this system, guinea-pig, mouse and human tissue 
responses can be measured in parallel. However, human donor tissue is much less 
readily available and as such, the number of replicate experiments with human vagus 
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nerves in this thesis ranges from 1 to 5. Furthermore, with the mouse and guinea-pig, 
the time from dissection to experimentation is short and consistent. With human tissue 
the time from retrieval to arrival at the laboratory can vary and as such the tissue may 
be less viable after several hours.  
 
In the final in vivo cough study, the number of coughs with 300 µg/ml PGE2 was 
increased compared to the initial dose response curve. This could be due to different 
experimental conditions on the day such as a change in the holding room environment 
or due to variation between batches of animals from the suppliers. Furthermore, using 
this concentration of PGE3 and 300 mg/kg L826266, the cough response was only 
reduced by around 50%. Unfortunately there was not more compound available to 
either repeat the study, or increase the dose of L826266. This was the only selective 
EP3 antagonist available and it is possible that this antagonist is not an optimum tool 
compound for in vivo use. There is limited published data using this compound and 
although I was able to measure plasma levels of the drug, there was no other 
information available regarding the pharmacokinetic profile, such as lipophilicity, 
metabolism and bioavailability.  
 
It may also have been useful to show that an EP3 agonist causes cough. Sulprostone is 
an EP3 agonist and was completely inhibited by 2 µM L826266 in the isolated vagus 
nerves. However, sulprostone is also an EP1 agonist and, in vivo, has been shown to 
cause airway smooth muscle contraction which could have impacted on the cough 
response. Selective agonists such as ONO-AE-249 would be extremely useful 
however they are not commercially available. 
 
In summary, identification of the receptor responsible for PGE2-induced cough 
represents a key step in the development of prostanoids as a therapy for airway 
inflammatory diseases. If the receptors conferring the beneficial effects of PGE2 are 
different, a prostanoid analogue could be developed that is a bronchodilator and an 
anti-inflammatory agent but devoid of the tussive side effects. 
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6.2 FUTURE DIRECTION 
 
The aim of this thesis was to identity the prostanoid receptor involved in the tussive 
response to PGE2. Having produced significant evidence that the EP3 receptor is 
responsible for the PGE2-induced sensory nerve activation and cough, this section 
identifies further work to confirm the involvement of the EP3 receptor. In addition, I 
will discuss the future directions to investigate prostanoids as a therapy for airway 
inflammatory diseases. 
 
6.2.1. Further investigation of the prostanoid receptor involved in PGE2-induced 
sensory nerve activation 
 
6.2.1.1. Recording from single airway afferent nerve fibres innervating the lung 
 
The in vitro isolated vagus nerve preparation, utilised in this thesis, represents a 
system in which sensory nerve activity can be investigated without the complexity of 
in vivo models. The experiments carried out using this system are reproducible and 
require less compound and fewer animals compared to in vivo experiments. 
Furthermore, results obtained from pharmacological experiments using the isolated 
vagus nerve preparation have been shown to translate into the clinic (Patel et al. 2003; 
Usmani et al. 2005). However the depolarisation recorded in the isolated vagus nerve 
system represents a summation of the change in membrane potential of all of the 
axons contained within the vagus nerve. The vagus nerve contains both afferent and 
efferent fibres innervating the upper and lower airways, in addition to those 
innervating other organs such as the heart and the gastro-intestinal tract. Despite the 
translational effects of the isolated vagus nerve system and cough, shown above, it 
would be advantageous to employ an additional in vitro model which could record 
from sensory afferent fibres known to innervate the airways and such systems have 
already been established (Fox et al. 1993; Fox et al. 1995; Riccio et al. 1996b). 
 
The extracellular model of single nerve fibres records the action potentials from single 
cell bodies in the ganglion. The ganglia are pulled into a separate compartment so that 
the ganglia and trachea can be separately perfused. An electrode is then inserted into 
the nodose or jugular ganglion and, once positioned, electrical, chemical and 
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mechanical stimulations can be recorded from isolated areas of the larynx, trachea and 
bronchi. The electrode can then be manipulated within the ganglion to record from a 
single nerve fibre that is innervating the trachea. Furthermore, the type of fibre that 
the electrode is recording from can be identified by the speed of conductance. This 
experimental technique would enable me to investigate the effects of prostanoids on 
specific nerve fibre types innervating the lung. 
 
6.2.1.2. Gene and protein assays 
 
Pharmacological studies identified the EP3 receptor as the prostanoid receptor 
involved in PGE2-induced vagal nerve activation and therefore subsequent 
investigations focussed on identifying the EP3 receptor in vagal nerve ganglia at the 
gene and protein level. It would also be of interest to carry out TaqMan and 
immunohistochemistry to identify other prostanoid receptors to build up a profile of 
their expression in sensory ganglia. It is clear from studies in this thesis that 
prostanoid agonists (PGD2, PGF2α, U46619, and Iloprost) depolarise the vagus nerve 
however these ligands could activate a number of different receptors and there has 
been little previous work carried out to profile the prostanoid receptors expressed on 
the vagus nerve. 
 
Another technique which would be extremely useful would be to carry out single cell 
RT PCR on ganglia cell bodies that are known to innervate the airways. A fluorescent 
tracer is administered to the animal (for example guinea-pig or mouse) which is taken 
up into the nerve terminals and transferred, by retrograde transport, to the cell body in 
the ganglia. The ganglia can then be dissociated and individual fluorescent cells 
selected for gene expression analysis (Kwong & Lee 2005; Nassenstein et al. 2008). 
 
 6.2.1.3. Guinea-pig cough studies 
 
Due to the amount of stock compound, the maximum dose of L826266 that was 
administered for the final study investigating PGE2-induced cough was 300 mg/kg. At 
this dose, the PGE2-induced cough was inhibited by approximately 50 %. To fully 
profile the effects of the EP3 antagonist in vivo, a dose response of the antagonist 
against PGE2 could be carried out. An alternative EP3 antagonist could also be 
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sourced as, based on preliminary data from Merck Frosst, this antagonist could be 
highly protein bound and thus have less efficacy in vivo (Gallant 2008). ONO 
Pharmaceuticals have a range of prostanoid receptor agonists and antagonists which 
could be requested for future investigations (Suzawa et al. 2000).  
 
6.2.2. Investigating PGE2-induced cough in disease models 
 
PGE2-induced cough has been observed in both normal subjects (Costello et al. 1985; 
Kawakami et al. 1973) and in patients with asthma and chronic bronchitis (Gauvreau 
et al. 1999; Kawakami et al. 1973; Melillo et al. 1994). In this thesis, the receptor 
responsible for PGE2-induced sensory nerve activation and cough has been 
investigated under „normal‟ conditions. It would therefore be interesting to identify 
the role of EP3-receptor mediated PGE2-induced cough in disease. 
 
Studies have suggested that PGE2 can sensitise the airway sensory nerves to other 
tussive stimuli such as capsaicin in vitro (Kwong & Lee 2002; Kwong & Lee 2005) 
and in vivo (Ho et al. 2000). And furthermore, prostanoids have been implicated in 
enhancing the cough response to capsaicin both in normal subjects and in patients 
with chronic cough, chronic bronchitis and asthma (Choudry et al. 1989; Fujimura et 
al. 1995; Stone et al. 1992). It has been reported that chronic cough can be associated 
with airway inflammatory diseases (Morice et al. 2004) and furthermore, endogenous 
prostanoids in the airways are often increased in patients with both idiopathic cough 
and airway inflammatory diseases (Birring et al. 2004; Montuschi et al. 2003; Profita 
et al. 2003). As inhaled PGE2 can also induce cough in both normal subjects and 
patients with airway disease it could be hypothesised that prostanoids play a role in 
cough associated with airway inflammatory diseases. Having identified in this thesis 
that the EP3 receptor is responsible for PGE2-induced cough, it could be suggested 
that endogenously released PGE2 may be responsible for an enhanced cough in 
disease. This could be further studied by investigating changes in gene expression and 
analysing the responses to PGE2 in the isolated vagus nerve preparation and the in 
vivo cough system using a range of inflammatory models of airway diseases such as 
those induced by ovalbumin (de Vries et al. 2006; McLeod et al. 2006), LPS (Birrell 
et al. 2004; Kaneko et al. 2007; Toward & Broadley 2002), elastase (Birrell et al. 
2005) and cigarette smoke exposure (Lewis et al. 2007; Stevenson et al. 2005).  
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6.2.3. Identification of the signalling pathway downstream of prostanoid receptor 
activation 
 
Having identified that the EP3 receptor is involved in PGE2-induced sensory nerve 
activation and cough, it would be interesting to investigate the downstream 
mechanism of PGE2-induced cough. The EP3 receptor is a G-protein coupled receptor 
and is thus unlikely to cause depolarisation alone. It could be hypothesised that the 
EP3 receptor is coupled to an ion channel via a signalling pathway. TRPV1 expression 
is increased in patients with chronic cough (Groneberg et al. 2004) and my group has 
preliminary data suggesting that the TRPV1 receptor may play a role in PGE2-induced 
depolarisation of the vagus nerve. The TRPV1 receptor antagonist SB366791 partially 
inhibited the response to PGE2 in the isolated vagus nerve preparation (Figure 6.1).  
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Inhibition of PGE2-induced depolarisation by the TRPV1 receptor 
antagonist SB366791. 
Guinea-pig isolated vagus nerves were dissected and mounted in a grease-gap 
chamber as previously described. Two reproducible responses to PGE2 were obtained 
and 1 μM SB366791 was perfused onto the nerve for 10 minutes. The response to 
PGE2, in the presence of antagonist was significantly inhibited. Data expressed as 
mean ± s.e.m., n=4, *p<0.05.  
 
Further investigation could be carried out by antagonising the depolarisation to PGE2 
with increasing concentrations of TRPV1 antagonists such as SB366791 and 5‟-
iodoresiniferatoxin, using isolated nerves from TRPV1 KO mice. The inhibitory 
effects of SB366791 could also be examined in an in vivo model of PGE2-induced 
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cough. There are other possible ion channels that could be involved that have also 
been shown to be expressed on sensory nerves innervating the lung. These include the 
TRPA1 receptor and voltage-gated sodium channels (Kwong et al. 2008; Nagata et al. 
2005; Nassenstein et al. 2008). Inhibitors of these ion channels, and of components of 
potential signalling pathways (p38 MAPK, PKA, PKC), could be employed to 
investigate the mechanism of PGE2-induced depolarisation of the vagus nerve. Any 
findings could then be investigated in the in vivo model of cough. Single cell RT PCR 
could be carried out as described above and expression of multiple genes could be 
investigated in a single vagal nerve cell innervating the airways. Furthermore, if the 
immunohistochemical technique was optimised for detection of multiple targets, the 
co-localisation of the EP3 receptor could be analysed in combination with any protein 
thought to be involved in the downstream signalling of PGE2. This could be achieved 
by using multiple fluorochromes, which could provide a method of detecting multiple 
targets in one section (Dinh et al. 2004; Nassenstein et al. 2006). 
 
6.2.4. Investigating the prostanoid receptor(s) involved in the beneficial effects 
conferred by PGE2 
 
As mentioned previously, a degree of concern surrounds the use of current first line 
treatments for airway inflammatory diseases and the development of new safe 
therapies are therefore vital. This thesis has identified the receptor involved in the 
detrimental effects of inhaled PGE2, however it also remains to be clarified which 
receptors mediate the bronchodilator and anti-inflammatory effects. The EP2 receptor 
has been implicated in mediating PGE2-induced bronchodilation (Norel et al. 1999; 
Sheller et al. 2000; Tilley et al. 2003); however an EP2 agonist AH13205 failed to 
induce significant bronchodilation in patients that responded to salmeterol (Nials et al. 
1993). Interestingly, this compound entered the clinic but revealed tussive side effects 
similar to those observed with PGE2 and what is more, this compound was 
subsequently shown to possess some affinity for the EP3 receptor.  
 
 To investigate the anti-inflammatory effects of PGE2, in vitro studies have shown that 
PGE2 inhibits pro-inflammatory cytokine (granulocyte-colony stimulating factor and 
granulocyte/macrophage-colony stimulating factor) production in human airway 
smooth muscle and inhibits TNFα release from human alveolar macrophages via EP2 
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and EP4 receptors (Clarke et al. 2005; Ratcliffe et al. 2007). Furthermore, activation 
of airway EP2 receptors has been reported to inhibit mast cell activation, inhibit 
eosinophil trafficking, protect human lung fibroblasts from cigarette smoke extract-
induced apoptosis and inhibit collagen expression/proliferation in human lung 
fibroblasts (Huang et al. 2007; Kay et al. 2006; Sturm et al. 2008; Sugiura et al. 
2007). This in vitro data from human cell-based assays would suggest a role for the 
EP2 and/or the EP4 receptor in anti-inflammatory effects mediated by PGE2. However, 
in contrast, one in vivo mouse study has suggested that the EP3 receptor could be 
protective in a model of asthma (Kunikata et al. 2005). These discrepancies could be 
due to species differences or in vitro versus in vivo modelling systems, however 
further investigations are clearly required to identify the receptors conferring the 
beneficial effects of PGE2.  
 
Using the range of receptor agonists/antagonists and KO mice that have been acquired 
during my PhD, I am now in a position to investigate the receptor involved in the 
bronchodilation and anti-inflammatory effects of PGE2. Using human, guinea-pig and 
mouse (wild type and KO) airway smooth muscle, in vitro tissue contraction studies 
could be used to profile the effects of PGE2 in these tissues to identify the receptor(s) 
involved in bronchodilation. Furthermore, any findings could be investigated in vivo 
using models of airway resistance/compliance and airway obstruction. To investigate 
the anti-inflammatory receptor(s) in vitro cell lines and human cell based assay 
systems could be utilised to assess the effects of PGE2 on a range of end points and 
biomarkers (Clarke et al. 2004). Furthermore, these same assays could be employed 
using mouse (wild type and KO) and guinea-pig primary cells to further probe the 
receptors involved. Asthma-like (Birrell et al. 2003; de Vries et al. 2006; McLeod et 
al. 2006; Underwood et al. 2002) and COPD-like (Birrell et al. 2005; Bonneau et al. 
2006; Lewis et al. 2007) in vivo models could be employed to investigate these 
receptors in the disease state.  
 
If the receptors responsible for the anti-inflammatory and bronchodilator effects of 
PGE2 are indeed different to the receptor responsible for the detrimental effects, then 
a prostanoid analogue could be developed that possesses the beneficial effects but is 
devoid of the tussive side effects. This research therefore represents a key step in the 
development of alternative therapies for airway inflammatory diseases. 
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Appendix 
Chemicals and reagents 
The table below outlines all the chemical reagents and compounds used in this thesis. 
The vehicle or diluents have been described where appropriate. 
 
Drug/reagent Source Vehicle or diluents 
(where applicable) 
Agarose Promega 2 % in 1xTBE 
AH6809 Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
AL8810 Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
Boric Acid Sigma-Aldrich - 
CaCl2 VWR - 
Capsaicin Sigma-Aldrich 0.1 % DMSO in Krebs 
solution (in vitro) 
Chloroform Sigma-Aldrich - 
DAB Vector Laboratories - 
DPX VWR - 
EDTA Promega - 
Ethanol VWR - 
Glucose VWR - 
GW627368X GlaxoSmithKline 0.1 % DMSO in Krebs 
solution (in vitro) 
GW848687X GlaxoSmithKline 0.1 % DMSO in Krebs 
solution (in vitro) 
Haematoxylin Sigma-Aldrich  
Hydrogen peroxide Sigma-Aldrich  
Iloprost Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
Isopropanol Sigma-Aldrich  
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KCl VWR  
KH2PO4 VWR  
L826266 Merck Frosst 0.1 % DMSO in Krebs 
solution (in vitro) 
0.5 % methylcellulose + 
Tween 80 in saline (in 
vivo) 
Methylcellulose Sigma-Aldrich - 
MgSO4 VWR - 
NaCl VWR - 
NaH2PO4 VWR - 
NaH2PO4.2H2O VWR - 
NaHCO3 VWR - 
Normal goat serum Invitrogen - 
Nuclease-free water Promega - 
PBS Sigma-Aldrich - 
Petroleum jelly Vaseline - 
PGD2 Sigma-Aldrich 0.1 % ethanol in Krebs 
solution (in vitro) 
PGE2 Sigma-Aldrich 0.1 % ethanol in Krebs 
solution (in vitro) 
0.1M phosphate buffer 
(in vivo) 
PGF2α Sigma-Aldrich 0.1 % ethanol in Krebs 
solution (in vitro) 
Polyclonal anti EP3 antibody 
produced in rabbit 
Santa Cruz - 
Polyclonal anti-PGP9.5 
antibody produced in rabbit 
Abcam - 
Polyclonal goat anti-rabbit 
immunoglobulins/biotinylated 
Dako - 
RO3244794 Roche Palo-Alto 0.1 % DMSO in Krebs 
solution (in vitro) 
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Saline (sterile) Fresenius Kabi - 
Sodium pentobarbitone Merial Animal Health - 
SQ29548 Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
Sulprostone  Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
TRI Reagent Sigma-Aldrich - 
Trizma Base Sigma-Aldrich - 
Tween 20 Sigma Aldrich - 
Tween 80 Sigma-Aldrich - 
U46619 Cayman Europe 0.1 % DMSO in Krebs 
solution (in vitro) 
Xylene VWR - 
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